Section 7 – Laboratory Reports and Analysis
Section Index
- Section 7.1 — Blood Markers and Laboratory Reports
- Section 7.2 — Understanding My Laboratory Results
- Section 7.3 — Laboratory Trends and Health Assessment
Section 7.1 – Blood Markers and Laboratory Reports
This page is designed for a review of the blood markers on a given lab report and to review a particular blood marker across all reports.
Blood Markers Index
- COMPLETE BLOOD COUNT
- White Blood Cell Count (WBC)
- Red Blood Cell Count (RBC)
- Hemoglobin
- Hematocrit
- MCV
- MCH
- MCHC
- RDW
- Platelet Count
- Mean Platelet Volume (MPV)
- Nucleated RBC (NRBC)
- WHITE BLOOD CELL DIFFERENTIAL
- Neutrophils (%)
- Lymphocytes (%)
- Monocytes (%)
- Eosinophils (%)
- Basophils (%)
- Absolute Neutrophils
- Absolute Lymphocytes
- Absolute Monocytes
- Absolute Eosinophils
- Absolute Basophils
- KIDNEY FUNCTION – BUN
- Creatinine
- BUN/Creatinine Ratio
- Estimated GFR (eGFR)
- Urine Albumin / Microalbumin
- Urine Albumin/Creatinine Ratio
- ELECTROLYTES AND MINERALS
- Sodium
- Potassium
- Chloride
- Carbon Dioxide (CO2)
- Calcium
- Magnesium, Serum
- Magnesium, RBC
- Zinc
- LIVER AND PROTEIN CHEMISTRY
- ALT (SGPT)
- AST (SGOT)
- Alkaline Phosphatase
- GGT
- Total Bilirubin
- Albumin
- Globulin
- Total Protein
- Albumin/Globulin Ratio
- LIPIDS AND CARDIOVASCULAR
- Total Cholesterol
- LDL Cholesterol
- HDL Cholesterol
- Triglycerides
- Non-HDL Cholesterol
- Total Cholesterol/HDL Ratio
- Apolipoprotein B (ApoB)
- Lipoprotein(a)
- LDL Particle Number
- LDL Small
- LDL Medium
- LDL Peak Size
- LDL Pattern
- HDL Large
- METABOLIC HEALTH
- Glucose
- Hemoglobin A1c
- Insulin
- Leptin
- Uric Acid
- Blood Ketones (Beta-Hydroxybutyrate)
- Glucose Ketone Index (GKI)
- INFLAMMATION AND AUTOIMMUNE
- C-Reactive Protein (CRP)
- High-Sensitivity CRP (hs-CRP)
- Erythrocyte Sedimentation Rate (ESR)
- ANA Screen
- ANA Titer
- ANA Pattern
- Anti-dsDNA Antibodies
- DNA Antibody, Crithidia IFA
- Rheumatoid Factor (RF)
- Rheumatoid Factor IgA
- Rheumatoid Factor IgG
- Rheumatoid Factor IgM
- CCP Antibody
- Mutated Citrullinated Vimentin Antibody
- Complement C3
- Complement C4
- Cardiolipin IgA Antibody
- Cardiolipin IgG Antibody
- Cardiolipin IgM Antibody
- Beta-2 Glycoprotein I IgA Antibody
- Beta-2 Glycoprotein I IgG Antibody
- Beta-2 Glycoprotein I IgM Antibody
- Smith (Sm) Antibody
- RNP Antibody
- Sm/RNP Antibody
- SSA (Ro) Antibody
- SSB (La) Antibody
- Scl-70 Antibody
- Centromere B Antibody
- Chromatin Antibody
- Jo-1 Antibody
- THYROID FUNCTION – TSH
- Free T4
- Free T3
- Thyroid Peroxidase (TPO) Antibodies
- Thyroglobulin Antibodies
- IRON AND NUTRITIONAL
- Iron
- Ferritin
- Total Iron Binding Capacity (TIBC)
- Unsaturated Iron Binding Capacity (UIBC)
- Iron Saturation (%)
- Vitamin B12
- Folate
- Methylmalonic Acid (MMA)
- Homocysteine
- Vitamin D, 25-OH
- FATTY ACID PROFILE
- Omega-3 Total / OmegaCheck
- Omega-3 EPA
- Omega-3 DHA
- Omega-3 DPA
- Omega-6 Total
- Omega-6 Linoleic Acid
- Omega-6 Arachidonic Acid
- Omega-6/Omega-3 Ratio
- Arachidonic Acid/EPA Ratio
- HORMONES AND MALE HEALTH
- PSA Total
- PSA Free
- PSA Free Percentage
- Testosterone Total
- Testosterone Free
- Sex Hormone Binding Globulin (SHBG)
- DHEA Sulfate
- Estradiol
- FSH – LH
- Prolactin
- Cortisol
- PANCREATIC ENZYMES
- Amylase
- Lipase
- URINALYSIS
- Urine Appearance
- Urine Color
- Urine Specific Gravity
- Urine pH
- Urine Protein
- Urine Glucose
- Urine Ketones
- Urine Occult Blood
- Urine Bilirubin
- Urine Nitrite
- Urine Leukocyte Esterase
- Urine RBC
- Urine WBC
- Urine Bacteria
- Urine Hyaline Casts
- Urine Squamous Epithelial Cells
- ENVIRONMENTAL TOXINS
- Lead
- Mercury
- ADDITIONAL MARKERS — IDENTIFIED IN REPORTS #2–15
- ANA Direct
- Aldolase
- B-Type Natriuretic Peptide (BNP)
- Blood Culture Aerobic
- Blood Culture Anaerobic
- Blood Culture Overall
- Creatine Kinase (CK)
- QuantiFERON Mitogen Control
- QuantiFERON Nil Control
- QuantiFERON TB1 Antigen
- QuantiFERON TB2 Antigen
- QuantiFERON-TB Gold Plus Overall
- SARS-CoV-2 IgG Antibody
- SARS-CoV-2 IgM Antibody
- Serum Protein Electrophoresis M-spike
- Urine Culture
- Urine Myoglobin
- 14.3.3 ETA RA Marker
- ABO Blood Group
- Rh Factor
- CYP2C19 Genotype
- CYP2C19 Phenotype
- Serum Tryptase
- Urine N-Methylhistamine
- 24h Urine Creatinine
- Urine Creatinine Concentration
- 24h Urine Volume
- Urine Collection Duration
- Urine 2,3-Dinor-11β-Prostaglandin F2α
- Urine Leukotriene E4
- ACTH
COMPLETE BLOOD COUNT
1. White Blood Cell Count (WBC)
| WBC Value (K/µL) | Laboratory Report |
|---|---|
| 4.4 | Report #1 |
| 6.1 | Report #2 |
| 4.2 | Report #3 |
| 4.3 | Report #4 |
| 4.8 | Report #5 |
| 4.5 | Report #6 |
| 4.9 | Report #7 |
| 6.7 | Report #8 |
| 5.5 | Report #10 |
| 7.1 | Report #11 |
| 7.8 | Report #13 |
| 5.7 | Report #15 |
| 5.9 | Report #16 |
| 6.4 | Report #20 |
| 6.1 | Report #27 |
| 5.9 | Report #28 |
| 6.4 | Report #29 |
| 5.9 | Report #30 |
| 4.3 | Report #31 |
| 4.8 | Report #32 |
| 5.2 | Report #33 |
| 4.7 | Report #34 |
| 4.2 | Report #36 |
| 4.27 | Report #39 |
| 4.6 | Report #40 |
2. Red Blood Cell Count (RBC)
| RBC Value (M/µL) | Laboratory Report |
|---|---|
| 4.11 | Report #11 |
| 3.84 | Report #13 |
| 4.25 | Report #15 |
| 4.37 | Report #16 |
| 4.25 | Report #20 |
| 4.05 | Report #28 |
| 3.96 | Report #29 |
| 3.73 | Report #30 |
| 4.36 | Report #31 |
| 3.71 | Report #32 |
| 3.71 | Report #33 |
| 4.15 | Report #34 |
| 4.3 | Report #36 |
| 4.18 | Report #39 |
| 3.97 | Report #40 |
3. Hemoglobin
| Hemoglobin Value (g/dL) | Laboratory Report |
|---|---|
| 13.0 | Report #1 |
| 12.8 | Report #2 |
| 12.7 | Report #3 |
| 13.3 | Report #4 |
| 12.5 | Report #5 |
| 12.8 | Report #6 |
| 12.8 | Report #7 |
| 13.1 | Report #8 |
| 13.5 | Report #10 |
| 12.3 | Report #11 |
| 11.4 | Report #13 |
| 12.9 | Report #15 |
| 13.4 | Report #16 |
| 13.1 | Report #20 |
| 13.8 | Report #27 |
| 12.3 | Report #28 |
| 11.8 | Report #29 |
| 11.3 | Report #30 |
| 13.1 | Report #31 |
| 11.2 | Report #32 |
| 11.3 | Report #33 |
| 12.6 | Report #34 |
| 12.9 | Report #36 |
| 13.6 | Report #38 |
| 12.4 | Report #39 |
| 12.3 | Report #40 |
4. Hematocrit
| Hematocrit Value (%) | Laboratory Report |
|---|---|
| 40.4 | Report #1 |
| 39.3 | Report #2 |
| 39.5 | Report #3 |
| 39.7 | Report #4 |
| 39.4 | Report #5 |
| 40.8 | Report #6 |
| 39.8 | Report #7 |
| 39.0 | Report #8 |
| 40.6 | Report #10 |
| 37.9 | Report #11 |
| 33.7 | Report #13 |
| 39.2 | Report #15 |
| 40.8 | Report #16 |
| 39.7 | Report #20 |
| 42.1 | Report #27 |
| 36.5 | Report #28 |
| 35.6 | Report #29 |
| 33.9 | Report #30 |
| 39.7 | Report #31 |
| 35.4 | Report #32 |
| 36.1 | Report #33 |
| 39.3 | Report #34 |
| 40.3 | Report #36 |
| 42.8 | Report #38 |
| 38.6 | Report #39 |
| 37.2 | Report #40 |
5. Mean Corpuscular Volume (MCV)
| MCV Value (fL) | Laboratory Report |
|---|---|
| 93 | Report #20 |
| 90 | Report #29 |
| 91 | Report #30 |
| 91 | Report #31 |
| 95 | Report #32 |
| 97 | Report #33 |
| 92.3 | Report #39 |
| 93.7 | Report #40 |
6. Mean Corpuscular Hemoglobin (MCH)
| MCH Value (pg) | Laboratory Report |
|---|---|
| 30.5 | Report #33 |
| 29.7 | Report #39 |
| 31.0 | Report #40 |
7. Mean Corpuscular Hemoglobin Concentration (MCHC)
| MCHC Value (g/dL) | Laboratory Report |
|---|---|
| 31.3 | Report #33 |
| 32.1 | Report #39 |
| 33.1 | Report #40 |
8. Red Cell Distribution Width (RDW)
| RDW Value (%) | Laboratory Report |
|---|---|
| 13.0 | Report #33 |
| 13.0 | Report #39 |
| 13.9 | Report #40 |
9. Platelet Count
| Platelet Count (K/µL) | Laboratory Report |
|---|---|
| 200 | Report #1 |
| 209 | Report #2 |
| 220 | Report #3 |
| 223 | Report #4 |
| 234 | Report #5 |
| 237 | Report #6 |
| 249 | Report #7 |
| 228 | Report #8 |
| 222 | Report #10 |
| 298 | Report #11 |
| 309 | Report #13 |
| 193 | Report #15 |
| 229 | Report #16 |
| 228 | Report #20 |
| 262 | Report #27 |
| 232 | Report #28 |
| 228 | Report #29 |
| 295 | Report #30 |
| 183 | Report #31 |
| 191 | Report #32 |
| 197 | Report #33 |
| 208 | Report #34 |
| 187 | Report #36 |
| 182 | Report #39 |
| 170 | Report #40 |
10. Mean Platelet Volume (MPV)
| MPV Value (fL) | Laboratory Report |
|---|---|
| 10.0 | Report #39 |
| 10.3 | Report #40 |
11. Nucleated Red Blood Cells (NRBC)
| NRBC Value (%) | Laboratory Report |
|---|---|
| 0.0 | Report #39 |
WHITE BLOOD CELL DIFFERENTIAL
12. Neutrophils (%)
| Neutrophils (%) | Laboratory Report |
|---|---|
| 42 | Report #32 |
| 52 | Report #34 |
| 51.8 | Report #39 |
| 49.9 | Report #40 |
13. Lymphocytes (%)
| Lymphocytes (%) | Laboratory Report |
|---|---|
| 31 | Report #32 |
| 29 | Report #34 |
| 32.1 | Report #39 |
| 35.1 | Report #40 |
14. Monocytes (%)
| Monocytes (%) | Laboratory Report |
|---|---|
| 7 | Report #32 |
| 11 | Report #34 |
| 11.0 | Report #39 |
| 9 | Report #40 |
15. Eosinophils (%)
| Eosinophils (%) | Laboratory Report |
|---|---|
| 19 | Report #32 |
| 8 | Report #34 |
| 4.2 | Report #39 |
| 5.3 | Report #40 |
16. Basophils (%)
| Basophils (%) | Laboratory Report |
|---|---|
| 0.7 | Report #39 |
| 0.7 | Report #40 |
17. Absolute Neutrophils
| Absolute Neutrophils — Recorded Value | Laboratory Report |
|---|---|
| 2.21 | Report #39 |
| 2295 | Report #40 |
18. Absolute Lymphocytes
| Absolute Lymphocytes — Recorded Value | Laboratory Report |
|---|---|
| 1.37 | Report #39 |
| 1615 | Report #40 |
19. Absolute Monocytes
| Absolute Monocytes — Recorded Value | Laboratory Report |
|---|---|
| 0.47 | Report #39 |
| 414 | Report #40 |
20. Absolute Eosinophils
| Absolute Eosinophils — Recorded Value | Laboratory Report |
|---|---|
| 0.9 | Report #32 |
| 0.4 | Report #34 |
| 0.18 | Report #39 |
| 244 | Report #40 |
21. Absolute Basophils
| Absolute Basophils — Recorded Value | Laboratory Report |
|---|---|
| 0.03 | Report #39 |
| 32 | Report #40 |
Kidney Function
22. Blood Urea Nitrogen (BUN)
| BUN Value (mg/dL) | Laboratory Report |
|---|---|
| 19 | Report #1 |
| 23 | Report #2 |
| 21 | Report #3 |
| 18 | Report #4 |
| 23 | Report #5 |
| 20 | Report #6 |
| 20 | Report #7 |
| 16 | Report #8 |
| 17 | Report #10 |
| 16 | Report #11 |
| 13 | Report #13 |
| 16 | Report #16 |
| 18 | Report #20 |
| 21 | Report #27 |
| 26 | Report #28 |
| 28 | Report #30 |
| 23 | Report #31 |
| 40 | Report #32 |
| 33 | Report #34 |
| 30 | Report #36 |
| 32 | Report #39 |
23. Creatinine
| Creatinine Value (mg/dL) | Laboratory Report |
|---|---|
| 1.01 | Report #1 |
| 0.93 | Report #2 |
| 1.06 | Report #3 |
| 0.82 | Report #4 |
| 0.96 | Report #5 |
| 0.93 | Report #6 |
| 0.97 | Report #7 |
| 1.04 | Report #8 |
| 0.91 | Report #10 |
| 0.92 | Report #11 |
| 0.86 | Report #13 |
| 0.86 | Report #16 |
| 0.93 | Report #20 |
| 0.91 | Report #27 |
| 1.03 | Report #28 |
| 0.93 | Report #30 |
| 1.01 | Report #31 |
| 0.92 | Report #32 |
| 0.88 | Report #34 |
| 0.90 | Report #36 |
| 0.90 | Report #39 |
| 1.09 | Report #40 |
24. BUN/Creatinine Ratio
| BUN/Creatinine Ratio | Laboratory Report |
|---|---|
| 25 | Report #2 |
| 43 | Report #32 |
| 38 | Report #34 |
| 34 | Report #40 |
25. Estimated Glomerular Filtration Rate (eGFR)
| eGFR Value (mL/min/1.73 m²) | Laboratory Report |
|---|---|
| 72 | Report #1 |
| 79 | Report #2 |
| 67 | Report #3 |
| 84 | Report #4 |
| 74 | Report #5 |
| 77 | Report #6 |
| 72 | Report #7 |
| 66 | Report #8 |
| 77 | Report #10 |
| 76 | Report #11 |
| 79 | Report #13 |
| 79 | Report #16 |
| 80 | Report #20 |
| 82 | Report #27 |
| 71 | Report #28 |
| 80 | Report #30 |
| 72 | Report #31 |
| 81 | Report #32 |
| 83 | Report #34 |
| 82 | Report #36 |
| 81.64 | Report #39 |
| 64 | Report #40 |
26. Urine Albumin / Microalbumin
| Urine Albumin / Microalbumin Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
27. Urine Albumin/Creatinine Ratio
| Urine Albumin/Creatinine Ratio | Laboratory Report |
|---|---|
| No recorded measurements | — |
Electrolytes and Minerals
28. Sodium
| Sodium Value (mmol/L) | Laboratory Report |
|---|---|
| 129 | Report #13 |
| 137 | Report #16 |
| 138 | Report #20 |
| 139 | Report #27 |
| 140 | Report #28 |
| 138 | Report #36 |
| 140 | Report #39 |
| 137 | Report #40 |
29. Potassium
| Potassium Value (mmol/L) | Laboratory Report |
|---|---|
| 4.2 | Report #13 |
| 4.4 | Report #16 |
| 4.2 | Report #20 |
| 4.5 | Report #27 |
| 4.6 | Report #28 |
| 4.5 | Report #36 |
| 4.4 | Report #39 |
| 4.3 | Report #40 |
30. Chloride
| Chloride Value (mmol/L) | Laboratory Report |
|---|---|
| 91 | Report #13 |
| 98 | Report #16 |
| 100 | Report #20 |
| 98 | Report #27 |
| 99 | Report #28 |
| 102 | Report #39 |
| 102 | Report #40 |
31. Carbon Dioxide (CO₂)
| Carbon Dioxide Value (mmol/L) | Laboratory Report |
|---|---|
| 27 | Report #16 |
| 27 | Report #27 |
| 28 | Report #28 |
| 29 | Report #39 |
32. Calcium
| Calcium Value (mg/dL) | Laboratory Report |
|---|---|
| 9.0 | Report #20 |
| 9.8 | Report #39 |
| 9.5 | Report #40 |
33. Magnesium, Serum
| Magnesium Value (mg/dL) | Laboratory Report |
|---|---|
| 2.1 | Report #2 |
| 2.1 | Report #3 |
| 2.1 | Report #11 |
| 2.3 | Report #31 |
| 2.0 | Report #32 |
| 2.2 | Report #34 |
34. Magnesium, RBC
| Magnesium, RBC Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
35. Zinc
| Zinc Value (µg/dL) | Laboratory Report |
|---|---|
| 107 | Report #32 |
| 121 | Report #34 |
| 139 | Report #36 |
Liver and Protein Chemistry
36. ALT (SGPT)
| ALT Value (U/L) | Laboratory Report |
|---|---|
| 23 | Report #1 |
| 28 | Report #2 |
| 14 | Report #3 |
| 15 | Report #4 |
| 15 | Report #5 |
| 16 | Report #6 |
| 14 | Report #7 |
| 26 | Report #8 |
| 21 | Report #10 |
| 13 | Report #11 |
| 14 | Report #13 |
| 25 | Report #16 |
| 20 | Report #27 |
| 17 | Report #28 |
| 18 | Report #30 |
| 30 | Report #31 |
| 27 | Report #34 |
| 27 | Report #36 |
| 28 | Report #39 |
| 20 | Report #40 |
37. AST (SGOT)
| AST Value (U/L) | Laboratory Report |
|---|---|
| 25 | Report #1 |
| 39 | Report #2 |
| 25 | Report #3 |
| 24 | Report #4 |
| 23 | Report #5 |
| 26 | Report #6 |
| 23 | Report #7 |
| 32 | Report #8 |
| 35 | Report #10 |
| 22 | Report #11 |
| 20 | Report #13 |
| 28 | Report #16 |
| 27 | Report #20 |
| 28 | Report #27 |
| 27 | Report #28 |
| 27 | Report #30 |
| 31 | Report #31 |
| 31 | Report #34 |
| 32 | Report #36 |
| 27 | Report #39 |
| 23 | Report #40 |
38. Alkaline Phosphatase
| Alkaline Phosphatase (U/L) | Laboratory Report |
|---|---|
| 61 | Report #1 |
| 67 | Report #2 |
| 73 | Report #3 |
| 64 | Report #4 |
| 60 | Report #5 |
| 65 | Report #6 |
| 59 | Report #7 |
| 65 | Report #8 |
| 64 | Report #10 |
| 71 | Report #11 |
| 65 | Report #13 |
| 65 | Report #16 |
| 67 | Report #20 |
| 89 | Report #27 |
| 75 | Report #28 |
| 61 | Report #30 |
| 67 | Report #31 |
| 59 | Report #34 |
| 51 | Report #39 |
| 51 | Report #40 |
GGT
39. Gamma-Glutamyl Transferase (GGT)
| GGT Value (U/L) | Laboratory Report |
|---|---|
| 11 | Report #20 |
| 10 | Report #35 |
40. Total Bilirubin
| Total Bilirubin (mg/dL) | Laboratory Report |
|---|---|
| 0.5 | Report #1 |
| 0.4 | Report #2 |
| 0.5 | Report #3 |
| 0.3 | Report #4 |
| 0.5 | Report #5 |
| 0.4 | Report #6 |
| 0.3 | Report #7 |
| 0.3 | Report #8 |
| 0.3 | Report #10 |
| 0.3 | Report #11 |
| 0.4 | Report #13 |
| 0.4 | Report #16 |
| 0.5 | Report #20 |
| 0.4 | Report #27 |
| 0.4 | Report #28 |
| 0.2 | Report #30 |
| 0.5 | Report #31 |
| 0.3 | Report #34 |
| 0.7 | Report #39 |
| 0.6 | Report #40 |
41. Albumin
| Albumin Value (g/dL) | Laboratory Report |
|---|---|
| 4.0 | Report #39 |
| 4.0 | Report #40 |
42. Globulin
| Globulin Value (g/dL) | Laboratory Report |
|---|---|
| 4.0 | Report #13 |
| 3.2 | Report #40 |
43. Total Protein
| Total Protein Value (g/dL) | Laboratory Report |
|---|---|
| 7.1 | Report #39 |
| 7.2 | Report #40 |
44. Albumin/Globulin Ratio
| Albumin/Globulin Ratio | Laboratory Report |
|---|---|
| 0.9 | Report #13 |
| 1.3 | Report #40 |
Lipids and Cardiovascular
45. Total Cholesterol
| Total Cholesterol (mg/dL) | Laboratory Report |
|---|---|
| 144 | Report #1 |
| 215 | Report #2 |
| 177 | Report #3 |
| 189 | Report #4 |
| 162 | Report #5 |
| 185 | Report #6 |
| 208 | Report #7 |
| 168 | Report #8 |
| 177 | Report #13 |
| 226 | Report #27 |
| 249 | Report #31 |
| 220 | Report #32 |
| 243 | Report #34 |
| 254 | Report #36 |
| 256 | Report #37 |
| 284 | Report #38 |
| 252 | Report #39 |
| 249 | Report #40 |
46. LDL Cholesterol
| LDL Cholesterol (mg/dL) | Laboratory Report |
|---|---|
| 68 | Report #1 |
| 138 | Report #2 |
| 102 | Report #3 |
| 107 | Report #4 |
| 91 | Report #5 |
| 101 | Report #6 |
| 126 | Report #7 |
| 89 | Report #8 |
| 105 | Report #13 |
| 151 | Report #27 |
| 151 | Report #31 |
| 136 | Report #32 |
| 141 | Report #34 |
| 150 | Report #36 |
| 151 | Report #37 |
| 183 | Report #38 |
| 168 | Report #39 |
| 157 | Report #40 |
47. HDL Cholesterol
| HDL Cholesterol (mg/dL) | Laboratory Report |
|---|---|
| 66 | Report #1 |
| 63 | Report #2 |
| 64 | Report #3 |
| 73 | Report #4 |
| 62 | Report #5 |
| 73 | Report #6 |
| 71 | Report #7 |
| 63 | Report #8 |
| 60 | Report #13 |
| 60 | Report #27 |
| 88 | Report #31 |
| 75 | Report #32 |
| 94 | Report #34 |
| 92 | Report #36 |
| 89 | Report #37 |
| 82 | Report #38 |
| 73 | Report #39 |
| 78 | Report #40 |
48. Triglycerides
| Triglycerides (mg/dL) | Laboratory Report |
|---|---|
| 52 | Report #1 |
| 68 | Report #2 |
| 53 | Report #3 |
| 45 | Report #4 |
| 44 | Report #5 |
| 55 | Report #6 |
| 57 | Report #7 |
| 80 | Report #8 |
| 64 | Report #13 |
| 86 | Report #27 |
| 60 | Report #31 |
| 50 | Report #32 |
| 52 | Report #34 |
| 41 | Report #36 |
| 60 | Report #37 |
| 85 | Report #38 |
| 54 | Report #39 |
| 45 | Report #40 |
49. Non-HDL Cholesterol
| Non-HDL Cholesterol (mg/dL) | Laboratory Report |
|---|---|
| 162 | Report #36 |
| 167 | Report #37 |
| 171 | Report #40 |
50. Total Cholesterol/HDL Ratio
| Total Cholesterol/HDL Ratio | Laboratory Report |
|---|---|
| 2.9 | Report #37 |
| 3.5 | Report #39 |
| 3.2 | Report #40 |
51. Apolipoprotein B (ApoB)
| ApoB Value (mg/dL) | Laboratory Report |
|---|---|
| 142 | Report #36 |
| 139 | Report #38 |
52. Lipoprotein(a)
| Lipoprotein(a) — Recorded Value | Laboratory Report |
|---|---|
| 14 | Report #36 |
| Low | Report #38 |
The master records Report #38 qualitatively as “Low.” The numerical value and units for Report #36 should be checked before creating a comparative graph.
53. LDL Particle Number
| LDL Particle Number (nmol/L) | Laboratory Report |
|---|---|
| 1836 | Report #36 |
| 2483 | Report #38 |
54. LDL Small
| LDL Small — Recorded Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
55. LDL Medium
| LDL Medium — Recorded Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
56. LDL Peak Size
| LDL Peak Size — Recorded Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
57. LDL Pattern
| LDL Pattern — Recorded Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
58. HDL Large
| HDL Large — Recorded Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
Metabolic Health
59. Glucose
| Glucose Value (mg/dL) | Laboratory Report |
|---|---|
| 78 | Report #1 |
| 80 | Report #2 |
| 87 | Report #3 |
| 90 | Report #4 |
| 84 | Report #5 |
| 86 | Report #6 |
| 83 | Report #7 |
| 80 | Report #8 |
| 58 | Report #10 |
| 94 | Report #11 |
| 90 | Report #13 |
| 85 | Report #16 |
| 96 | Report #27 |
| 83 | Report #28 |
| 87 | Report #30 |
| 87 | Report #34 |
| 93 | Report #36 |
| 66 | Report #38 |
| 84 | Report #39 |
| 84 | Report #40 |
60. Hemoglobin A1c (HbA1c)
| Hemoglobin A1c Value (%) | Laboratory Report |
|---|---|
| 5.9 | Report #2 |
| 5.7 | Report #3 |
| 5.1 | Report #4 |
| 5.6 | Report #5 |
| 5.3 | Report #6 |
| 5.5 | Report #7 |
| 5.4 | Report #8 |
| 5.6 | Report #10 |
| 5.8 | Report #13 |
| 5.7 | Report #27 |
| 5.6 | Report #28 |
| 5.8 | Report #30 |
| 5.4 | Report #33 |
| 5.8 | Report #34 |
| 5.4 | Report #36 |
| 5.5 | Report #38 |
| 5.4 | Report #40 |
61. Insulin
| Insulin Value (µIU/mL) | Laboratory Report |
|---|---|
| 4.6 | Report #36 |
| 2.1 | Report #38 |
| 2.1 | Report #40 |
62. Leptin
| Leptin — Recorded Value | Laboratory Report |
|---|---|
| 1.1 | Report #35 |
| 1.1 | Report #36 |
| 0.4 | Report #38 |
The leptin values are reproduced as recorded. Units should be confirmed from the original reports before preparing comparative graphs.
63. Uric Acid
| Uric Acid Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
64. Blood Ketones (Beta-Hydroxybutyrate)
| Blood Ketones Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
65. Glucose Ketone Index (GKI)
| Glucose Ketone Index | Laboratory Report |
|---|---|
| No recorded measurements | — |
Inflammation and Autoimmune
66. C-Reactive Protein (CRP)
| CRP Value (mg/L) | Laboratory Report |
|---|---|
| 37 | Report #11 |
| 7 | Report #12 |
| 32 | Report #13 |
| 2 | Report #15 |
| 4 | Report #16 |
| 1 | Report #17 |
| 3 | Report #18 |
| 2 | Report #19 |
| 2 | Report #20 |
| 6 | Report #22 |
| 2 | Report #32 |
| 1 | Report #34 |
| <1.0 | Report #39 |
67. High-Sensitivity CRP (hs-CRP)
| hs-CRP Value (mg/L) | Laboratory Report |
|---|---|
| 1.8 | Report #36 |
| 2.3 | Report #40 |
68. Erythrocyte Sedimentation Rate (ESR)
| ESR Value | Laboratory Report |
|---|---|
| 57 | Report #11 |
| 19 | Report #12 |
| 71 | Report #13 |
| 15 | Report #15 |
| 6 | Report #16 |
| 13 | Report #17 |
| 16 | Report #18 |
| 4 | Report #19 |
| 8 | Report #20 |
| 13 | Report #22 |
| 27 | Report #30 |
| 6 | Report #38 |
| 18 | Report #39 |
69. ANA Screen
| ANA Screen Result | Laboratory Report |
|---|---|
| Positive | Report #35 |
| Positive | Report #36 |
| Positive | Report #38 |
70. ANA Titer
| ANA Titer | Laboratory Report |
|---|---|
| 1:320 | Report #35 |
| 1:320 | Report #36 |
| 1:1280 | Report #38 |
| 1:640 | Report #39 |
71. ANA Pattern
| ANA Pattern | Laboratory Report |
|---|---|
| Homogeneous | Report #35 |
| Homogeneous | Report #36 |
| Homogeneous | Report #38 |
| Homogeneous | Report #39 |
72. Anti-dsDNA Antibodies
| Anti-dsDNA Result | Laboratory Report |
|---|---|
| 3 | Report #15 |
| Negative | Report #38 |
| 2.6 | Report #39 |
Units and testing methods differ between reports; values are preserved as recorded.
73. DNA Antibody, Crithidia IFA
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
74. Rheumatoid Factor (RF)
| Rheumatoid Factor Result | Laboratory Report |
|---|---|
| <10 | Report #11 |
| Negative | Report #35 |
| Negative | Report #36 |
| Negative | Report #38 |
75. Rheumatoid Factor IgA
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
76. Rheumatoid Factor IgG
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
77. Rheumatoid Factor IgM
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
78. CCP Antibody
| CCP Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #38 |
79. Mutated Citrullinated Vimentin Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
80. Complement C3
| Complement C3 Value | Laboratory Report |
|---|---|
| 104 | Report #15 |
81. Complement C4
| Complement C4 Value | Laboratory Report |
|---|---|
| 25 | Report #15 |
82. Cardiolipin IgA Antibody
| Cardiolipin IgA Result | Laboratory Report |
|---|---|
| <9 | Report #39 |
83. Cardiolipin IgG Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
84. Cardiolipin IgM Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
85. Beta-2 Glycoprotein I IgA Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
86. Beta-2 Glycoprotein I IgG Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
87. Beta-2 Glycoprotein I IgM Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
88. Smith (Sm) Antibody
| Smith (Sm) Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #38 |
89. RNP Antibody
| RNP Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #38 |
90. Sm/RNP Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
91. SSA (Ro) Antibody
| SSA (Ro) Antibody Result | Laboratory Report |
|---|---|
| <0.2 | Report #18 |
| Negative | Report #38 |
92. SSB (La) Antibody
| SSB (La) Antibody Result | Laboratory Report |
|---|---|
| <0.2 | Report #18 |
| Negative | Report #38 |
93. Scl-70 Antibody
| Scl-70 Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #38 |
94. Centromere B Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
95. Chromatin Antibody
| Result | Laboratory Report |
|---|---|
| No recorded measurements | — |
96. Jo-1 Antibody
| Jo-1 Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #38 |
Thyroid Function
97. Thyroid-Stimulating Hormone (TSH)
| TSH Value (µIU/mL) | Laboratory Report |
|---|---|
| 1.540 | Report #1 |
| 0.647 | Report #2 |
| 0.899 | Report #3 |
| 2.410 | Report #4 |
| 1.910 | Report #5 |
| 2.170 | Report #6 |
| 2.810 | Report #7 |
| 1.950 | Report #8 |
| 2.140 | Report #10 |
| 3.060 | Report #11 |
| 4.170 | Report #13 |
| 0.912 | Report #17 |
| 1.300 | Report #27 |
| 1.680 | Report #28 |
| 1.090 | Report #30 |
| 0.819 | Report #32 |
| 1.110 | Report #34 |
| 0.67 | Report #39 |
98. Free T4 (Thyroxine)
| Free T4 Value (ng/dL) | Laboratory Report |
|---|---|
| 1.16 | Report #6 |
| 1.13 | Report #7 |
| 1.16 | Report #8 |
| 1.23 | Report #10 |
| 1.19 | Report #11 |
| 1.11 | Report #13 |
| 1.33 | Report #17 |
| 1.36 | Report #27 |
| 1.12 | Report #28 |
| 1.27 | Report #30 |
| 1.31 | Report #32 |
| 1.24 | Report #34 |
| 1.11 | Report #39 |
99. Free T3 (Triiodothyronine)
| Free T3 Value (pg/mL) | Laboratory Report |
|---|---|
| 2.1 | Report #36 |
| 1.6 | Report #38 |
| 2.27 | Report #39 |
100. Thyroid Peroxidase Antibodies (TPO)
| TPO Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #35 |
| Negative | Report #36 |
101. Thyroglobulin Antibodies
| Thyroglobulin Antibody Result | Laboratory Report |
|---|---|
| Negative | Report #35 |
| Negative | Report #36 |
Iron and Nutritional Markers
102. Iron
| Iron Value (µg/dL) | Laboratory Report |
|---|---|
| 118 | Report #15 |
| 95 | Report #31 |
| 121 | Report #32 |
| 103 | Report #39 |
103. Ferritin
| Ferritin Value (ng/mL) | Laboratory Report |
|---|---|
| 43 | Report #15 |
| 144 | Report #30 |
| 95 | Report #31 |
| 152 | Report #32 |
| 107 | Report #36 |
| 117.3 | Report #39 |
104. Total Iron Binding Capacity (TIBC)
| TIBC Value (µg/dL) | Laboratory Report |
|---|---|
| 313 | Report #15 |
| 287 | Report #31 |
| 251 | Report #32 |
| 298 | Report #39 |
105. Unsaturated Iron Binding Capacity (UIBC)
| UIBC Value (µg/dL) | Laboratory Report |
|---|---|
| 195 | Report #39 |
106. Iron Saturation
| Iron Saturation (%) | Laboratory Report |
|---|---|
| 38 | Report #15 |
| 33 | Report #31 |
| 48 | Report #32 |
| 35 | Report #39 |
107. Vitamin B12
| Vitamin B12 Value (pg/mL) | Laboratory Report |
|---|---|
| >2000 | Report #31 |
| 1208 | Report #32 |
| 1062 | Report #34 |
108. Folate
| Folate Value (ng/mL) | Laboratory Report |
|---|---|
| >20.0 | Report #31 |
| 11.9 | Report #32 |
| 9.7 | Report #34 |
109. Methylmalonic Acid (MMA)
| MMA Value — Recorded | Laboratory Report |
|---|---|
| 112 | Report #35 |
| 112 | Report #36 |
110. Homocysteine
| Homocysteine Value — Recorded | Laboratory Report |
|---|---|
| 13.4 | Report #36 |
111. Vitamin D, 25-OH
| Vitamin D Value (ng/mL) | Laboratory Report |
|---|---|
| 133 | Report #36 |
Fatty Acid Profile
112. Omega-3 Total / OmegaCheck
| Omega-3 Total / OmegaCheck Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
113. Omega-3 EPA
| EPA Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
114. Omega-3 DHA
| DHA Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
115. Omega-3 DPA
| DPA Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
116. Omega-6 Total
| Omega-6 Total Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
117. Omega-6 Linoleic Acid
| Linoleic Acid Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
118. Omega-6 Arachidonic Acid
| Arachidonic Acid Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
119. Omega-6/Omega-3 Ratio
| Omega-6/Omega-3 Ratio | Laboratory Report |
|---|---|
| No recorded measurements | — |
120. Arachidonic Acid/EPA Ratio
| Arachidonic Acid/EPA Ratio | Laboratory Report |
|---|---|
| No recorded measurements | — |
Harmones and Male Health
121. PSA Total
| PSA Total Value (ng/mL) | Laboratory Report |
|---|---|
| 2.2 | Report #1 |
| 2.3 | Report #2 |
| 2.7 | Report #3 |
| 2.7 | Report #4 |
| 3.1 | Report #5 |
| 3.4 | Report #6 |
| 4.4 | Report #7 |
| 3.8 | Report #8 |
| 3.5 | Report #10 |
| 4.0 | Report #36 |
122. PSA Free
| PSA Free Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
123. PSA Free Percentage
| PSA Free Percentage (%) | Laboratory Report |
|---|---|
| No recorded measurements | — |
124. Testosterone Total
| Testosterone Total Value (ng/dL) | Laboratory Report |
|---|---|
| 407 | Report #36 |
125. Testosterone Free
| Testosterone Free Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
126. Sex Hormone Binding Globulin (SHBG)
| SHBG Value — Recorded | Laboratory Report |
|---|---|
| 95 | Report #36 |
127. DHEA Sulfate
| DHEA Sulfate Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
128. Estradiol
| Estradiol Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
FSH
129. Follicle-Stimulating Hormone (FSH)
| FSH Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
130. Luteinizing Hormone (LH)
| LH Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
131. Prolactin
| Prolactin Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
132. Cortisol
| Cortisol Value (µg/dL) | Laboratory Report |
|---|---|
| 7.1 | Report #31 |
Pancreatic Enzymes
133. Amylase
| Amylase Value (U/L) | Laboratory Report |
|---|---|
| No recorded measurements | — |
134. Lipase
| Lipase Value (U/L) | Laboratory Report |
|---|---|
| No recorded measurements | — |
Urinalysis
135. Urine Appearance
| Urine Appearance | Laboratory Report |
|---|---|
| Cloudy | Report #27 |
| Cloudy | Report #28 |
| Clear | Report #34 |
| Cloudy | Report #40 |
136. Urine Color
| Urine Color | Laboratory Report |
|---|---|
| Yellow | Report #40 |
137. Urine Specific Gravity
| Urine Specific Gravity | Laboratory Report |
|---|---|
| 1.008 | Report #40 |
138. Urine pH
| Urine pH Value | Laboratory Report |
|---|---|
| 8.0 | Report #4 |
| 8.0 | Report #6 |
| 8.0 | Report #7 |
| 7.5 | Report #8 |
| 8.0 | Report #27 |
| 8.0 | Report #28 |
| 8.0 | Report #31 |
| 5.5 | Report #36 |
| 5.5 | Report #40 |
139. Urine Protein
| Urine Protein Result | Laboratory Report |
|---|---|
| Negative | Report #15 |
| Negative | Report #34 |
| Negative | Report #40 |
140. Urine Glucose
| Urine Glucose Result | Laboratory Report |
|---|---|
| Negative | Report #15 |
| Negative | Report #34 |
| Negative | Report #40 |
141. Urine Ketones
| Urine Ketones Result | Laboratory Report |
|---|---|
| Negative | Report #15 |
| Negative | Report #34 |
| Negative | Report #40 |
142. Urine Occult Blood
| Urine Occult Blood Result | Laboratory Report |
|---|---|
| Negative | Report #15 |
| Negative | Report #34 |
| Negative | Report #40 |
143. Urine Bilirubin
| Urine Bilirubin Result | Laboratory Report |
|---|---|
| Negative | Report #40 |
144. Urine Nitrite
| Urine Nitrite Result | Laboratory Report |
|---|---|
| Negative | Report #34 |
| Negative | Report #40 |
145. Urine Leukocyte Esterase
| Urine Leukocyte Esterase Result | Laboratory Report |
|---|---|
| Negative | Report #34 |
| Negative | Report #40 |
146. Urine RBC
| Urine RBC Result | Laboratory Report |
|---|---|
| None | Report #15 |
| None seen | Report #40 |
147. Urine WBC
| Urine WBC Result | Laboratory Report |
|---|---|
| None | Report #15 |
| None seen | Report #40 |
148. Urine Bacteria
| Urine Bacteria Result | Laboratory Report |
|---|---|
| None | Report #15 |
| None seen | Report #40 |
149. Urine Hyaline Casts
| Urine Hyaline Casts Result | Laboratory Report |
|---|---|
| None | Report #15 |
| None seen | Report #40 |
150. Urine Squamous Epithelial Cells
| Urine Squamous Epithelial Cells Result | Laboratory Report |
|---|---|
| None seen | Report #40 |
Environmental Toxins
151. Lead
| Lead Value | Laboratory Report |
|---|---|
| No recorded measurements | — |
152. Mercury
| Mercury Value | Laboratory Report |
|---|---|
| No recorded measurements |
Additional Markers — Identified in Reports #2–15
153. ANA Direct
| ANA Direct Result | Laboratory Report |
|---|---|
| Negative | Report #11 |
| Negative | Report #30 |
154. Aldolase
| Aldolase Value (U/L) | Laboratory Report |
|---|---|
| 1.7 | Report #13 |
| 2.0 | Report #20 |
155. B-Type Natriuretic Peptide (BNP)
| BNP Value (pg/mL) | Laboratory Report |
|---|---|
| 85.5 | Report #1 |
| 37.9 | Report #2 |
| 612.9 | Report #8 |
| 18.2 | Report #10 |
| 19.6 | Report #11 |
| 26.1 | Report #13 |
| 80.0 | Report #27 |
| 80.2 | Report #28 |
156. Blood Culture Aerobic
| Blood Culture Aerobic Result | Laboratory Report |
|---|---|
| No growth | Report #14 |
157. Blood Culture Anaerobic
| Blood Culture Anaerobic Result | Laboratory Report |
|---|---|
| No growth | Report #14 |
158. Blood Culture Overall
| Blood Culture Overall Result | Laboratory Report |
|---|---|
| No growth | Report #13 |
| Negative | Report #14 |
159. Creatine Kinase (CK)
| CK Value (U/L) | Laboratory Report |
|---|---|
| 110 | Report #2 |
| 74 | Report #13 |
| 108 | Report #20 |
160. QuantiFERON Mitogen Control
| Mitogen Control Value (IU/mL) | Laboratory Report |
|---|---|
| 7.75 | Report #9 |
161. QuantiFERON Nil Control
| Nil Control Value (IU/mL) | Laboratory Report |
|---|---|
| 0.01 | Report #9 |
162. QuantiFERON TB1 Antigen
| TB1 Antigen Value (IU/mL) | Laboratory Report |
|---|---|
| 0.01 | Report #9 |
163. QuantiFERON TB2 Antigen
| TB2 Antigen Value (IU/mL) | Laboratory Report |
|---|---|
| 0.01 | Report #9 |
164. QuantiFERON-TB Gold Plus Overall
| QuantiFERON-TB Gold Plus Result | Laboratory Report |
|---|---|
| Negative | Report #9 |
165. SARS-CoV-2 IgG Antibody
| SARS-CoV-2 IgG Result | Laboratory Report |
|---|---|
| Negative | Report #8 |
166. SARS-CoV-2 IgM Antibody
| SARS-CoV-2 IgM Result | Laboratory Report |
|---|---|
| Negative | Report #8 |
167. Serum Protein Electrophoresis M-spike
| M-spike Result | Laboratory Report |
|---|---|
| Not detected | Report #13 |
168. Urine Culture
| Urine Culture Result | Laboratory Report |
|---|---|
| No growth | Report #13 |
169. Urine Myoglobin
| Urine Myoglobin Value | Laboratory Report |
|---|---|
| 2 | Report #13 |
170. 14.3.3 ETA RA Marker
| 14.3.3 ETA RA Marker (ng/mL) | Laboratory Report |
|---|---|
| <0.20 | Report #17 |
171. ABO Blood Group
| ABO Blood Group | Laboratory Report |
|---|---|
| A | Report #17 |
172. Rh Factor
| Rh Factor | Laboratory Report |
|---|---|
| Positive | Report #17 |
173. CYP2C19 Genotype
| CYP2C19 Genotype | Laboratory Report |
|---|---|
| *1/*2 | Report #21 |
174. CYP2C19 Phenotype
| CYP2C19 Phenotype | Laboratory Report |
|---|---|
| Intermediate metabolizer | Report #21 |
175. Serum Tryptase
| Serum Tryptase (mcg/L) | Laboratory Report |
|---|---|
| 6.5 | Report #23 |
176. Urine N-Methylhistamine
| Urine N-Methylhistamine (mcg/g creatinine) | Laboratory Report |
|---|---|
| 109 | Report #24 |
177. 24h Urine Creatinine
| 24h Urine Creatinine (mg/24h) | Laboratory Report |
|---|---|
| 1276 | Report #24 |
| 1342 | Report #25 |
| 1342 | Report #26 |
178. Urine Creatinine Concentration
| Urine Creatinine (mg/dL) | Laboratory Report |
|---|---|
| 58 | Report #24 |
| 61 | Report #25 |
| 61 | Report #26 |
179. 24h Urine Volume
| Urine Volume (mL) | Laboratory Report |
|---|---|
| 2200 | Report #24 |
| 2200 | Report #25 |
| 2200 | Report #26 |
180. Urine Collection Duration
| Collection Duration (hours) | Laboratory Report |
|---|---|
| 24 | Report #24 |
| 24 | Report #25 |
| 24 | Report #26 |
181. Urine 2,3-Dinor-11β-Prostaglandin F2α
| Urine 2,3-Dinor-11β-Prostaglandin F2α (pg/mg creatinine) | Laboratory Report |
|---|---|
| <513 | Report #25 |
182. Urine Leukotriene E4
| Urine Leukotriene E4 (pg/mg creatinine) | Laboratory Report |
|---|---|
| 139 | Report #26 |
183. ACTH (Adrenocorticotropic Hormone)
| ACTH Value (pg/mL) | Laboratory Report |
|---|---|
| 22.4 | Report #31 |
Laboratory Report Index
- 2013 Report #1 — April 8, 2013
- 2014 Report #2 — May 8, 2014
- 2015 Report #3 — May 29, 2015
- 2016 Report #4 — June 4, 2016
- 2017 Report #5 — June 9, 2017
- 2018 Report #6 — July 31, 2018
- 2019 Report #7 — August 3, 2019
- 2020 2 Reports
- 2021 6 Reports
- Report #10 — February 4, 2021
- Report #11 — September 1, 2021
- Report #12 — September 8, 2021
- Report #13 — October 19, 2021
- Report #14 — October 19, 2021
- Report #15 — December 16, 2021
- 2022 12 Reports
- Report #16 — January 13, 2022
- Report #17 — February 15, 2022
- Report #18 — March 8, 2022
- Report #19 — June 7, 2022
- Report #20 — April 14, 2022
- Report #21 — June 17, 2022
- Report #22 — July 12, 2022
- Report #23 — August 2, 2022
- Report #24 — August 2, 2022
- Report #25 — August 4, 2022
- Report #26 — August 5, 2022
- Report #27 — December 9, 2022
- 2023 4 Reports
- Report #28 — June 29, 2023
- Report #29 — July 20, 2023
- Report #30 — September 14, 2023
- Report #31 — November 14, 2023
- 2024 3 Reports
- Report #32 — June 29, 2024
- Report #33 — August 13, 2024
- Report #34 —November 16, 2024
- 2025 4 Reports
- Report #35 — June 28, 2025
- Report #36 — November 2025
- Report #37 — December 2025
- 2026 3 Reports
- Report #38 — June 28, 2026
- Report #39 — September 2026
- Report #40 — December 2026
- 2027 4 Reports
- Report #41 — March 2027
- Report #42 — June 2027
- Report #43 — September 2027
- Report #44 — December 2027
Laboratory Reports
Laboratory Report #1 — April 5, 2013
Laboratory: Labcorp
Laboratory Report: #1
Date: April 5, 2013
This is the first of our 40 Laboratory Report tables. It contains 19 laboratory measurements, presented in the same two-column format you have been using successfully in WordPress.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.4 K/µL |
| Hemoglobin | 13.0 g/dL |
| Hematocrit | 40.4% |
| Platelet Count | 200 K/µL |
| Blood Urea Nitrogen (BUN) | 19 mg/dL |
| Creatinine | 1.01 mg/dL |
| Estimated GFR (eGFR) | 72 mL/min/1.73 m² |
| ALT (SGPT) | 23 U/L |
| AST (SGOT) | 25 U/L |
| Alkaline Phosphatase | 61 U/L |
| Total Bilirubin | 0.5 mg/dL |
| Total Cholesterol | 144 mg/dL |
| LDL Cholesterol | 68 mg/dL |
| HDL Cholesterol | 66 mg/dL |
| Triglycerides | 52 mg/dL |
| B-Type Natriuretic Peptide (BNP) | 85.5 pg/mL |
| Glucose | 78 mg/dL |
| Thyroid-Stimulating Hormone (TSH) | 1.540 µIU/mL |
| PSA Total | 2.2 ng/mL |
Laboratory Report #2 — May 7, 2014
Laboratory: Labcorp
Laboratory Report: #2
Date: May 7, 2014
This report contains 23 laboratory measurements, presented in the same two-column WordPress format established for Report #1. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 6.1 K/µL |
| Hemoglobin | 12.8 g/dL |
| Hematocrit | 39.3% |
| Platelet Count | 209 K/µL |
| Blood Urea Nitrogen (BUN) | 23 mg/dL |
| Creatinine | 0.93 mg/dL |
| BUN/Creatinine Ratio | 25 |
| Estimated GFR (eGFR) | 79 mL/min/1.73 m² |
| Magnesium, Serum | 2.1 mg/dL |
| ALT (SGPT) | 28 U/L |
| AST (SGOT) | 39 U/L |
| Alkaline Phosphatase | 67 U/L |
| Total Bilirubin | 0.4 mg/dL |
| Total Cholesterol | 215 mg/dL |
| LDL Cholesterol | 138 mg/dL |
| HDL Cholesterol | 63 mg/dL |
| Triglycerides | 68 mg/dL |
| Glucose | 80 mg/dL |
| Hemoglobin A1c | 5.9% |
| Thyroid-Stimulating Hormone (TSH) | 0.647 µIU/mL |
| PSA Total | 2.3 ng/mL |
| B-Type Natriuretic Peptide (BNP) | 37.9 pg/mL |
| Creatine Kinase (CK) | 110 U/L |
Laboratory Report #3 — May 28, 2015
Laboratory: Labcorp
Laboratory Report: #3
Date: May 28, 2015
This report contains 20 laboratory measurements, presented in the same two-column WordPress format established for Reports #1 and #2. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.2 K/µL |
| Hemoglobin | 12.7 g/dL |
| Hematocrit | 39.5% |
| Platelet Count | 220 K/µL |
| Blood Urea Nitrogen (BUN) | 21 mg/dL |
| Creatinine | 1.06 mg/dL |
| Estimated GFR (eGFR) | 67 mL/min/1.73 m² |
| Magnesium, Serum | 2.1 mg/dL |
| ALT (SGPT) | 14 U/L |
| AST (SGOT) | 25 U/L |
| Alkaline Phosphatase | 73 U/L |
| Total Bilirubin | 0.5 mg/dL |
| Total Cholesterol | 177 mg/dL |
| LDL Cholesterol | 102 mg/dL |
| HDL Cholesterol | 64 mg/dL |
| Triglycerides | 53 mg/dL |
| Glucose | 87 mg/dL |
| Hemoglobin A1c | 5.7% |
| Thyroid-Stimulating Hormone (TSH) | 0.899 µIU/mL |
| PSA Total | 2.7 ng/mL |
Laboratory Report #4 lab-rep-— June 3, 2016
Laboratory: Labcorp
Laboratory Report: #4
Date: June 3, 2016
This report contains 20 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–3. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.3 K/µL |
| Hemoglobin | 13.3 g/dL |
| Hematocrit | 39.7% |
| Platelet Count | 223 K/µL |
| Blood Urea Nitrogen (BUN) | 18 mg/dL |
| Creatinine | 0.82 mg/dL |
| Estimated GFR (eGFR) | 84 mL/min/1.73 m² |
| ALT (SGPT) | 15 U/L |
| AST (SGOT) | 24 U/L |
| Alkaline Phosphatase | 64 U/L |
| Total Bilirubin | 0.3 mg/dL |
| Total Cholesterol | 189 mg/dL |
| LDL Cholesterol | 107 mg/dL |
| HDL Cholesterol | 73 mg/dL |
| Triglycerides | 45 mg/dL |
| Glucose | 90 mg/dL |
| Hemoglobin A1c | 5.1% |
| Thyroid-Stimulating Hormone (TSH) | 2.410 µIU/mL |
| PSA Total | 2.7 ng/mL |
| Urine pH | 8.0 |
Laboratory Report #5 — June 8, 2017
Laboratory: Labcorp
Laboratory Report: #5
Date: June 8, 2017
This report contains 19 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–4. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.8 K/µL |
| Hemoglobin | 12.5 g/dL |
| Hematocrit | 39.4% |
| Platelet Count | 234 K/µL |
| Blood Urea Nitrogen (BUN) | 23 mg/dL |
| Creatinine | 0.96 mg/dL |
| Estimated GFR (eGFR) | 74 mL/min/1.73 m² |
| ALT (SGPT) | 15 U/L |
| AST (SGOT) | 23 U/L |
| Alkaline Phosphatase | 60 U/L |
| Total Bilirubin | 0.5 mg/dL |
| Total Cholesterol | 162 mg/dL |
| LDL Cholesterol | 91 mg/dL |
| HDL Cholesterol | 62 mg/dL |
| Triglycerides | 44 mg/dL |
| Glucose | 84 mg/dL |
| Hemoglobin A1c | 5.6% |
| Thyroid-Stimulating Hormone (TSH) | 1.910 µIU/mL |
| PSA Total | 3.1 ng/mL |
Laboratory Report #6 — July 30, 2018
Laboratory: Labcorp
Laboratory Report: #6
Date: July 30, 2018
This report contains 21 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–5. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.5 K/µL |
| Hemoglobin | 12.8 g/dL |
| Hematocrit | 40.8% |
| Platelet Count | 237 K/µL |
| Blood Urea Nitrogen (BUN) | 20 mg/dL |
| Creatinine | 0.93 mg/dL |
| Estimated GFR (eGFR) | 77 mL/min/1.73 m² |
| ALT (SGPT) | 16 U/L |
| AST (SGOT) | 26 U/L |
| Alkaline Phosphatase | 65 U/L |
| Total Bilirubin | 0.4 mg/dL |
| Total Cholesterol | 185 mg/dL |
| LDL Cholesterol | 101 mg/dL |
| HDL Cholesterol | 73 mg/dL |
| Triglycerides | 55 mg/dL |
| Glucose | 86 mg/dL |
| Hemoglobin A1c | 5.3% |
| Thyroid-Stimulating Hormone (TSH) | 2.170 µIU/mL |
| Free T4 | 1.16 ng/dL |
| PSA Total | 3.4 ng/mL |
| Urine pH | 8.0 |
Laboratory Report #7 — August 2, 2019
Laboratory: Labcorp
Laboratory Report: #7
Date: August 2, 2019
This report contains 21 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–6. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.9 K/µL |
| Hemoglobin | 12.8 g/dL |
| Hematocrit | 39.8% |
| Platelet Count | 249 K/µL |
| Blood Urea Nitrogen (BUN) | 20 mg/dL |
| Creatinine | 0.97 mg/dL |
| Estimated GFR (eGFR) | 72 mL/min/1.73 m² |
| ALT (SGPT) | 14 U/L |
| AST (SGOT) | 23 U/L |
| Alkaline Phosphatase | 59 U/L |
| Total Bilirubin | 0.3 mg/dL |
| Total Cholesterol | 208 mg/dL |
| LDL Cholesterol | 126 mg/dL |
| HDL Cholesterol | 71 mg/dL |
| Triglycerides | 57 mg/dL |
| Glucose | 83 mg/dL |
| Hemoglobin A1c | 5.5% |
| Thyroid-Stimulating Hormone (TSH) | 2.810 µIU/mL |
| Free T4 | 1.13 ng/dL |
| PSA Total | 4.4 ng/mL |
| Urine pH | 8.0 |
Laboratory Report #8 — August 5, 2020
Laboratory: Labcorp
Laboratory Report: #8
Date: August 5, 2020
This report contains 24 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–7. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 6.7 K/µL |
| Hemoglobin | 13.1 g/dL |
| Hematocrit | 39.0% |
| Platelet Count | 228 K/µL |
| Blood Urea Nitrogen (BUN) | 16 mg/dL |
| Creatinine | 1.04 mg/dL |
| Estimated GFR (eGFR) | 66 mL/min/1.73 m² |
| ALT (SGPT) | 26 U/L |
| AST (SGOT) | 32 U/L |
| Alkaline Phosphatase | 65 U/L |
| Total Bilirubin | 0.3 mg/dL |
| Total Cholesterol | 168 mg/dL |
| LDL Cholesterol | 89 mg/dL |
| HDL Cholesterol | 63 mg/dL |
| Triglycerides | 80 mg/dL |
| Glucose | 80 mg/dL |
| Hemoglobin A1c | 5.4% |
| Thyroid-Stimulating Hormone (TSH) | 1.950 µIU/mL |
| Free T4 | 1.16 ng/dL |
| PSA Total | 3.8 ng/mL |
| Urine pH | 7.5 |
| B-Type Natriuretic Peptide (BNP) | 612.9 pg/mL |
| SARS-CoV-2 IgG Antibody | Negative |
| SARS-CoV-2 IgM Antibody | Negative |
Laboratory Report #9 — August 12, 2020
Laboratory: Labcorp
Laboratory Report: #9
Date: August 12, 2020
Report Type: Targeted Laboratory Testing
This report contains 5 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–8. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| QuantiFERON Mitogen Control | 7.75 IU/mL |
| QuantiFERON Nil Control | 0.01 IU/mL |
| QuantiFERON TB1 Antigen | 0.01 IU/mL |
| QuantiFERON TB2 Antigen | 0.01 IU/mL |
| QuantiFERON-TB Gold Plus Overall | Negative |
Laboratory Report #10 — February 3, 2021
Laboratory: Labcorp
Laboratory Report: #10
Date: February 3, 2021
This report contains 17 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–9. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 5.5 K/µL |
| Hemoglobin | 13.5 g/dL |
| Hematocrit | 40.6% |
| Platelet Count | 222 K/µL |
| Blood Urea Nitrogen (BUN) | 17 mg/dL |
| Creatinine | 0.91 mg/dL |
| Estimated GFR (eGFR) | 77 mL/min/1.73 m² |
| ALT (SGPT) | 21 U/L |
| AST (SGOT) | 35 U/L |
| Alkaline Phosphatase | 64 U/L |
| Total Bilirubin | 0.3 mg/dL |
| Glucose | 58 mg/dL |
| Hemoglobin A1c | 5.6% |
| Thyroid-Stimulating Hormone (TSH) | 2.140 µIU/mL |
| Free T4 | 1.23 ng/dL |
| PSA Total | 3.5 ng/mL |
| B-Type Natriuretic Peptide (BNP) | 18.2 pg/mL |
Laboratory Report #11 — August 31, 2021
Laboratory: Labcorp
Laboratory Report: #11
Date: August 31, 2021
This report contains 21 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–10. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 7.1 K/µL |
| Red Blood Cell Count (RBC) | 4.11 M/µL |
| Hemoglobin | 12.3 g/dL |
| Hematocrit | 37.9% |
| Platelet Count | 298 K/µL |
| Blood Urea Nitrogen (BUN) | 16 mg/dL |
| Creatinine | 0.92 mg/dL |
| Estimated GFR (eGFR) | 76 mL/min/1.73 m² |
| Magnesium, Serum | 2.1 mg/dL |
| ALT (SGPT) | 13 U/L |
| AST (SGOT) | 22 U/L |
| Alkaline Phosphatase | 71 U/L |
| Total Bilirubin | 0.3 mg/dL |
| Glucose | 94 mg/dL |
| C-Reactive Protein (CRP) | 37 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 57 mm/hr |
| Rheumatoid Factor (RF) | <10 IU/mL |
| Thyroid-Stimulating Hormone (TSH) | 3.060 µIU/mL |
| Free T4 | 1.19 ng/dL |
| ANA Direct | Negative |
| B-Type Natriuretic Peptide (BNP) | 19.6 pg/mL |
Laboratory Report #12 — September 7, 2021
Laboratory: Labcorp
Laboratory Report: #12
Date: September 7, 2021
This report contains 2 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–11. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| C-Reactive Protein (CRP) | 7 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 19 mm/hr |
Laboratory Report #13 — October 13, 2021
Laboratory: Labcorp
Laboratory Report: #13
Collection Date: October 13, 2021
Report Date: October 19, 2021
This report contains 34 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–12. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 7.8 K/µL |
| Red Blood Cell Count (RBC) | 3.84 M/µL |
| Hemoglobin | 11.4 g/dL |
| Hematocrit | 33.7% |
| Platelet Count | 309 K/µL |
| Blood Urea Nitrogen (BUN) | 13 mg/dL |
| Creatinine | 0.86 mg/dL |
| Estimated GFR (eGFR) | 79 mL/min/1.73 m² |
| Sodium | 129 mmol/L |
| Potassium | 4.2 mmol/L |
| Chloride | 91 mmol/L |
| ALT (SGPT) | 14 U/L |
| AST (SGOT) | 20 U/L |
| Alkaline Phosphatase | 65 U/L |
| Total Bilirubin | 0.4 mg/dL |
| Globulin | 4.0 g/dL |
| Albumin/Globulin Ratio | 0.9 |
| Total Cholesterol | 177 mg/dL |
| LDL Cholesterol | 105 mg/dL |
| HDL Cholesterol | 60 mg/dL |
| Triglycerides | 64 mg/dL |
| Glucose | 90 mg/dL |
| Hemoglobin A1c | 5.8% |
| C-Reactive Protein (CRP) | 32 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 71 mm/hr |
| Thyroid-Stimulating Hormone (TSH) | 4.170 µIU/mL |
| Free T4 | 1.11 ng/dL |
| Aldolase | 1.7 U/L |
| B-Type Natriuretic Peptide (BNP) | 26.1 pg/mL |
| Blood Culture Overall | No growth |
| Creatine Kinase (CK) | 74 U/L |
| Serum Protein Electrophoresis M-spike | Not detected |
| Urine Culture | No growth |
| Urine Myoglobin | 2 |
Laboratory Report #14 — October 13, 2021
Laboratory: Labcorp
Laboratory Report: #14
Collection Date: October 13, 2021
Report Date: October 19, 2021
Report Type: Targeted Laboratory Testing — Blood Cultures
This report contains 3 laboratory results, presented in the same two-column WordPress format established for Reports #1–13. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| Blood Culture Aerobic | No growth |
| Blood Culture Anaerobic | No growth |
| Blood Culture Overall | Negative |
Laboratory Report #15 — December 15, 2021
Laboratory: Labcorp
Laboratory Report: #15
Collection Date: December 15, 2021
Report Date: December 16, 2021
This report contains 22 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–14. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 5.7 K/µL |
| Red Blood Cell Count (RBC) | 4.25 M/µL |
| Hemoglobin | 12.9 g/dL |
| Hematocrit | 39.2% |
| Platelet Count | 193 K/µL |
| C-Reactive Protein (CRP) | 2 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 15 mm/hr |
| Anti-dsDNA Antibodies | 3 |
| Complement C3 | 104 |
| Complement C4 | 25 |
| Iron | 118 µg/dL |
| Ferritin | 43 ng/mL |
| Total Iron Binding Capacity (TIBC) | 313 µg/dL |
| Iron Saturation | 38% |
| Urine Protein | Negative |
| Urine Glucose | Negative |
| Urine Ketones | Negative |
| Urine Occult Blood | Negative |
| Urine RBC | None |
| Urine WBC | None |
| Urine Bacteria | None |
| Urine Hyaline Casts | None |
Laboratory Report #16 — January 12, 2022
Laboratory: Labcorp
Laboratory Report: #16
Collection Date: January 12, 2022
Report Date: January 13, 2022
This report contains 19 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–15. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 5.9 K/µL |
| Red Blood Cell Count (RBC) | 4.37 M/µL |
| Hemoglobin | 13.4 g/dL |
| Hematocrit | 40.8% |
| Platelet Count | 229 K/µL |
| Blood Urea Nitrogen (BUN) | 16 mg/dL |
| Creatinine | 0.86 mg/dL |
| Estimated GFR (eGFR) | 79 mL/min/1.73 m² |
| Sodium | 137 mmol/L |
| Potassium | 4.4 mmol/L |
| Chloride | 98 mmol/L |
| Carbon Dioxide (CO2) | 27 mmol/L |
| ALT (SGPT) | 25 U/L |
| AST (SGOT) | 28 U/L |
| Alkaline Phosphatase | 65 U/L |
| Total Bilirubin | 0.4 mg/dL |
| Glucose | 85 mg/dL |
| C-Reactive Protein (CRP) | 4 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 6 mm/hr |
Laboratory Report #17 — February 9, 2022
Laboratory: Labcorp
Laboratory Report: #17
Date: February 9, 2022
This report contains 7 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–16. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| C-Reactive Protein (CRP) | 1 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 13 mm/hr |
| Thyroid-Stimulating Hormone (TSH) | 0.912 µIU/mL |
| Free T4 | 1.33 ng/dL |
| 14.3.3 ETA RA Marker | <0.20 ng/mL |
| ABO Blood Group | A |
| Rh Factor | Positive |
Laboratory Report #18 — March 7, 2022
Laboratory: Labcorp
Laboratory Report: #18
Collection Date: March 7, 2022
Report Date: March 8, 2022
This report contains 4 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–17. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| C-Reactive Protein (CRP) | 3 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 16 mm/hr |
| SSA (Ro) Antibody | <0.2 |
| SSB (La) Antibody | <0.2 |
Laboratory Report #19 — June 6, 2022
Laboratory: Labcorp
Laboratory Report: #19
Collection Date: June 6, 2022
Report Date: June 7, 2022
Report Type: Targeted Laboratory Testing — Inflammation Markers
This report contains 2 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–18. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| C-Reactive Protein (CRP) | 2 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 4 mm/hr |
Laboratory Report #20 — April 12, 2022
Laboratory: Labcorp
Laboratory Report: #20
Date: April 12, 2022
This report contains 21 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–19. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 6.4 K/µL |
| Red Blood Cell Count (RBC) | 4.25 M/µL |
| Hemoglobin | 13.1 g/dL |
| Hematocrit | 39.7% |
| MCV | 93 fL |
| Platelet Count | 228 K/µL |
| Blood Urea Nitrogen (BUN) | 18 mg/dL |
| Creatinine | 0.93 mg/dL |
| Estimated GFR (eGFR) | 80 mL/min/1.73 m² |
| Sodium | 138 mmol/L |
| Potassium | 4.2 mmol/L |
| Chloride | 100 mmol/L |
| Calcium | 9.0 mg/dL |
| AST (SGOT) | 27 U/L |
| Alkaline Phosphatase | 67 U/L |
| GGT | 11 U/L |
| Total Bilirubin | 0.5 mg/dL |
| C-Reactive Protein (CRP) | 2 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 8 mm/hr |
| Aldolase | 2.0 U/L |
| Creatine Kinase (CK) | 108 U/L |
Laboratory Report #21 — June 7, 2022
Laboratory: Labcorp / Monogram
Laboratory Report: #21
Collection Date: June 7, 2022
Report Date: June 17, 2022
Report Type: Pharmacogenetic Testing — CYP2C19
This report contains 2 laboratory results, presented in the same two-column WordPress format established for Reports #1–20. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| CYP2C19 Genotype | *1/*2 |
| CYP2C19 Phenotype | Intermediate metabolizer |
Laboratory Report #22 — July 11, 2022
Laboratory: Labcorp
Laboratory Report: #22
Collection Date: July 11, 2022
Report Date: July 12, 2022
Report Type: Targeted Laboratory Testing — Inflammation Markers
This report contains 2 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–21. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| C-Reactive Protein (CRP) | 6 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 13 mm/hr |
Laboratory Report #23 — July 26, 2022
Laboratory: Quest / Mayo
Laboratory Report: #23
Collection Date: July 26, 2022
Report Date: August 2, 2022
Report Type: Targeted Laboratory Testing — Serum Tryptase
This report contains 1 laboratory measurement, presented in the same two-column WordPress format established for Reports #1–22. The marker follows the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| Serum Tryptase | 6.5 mcg/L |
Laboratory Report #24 — July 26, 2022
Laboratory: Quest / Mayo
Laboratory Report: #24
Collection Date: July 26, 2022
Report Date: August 2, 2022
Report Type: Targeted Laboratory Testing — Urine N-Methylhistamine
This report contains 5 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–23. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| Urine N-Methylhistamine | 109 mcg/g creatinine |
| 24h Urine Creatinine | 1276 mg/24h |
| Urine Creatinine Concentration | 58 mg/dL |
| 24h Urine Volume | 2200 mL |
| Urine Collection Duration | 24 hours |
Laboratory Report #25 — July 26, 2022
Laboratory: Quest / Mayo
Laboratory Report: #25
Collection Date: July 26, 2022
Report Date: August 4, 2022
Report Type: Targeted Laboratory Testing — Urinary Prostaglandin Metabolite
This report contains 5 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–24. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| 24h Urine Creatinine | 1342 mg/24h |
| Urine Creatinine Concentration | 61 mg/dL |
| 24h Urine Volume | 2200 mL |
| Urine Collection Duration | 24 hours |
| Urine 2,3-Dinor-11β-Prostaglandin F2α | <513 pg/mg creatinine |
Laboratory Report #26 — July 26, 2022
Laboratory: Quest / Mayo
Laboratory Report: #26
Collection Date: July 26, 2022
Report Type: Targeted Laboratory Testing — Urinary Leukotriene E4
This report contains 5 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–25. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| 24h Urine Creatinine | 1342 mg/24h |
| Urine Creatinine Concentration | 61 mg/dL |
| 24h Urine Volume | 2200 mL |
| Urine Collection Duration | 24 hours |
| Urine Leukotriene E4 | 139 pg/mg creatinine |
Laboratory Report #27 — December 7, 2022
Laboratory: Labcorp
Laboratory Report: #27
Collection Date: December 7, 2022
Report Date: December 9, 2022
This report contains 26 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–26. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 6.1 K/µL |
| Hemoglobin | 13.8 g/dL |
| Hematocrit | 42.1% |
| Platelet Count | 262 K/µL |
| Blood Urea Nitrogen (BUN) | 21 mg/dL |
| Creatinine | 0.91 mg/dL |
| Estimated GFR (eGFR) | 82 mL/min/1.73 m² |
| Sodium | 139 mmol/L |
| Potassium | 4.5 mmol/L |
| Chloride | 98 mmol/L |
| Carbon Dioxide (CO2) | 27 mmol/L |
| ALT (SGPT) | 20 U/L |
| AST (SGOT) | 28 U/L |
| Alkaline Phosphatase | 89 U/L |
| Total Bilirubin | 0.4 mg/dL |
| Total Cholesterol | 226 mg/dL |
| LDL Cholesterol | 151 mg/dL |
| HDL Cholesterol | 60 mg/dL |
| Triglycerides | 86 mg/dL |
| Glucose | 96 mg/dL |
| Hemoglobin A1c | 5.7% |
| Thyroid-Stimulating Hormone (TSH) | 1.300 µIU/mL |
| Free T4 | 1.36 ng/dL |
| Urine Appearance | Cloudy |
| Urine pH | 8.0 |
| B-Type Natriuretic Peptide (BNP) | 80 pg/mL |
Laboratory Report #28 — June 28, 2023
Laboratory: Labcorp
Laboratory Report: #28
Collection Date: June 28, 2023
Report Date: June 29, 2023
This report contains 23 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–27. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 5.9 K/µL |
| Red Blood Cell Count (RBC) | 4.05 M/µL |
| Hemoglobin | 12.3 g/dL |
| Hematocrit | 36.5% |
| Platelet Count | 232 K/µL |
| Blood Urea Nitrogen (BUN) | 26 mg/dL |
| Creatinine | 1.03 mg/dL |
| Estimated GFR (eGFR) | 71 mL/min/1.73 m² |
| Sodium | 140 mmol/L |
| Potassium | 4.6 mmol/L |
| Chloride | 99 mmol/L |
| Carbon Dioxide (CO2) | 28 mmol/L |
| ALT (SGPT) | 17 U/L |
| AST (SGOT) | 27 U/L |
| Alkaline Phosphatase | 75 U/L |
| Total Bilirubin | 0.4 mg/dL |
| Glucose | 83 mg/dL |
| Hemoglobin A1c | 5.6% |
| Thyroid-Stimulating Hormone (TSH) | 1.680 µIU/mL |
| Free T4 | 1.12 ng/dL |
| Urine Appearance | Cloudy |
| Urine pH | 8.0 |
| B-Type Natriuretic Peptide (BNP) | 80.2 pg/mL |
Laboratory Report #29 — July 19, 2023
Laboratory: Labcorp
Laboratory Report: #29
Collection Date: July 19, 2023
Report Date: July 20, 2023
Report Type: Targeted Laboratory Testing — Complete Blood Count
This report contains 6 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–28. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 6.4 K/µL |
| Red Blood Cell Count (RBC) | 3.96 M/µL |
| Hemoglobin | 11.8 g/dL |
| Hematocrit | 35.6% |
| MCV | 90 fL |
| Platelet Count | 228 K/µL |
Laboratory Report #30 — September 12, 2023
Laboratory: Labcorp
Laboratory Report: #30
Collection Date: September 12, 2023
Report Date: September 14, 2023
This report contains 20 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–29. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 5.9 K/µL |
| Red Blood Cell Count (RBC) | 3.73 M/µL |
| Hemoglobin | 11.3 g/dL |
| Hematocrit | 33.9% |
| MCV | 91 fL |
| Platelet Count | 295 K/µL |
| Blood Urea Nitrogen (BUN) | 28 mg/dL |
| Creatinine | 0.93 mg/dL |
| Estimated GFR (eGFR) | 80 mL/min/1.73 m² |
| ALT (SGPT) | 18 U/L |
| AST (SGOT) | 27 U/L |
| Alkaline Phosphatase | 61 U/L |
| Total Bilirubin | 0.2 mg/dL |
| Glucose | 87 mg/dL |
| Hemoglobin A1c | 5.8% |
| Erythrocyte Sedimentation Rate (ESR) | 27 mm/hr |
| Thyroid-Stimulating Hormone (TSH) | 1.09 µIU/mL |
| Free T4 | 1.27 ng/dL |
| Ferritin | 144 ng/mL |
| ANA Direct | Negative |
Laboratory Report #31 — November 13, 2023
Laboratory: Labcorp
Laboratory Report: #31
Collection Date: November 13, 2023
Report Date: November 14, 2023
This report contains 27 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–30. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.3 K/µL |
| Red Blood Cell Count (RBC) | 4.36 M/µL |
| Hemoglobin | 13.1 g/dL |
| Hematocrit | 39.7% |
| MCV | 91 fL |
| Platelet Count | 183 K/µL |
| Blood Urea Nitrogen (BUN) | 23 mg/dL |
| Creatinine | 1.01 mg/dL |
| Estimated GFR (eGFR) | 72 mL/min/1.73 m² |
| Magnesium, Serum | 2.3 mg/dL |
| ALT (SGPT) | 30 U/L |
| AST (SGOT) | 31 U/L |
| Alkaline Phosphatase | 67 U/L |
| Total Bilirubin | 0.5 mg/dL |
| Total Cholesterol | 249 mg/dL |
| LDL Cholesterol | 151 mg/dL |
| HDL Cholesterol | 88 mg/dL |
| Triglycerides | 60 mg/dL |
| Iron | 95 µg/dL |
| Ferritin | 95 ng/mL |
| Total Iron Binding Capacity (TIBC) | 287 µg/dL |
| Iron Saturation | 33% |
| Vitamin B12 | >2000 pg/mL |
| Folate | >20.0 ng/mL |
| Cortisol | 7.1 |
| Urine pH | 8.0 |
| ACTH (Adrenocorticotropic Hormone) | 22.4 pg/mL |
Laboratory Report #32 — June 26, 2024
Laboratory: Labcorp
Laboratory Report: #32
Collection Date: June 26, 2024
Report Date: June 29, 2024
This report contains 30 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–31. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.8 K/µL |
| Red Blood Cell Count (RBC) | 3.71 M/µL |
| Hemoglobin | 11.2 g/dL |
| Hematocrit | 35.4% |
| MCV | 95 fL |
| Platelet Count | 191 K/µL |
| Neutrophils (%) | 42% |
| Lymphocytes (%) | 31% |
| Monocytes (%) | 7% |
| Eosinophils (%) | 19% |
| Absolute Eosinophils | 0.9 K/µL |
| Blood Urea Nitrogen (BUN) | 40 mg/dL |
| Creatinine | 0.92 mg/dL |
| BUN/Creatinine Ratio | 43 |
| Estimated GFR (eGFR) | 81 mL/min/1.73 m² |
| Magnesium, Serum | 2.0 mg/dL |
| Zinc | 107 µg/dL |
| Total Cholesterol | 220 mg/dL |
| LDL Cholesterol | 136 mg/dL |
| HDL Cholesterol | 75 mg/dL |
| Triglycerides | 50 mg/dL |
| C-Reactive Protein (CRP) | 2 mg/L |
| Thyroid-Stimulating Hormone (TSH) | 0.819 µIU/mL |
| Free T4 | 1.31 ng/dL |
| Iron | 121 µg/dL |
| Ferritin | 152 ng/mL |
| Total Iron Binding Capacity (TIBC) | 251 µg/dL |
| Iron Saturation | 48% |
| Vitamin B12 | 1208 pg/mL |
| Folate | 11.9 ng/mL |
Laboratory Report #33 — August 12, 2024
Laboratory: Labcorp
Laboratory Report: #33
Collection Date: August 12, 2024
Report Date: August 13, 2024
Report Type: Complete Blood Count and Hemoglobin A1c
This report contains 10 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–32. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 5.2 K/µL |
| Red Blood Cell Count (RBC) | 3.71 M/µL |
| Hemoglobin | 11.3 g/dL |
| Hematocrit | 36.1% |
| MCV | 97 fL |
| MCH | 30.5 pg |
| MCHC | 31.3 g/dL |
| RDW | 13.0% |
| Platelet Count | 197 K/µL |
| Hemoglobin A1c | 5.4% |
Laboratory Report #34 — November 12, 2024
Laboratory: Labcorp
Laboratory Report: #34
Collection Date: November 12, 2024
Report Date: November 16, 2024
This report contains 38 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–33. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.7 K/µL |
| Red Blood Cell Count (RBC) | 4.15 M/µL |
| Hemoglobin | 12.6 g/dL |
| Hematocrit | 39.3% |
| Platelet Count | 208 K/µL |
| Neutrophils (%) | 52% |
| Lymphocytes (%) | 29% |
| Monocytes (%) | 11% |
| Eosinophils (%) | 8% |
| Absolute Eosinophils | 0.4 K/µL |
| Blood Urea Nitrogen (BUN) | 33 mg/dL |
| Creatinine | 0.88 mg/dL |
| BUN/Creatinine Ratio | 38 |
| Estimated GFR (eGFR) | 83 mL/min/1.73 m² |
| Magnesium, Serum | 2.2 mg/dL |
| Zinc | 121 µg/dL |
| ALT (SGPT) | 27 U/L |
| AST (SGOT) | 31 U/L |
| Alkaline Phosphatase | 59 U/L |
| Total Bilirubin | 0.3 mg/dL |
| Total Cholesterol | 243 mg/dL |
| LDL Cholesterol | 141 mg/dL |
| HDL Cholesterol | 94 mg/dL |
| Triglycerides | 52 mg/dL |
| Glucose | 87 mg/dL |
| Hemoglobin A1c | 5.8% |
| C-Reactive Protein (CRP) | 1 mg/L |
| Thyroid-Stimulating Hormone (TSH) | 1.11 µIU/mL |
| Free T4 | 1.24 ng/dL |
| Vitamin B12 | 1062 pg/mL |
| Folate | 9.7 ng/mL |
| Urine Appearance | Clear |
| Urine Protein | Negative |
| Urine Glucose | Negative |
| Urine Ketones | Negative |
| Urine Occult Blood | Negative |
| Urine Nitrite | Negative |
| Urine Leukocyte Esterase | Negative |
Laboratory Report #35 — June 2025
Laboratory: Function Health / Quest
Laboratory Report: #35
Collection Period: June 2025
This report contains 7 recorded laboratory results, presented in the same two-column WordPress format established for Reports #1–34. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| GGT (Gamma-Glutamyl Transferase) | 10 U/L |
| Leptin | 1.1 |
| ANA Screen | Positive |
| ANA Titer | 1:320 |
| ANA Pattern | Homogeneous |
| Rheumatoid Factor (RF) | Negative |
| Methylmalonic Acid (MMA) | 112 |
Laboratory Report #36 — November 2025
Laboratory: Function Health / Quest
Laboratory Report: #36
Collection Period: November 2025
This report contains 41 recorded laboratory measurements, presented in the same two-column WordPress format established for Reports #1–35. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.2 K/µL |
| Red Blood Cell Count (RBC) | 4.30 M/µL |
| Hemoglobin | 12.9 g/dL |
| Hematocrit | 40.3% |
| Platelet Count | 187 K/µL |
| Blood Urea Nitrogen (BUN) | 30 mg/dL |
| Creatinine | 0.90 mg/dL |
| Estimated GFR (eGFR) | 82 mL/min/1.73 m² |
| Sodium | 138 mmol/L |
| Potassium | 4.5 mmol/L |
| Zinc | 139 µg/dL |
| ALT (SGPT) | 27 U/L |
| AST (SGOT) | 32 U/L |
| Total Cholesterol | 254 mg/dL |
| LDL Cholesterol | 150 mg/dL |
| HDL Cholesterol | 92 mg/dL |
| Triglycerides | 41 mg/dL |
| Non-HDL Cholesterol | 162 mg/dL |
| Apolipoprotein B (ApoB) | 142 mg/dL |
| Lipoprotein(a) | 14 |
| LDL Particle Number | 1836 |
| Glucose | 93 mg/dL |
| Hemoglobin A1c | 5.4% |
| Insulin | 4.6 |
| Leptin | 1.1 |
| High-Sensitivity CRP (hs-CRP) | 1.8 mg/L |
| ANA Screen | Positive |
| ANA Titer | 1:320 |
| ANA Pattern | Homogeneous |
| Rheumatoid Factor (RF) | Negative |
| Thyroid-Stimulating Hormone (TSH) | 1.81 µIU/mL |
| Free T4 | 1.1 ng/dL |
| Free T3 | 2.1 pg/mL |
| Ferritin | 107 ng/mL |
| Methylmalonic Acid (MMA) | 112 |
| Homocysteine | 13.4 µmol/L |
| Vitamin D, 25-OH | 133 ng/mL |
| PSA Total | 4.0 ng/mL |
| Testosterone Total | 407 ng/dL |
| Sex Hormone Binding Globulin (SHBG) | 95 |
| Urine pH | 5.5 |
Laboratory Report #37 — December 15, 2025
Laboratory: Quest / Cardio IQ
Laboratory Report: #37
Collection Date: December 15, 2025
Report Date: December 20, 2025
Report Type: Lipid Profile
This report contains 6 laboratory measurements, presented in the same two-column WordPress format established for Reports #1–36. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| Total Cholesterol | 256 mg/dL |
| LDL Cholesterol | 151 mg/dL |
| HDL Cholesterol | 89 mg/dL |
| Triglycerides | 60 mg/dL |
| Non-HDL Cholesterol | 167 mg/dL |
| Total Cholesterol/HDL Ratio | 2.9 |
Laboratory Report #38 — June 2026
Laboratory: Function Health
Laboratory Report: #38
Collection Period: June 2026
This report contains 28 recorded laboratory measurements, presented in the same two-column WordPress format established for Reports #1–37. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| Hemoglobin | 13.6 g/dL |
| Hematocrit | 42.8% |
| Total Cholesterol | 284 mg/dL |
| LDL Cholesterol | 183 mg/dL |
| HDL Cholesterol | 82 mg/dL |
| Triglycerides | 85 mg/dL |
| Apolipoprotein B (ApoB) | 139 mg/dL |
| Lipoprotein(a) | Low |
| LDL Particle Number | 2483 |
| Glucose | 66 mg/dL |
| Hemoglobin A1c | 5.5% |
| Insulin | 2.1 |
| Leptin | 0.4 |
| Erythrocyte Sedimentation Rate (ESR) | 6 mm/hr |
| ANA Screen | Positive |
| ANA Titer | 1:1280 |
| ANA Pattern | Homogeneous |
| Anti-dsDNA Antibodies | Negative |
| Rheumatoid Factor (RF) | Negative |
| CCP Antibody | Negative |
| Smith (Sm) Antibody | Negative |
| RNP Antibody | Negative |
| SSA (Ro) Antibody | Negative |
| SSB (La) Antibody | Negative |
| Scl-70 Antibody | Negative |
| Jo-1 Antibody | Negative |
| Free T4 | 1.2 ng/dL |
| Free T3 | 1.6 pg/mL |
Laboratory Report #39 — September 22, 2026
Laboratory: WellMed
Laboratory Report: #39
Collection Date: September 22, 2026
Report Dates: September 23–28, 2026
This report contains 55 recorded laboratory results, presented in the same two-column WordPress format established for Reports #1–38. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.27 K/µL |
| Red Blood Cell Count (RBC) | 4.18 M/µL |
| Hemoglobin | 12.4 g/dL |
| Hematocrit | 38.6% |
| MCV | 92.3 fL |
| MCH | 29.7 pg |
| MCHC | 32.1 g/dL |
| RDW | 13.0% |
| Platelet Count | 182 K/µL |
| Mean Platelet Volume (MPV) | 10.0 fL |
| Nucleated RBC (NRBC) | 0 |
| Neutrophils (%) | 51.8% |
| Lymphocytes (%) | 32.1% |
| Monocytes (%) | 11.0% |
| Eosinophils (%) | 4.2% |
| Basophils (%) | 0.7% |
| Absolute Neutrophils | 2.21 K/µL |
| Absolute Lymphocytes | 1.37 K/µL |
| Absolute Monocytes | 0.47 K/µL |
| Absolute Eosinophils | 0.18 K/µL |
| Absolute Basophils | 0.03 K/µL |
| Blood Urea Nitrogen (BUN) | 32 mg/dL |
| Creatinine | 0.90 mg/dL |
| Estimated GFR (eGFR) | 81.64 mL/min/1.73 m² |
| Sodium | 140 mmol/L |
| Potassium | 4.4 mmol/L |
| Chloride | 102 mmol/L |
| Carbon Dioxide (CO2) | 29 mmol/L |
| Calcium | 9.8 mg/dL |
| ALT (SGPT) | 28 U/L |
| AST (SGOT) | 27 U/L |
| Alkaline Phosphatase | 51 U/L |
| Total Bilirubin | 0.7 mg/dL |
| Albumin | 4.0 g/dL |
| Total Protein | 7.1 g/dL |
| Total Cholesterol | 252 mg/dL |
| LDL Cholesterol | 168 mg/dL |
| HDL Cholesterol | 73 mg/dL |
| Triglycerides | 54 mg/dL |
| Total Cholesterol/HDL Ratio | 3.5 |
| Glucose | 84 mg/dL |
| C-Reactive Protein (CRP) | <1.0 mg/L |
| Erythrocyte Sedimentation Rate (ESR) | 18 mm/hr |
| ANA Titer | 1:640 |
| ANA Pattern | Homogeneous |
| Anti-dsDNA Antibodies | 2.6 |
| Cardiolipin IgA Antibody | <9 |
| Thyroid-Stimulating Hormone (TSH) | 0.67 µIU/mL |
| Free T4 | 1.11 ng/dL |
| Free T3 | 2.27 pg/mL |
| Iron | 103 µg/dL |
| Ferritin | 117.3 ng/mL |
| Total Iron Binding Capacity (TIBC) | 298 µg/dL |
| Unsaturated Iron Binding Capacity (UIBC) | 195 µg/dL |
| Iron Saturation | 35% |
Laboratory Report #40 — November 2026
Laboratory: Function Health
Laboratory Report: #40
Collection Period: November 2026
This report contains 62 recorded laboratory results, presented in the same two-column WordPress format established for Reports #1–39. The markers follow the order of the Master Laboratory Spreadsheet.
| Laboratory Marker | Recorded Value |
|---|---|
| White Blood Cell Count (WBC) | 4.6 K/µL |
| Red Blood Cell Count (RBC) | 3.97 M/µL |
| Hemoglobin | 12.3 g/dL |
| Hematocrit | 37.2% |
| MCV | 93.7 fL |
| MCH | 31.0 pg |
| MCHC | 33.1 g/dL |
| RDW | 13.9% |
| Platelet Count | 170 K/µL |
| Mean Platelet Volume (MPV) | 10.3 fL |
| Neutrophils (%) | 49.9% |
| Lymphocytes (%) | 35.1% |
| Monocytes (%) | 9.0% |
| Eosinophils (%) | 5.3% |
| Basophils (%) | 0.7% |
| Absolute Neutrophils | 2,295 cells/µL |
| Absolute Lymphocytes | 1,615 cells/µL |
| Absolute Monocytes | 414 cells/µL |
| Absolute Eosinophils | 244 cells/µL |
| Absolute Basophils | 32 cells/µL |
| Creatinine | 1.09 mg/dL |
| BUN/Creatinine Ratio | 34 |
| Estimated GFR (eGFR) | 64 mL/min/1.73 m² |
| Sodium | 137 mmol/L |
| Potassium | 4.3 mmol/L |
| Chloride | 102 mmol/L |
| Calcium | 9.5 mg/dL |
| ALT (SGPT) | 20 U/L |
| AST (SGOT) | 23 U/L |
| Alkaline Phosphatase | 51 U/L |
| Total Bilirubin | 0.6 mg/dL |
| Albumin | 4.0 g/dL |
| Globulin | 3.2 g/dL |
| Total Protein | 7.2 g/dL |
| Albumin/Globulin Ratio | 1.3 |
| Total Cholesterol | 249 mg/dL |
| LDL Cholesterol | 157 mg/dL |
| HDL Cholesterol | 78 mg/dL |
| Triglycerides | 45 mg/dL |
| Non-HDL Cholesterol | 171 mg/dL |
| Total Cholesterol/HDL Ratio | 3.2 |
| Glucose | 84 mg/dL |
| Hemoglobin A1c | 5.4% |
| Insulin | 2.1 |
| High-Sensitivity CRP (hs-CRP) | 2.3 mg/L |
| Free T3 | 2.4 pg/mL |
| Urine Appearance | Cloudy |
| Urine Color | Yellow |
| Urine Specific Gravity | 1.008 |
| Urine pH | 5.5 |
| Urine Protein | Negative |
| Urine Glucose | Negative |
| Urine Ketones | Negative |
| Urine Occult Blood | Negative |
| Urine Bilirubin | Negative |
| Urine Nitrite | Negative |
| Urine Leukocyte Esterase | Negative |
| Urine RBC | None seen |
| Urine WBC | None seen |
| Urine Bacteria | None seen |
| Urine Hyaline Casts | None seen |
| Urine Squamous Epithelial Cells | None seen |
Laboratory Report #41
Section 7.2 — Understanding My Laboratory Results
These subsections would be organized around health systems and clinical significance rather than simply following the order of the 183 laboratory markers.
| Subsection | Title | Principal Measurements |
|---|---|---|
| 7.2.1 | Cardiovascular Health | Cholesterol, LDL, HDL, triglycerides, ApoB, Lp(a), BNP |
| 7.2.2 | Kidney Function and Electrolytes | BUN, creatinine, eGFR, sodium, potassium, chloride |
| 7.2.3 | Thyroid Function | TSH, Free T4, Free T3, thyroid antibodies |
| 7.2.4 | Inflammation and Autoimmune Health | CRP, ESR, ANA, rheumatoid factor, autoimmune antibodies |
| 7.2.5 | Complete Blood Count and Immune Cells | Hemoglobin, hematocrit, RBC, WBC, platelets, differential |
| 7.2.6 | Metabolic Health | Glucose, HbA1c, insulin, leptin |
| 7.2.7 | Liver Function and Protein Chemistry | ALT, AST, GGT, bilirubin, albumin, total protein |
| 7.2.8 | Nutritional Health | Iron, ferritin, B12, folate, vitamin D, magnesium, zinc |
| 7.2.9 | Hormones and Male Health | PSA, testosterone, SHBG, cortisol |
| 7.2.10 | Specialized Laboratory Testing | Urinalysis, genetic testing, immune investigations, other specialized markers |
Section Introduction
Laboratory testing provides important information about the condition and function of the human body. Blood and urine measurements help evaluate cardiovascular health, kidney function, thyroid activity, inflammation, nutritional status, metabolic health, and other physiological processes. Understanding these measurements makes it possible to recognize their significance and appreciate how different aspects of health are connected.
My Laboratory Library, presented in Section 7.1, contains the recorded measurements from 40 laboratory reports covering 2013 through November 2026. These records provide the factual foundation for understanding my laboratory history.
The purpose of Section 7.2 is to explain what the important laboratory markers measure, why they are clinically relevant, and how they relate to my health history. Particular attention is given to cardiovascular health, kidney function, thyroid function, inflammation and autoimmune activity, blood counts, and metabolic health.
The explanations are organized into ten categories, allowing related measurements to be considered together. Not every laboratory marker requires an extended explanation. Emphasis is placed on those measurements that provide meaningful information about my health and medical conditions.
Section 7.2 is intended to improve my understanding of laboratory testing, not to replace medical evaluation. Laboratory results must be considered alongside medical history, symptoms, medications, examination findings, and the reference ranges and methods used by the testing laboratory.
The actual measurements remain in Section 7.1, while Section 7.3 examines how selected measurements have changed over time.
Together, these three sections provide a systematic approach to understanding my laboratory history: the recorded measurements, their medical significance, and their changes over time.
7.2.1 — Cardiovascular Health
Overview
Cardiovascular health involves the condition and function of the heart, blood vessels, and circulatory system. Laboratory testing provides important information about cholesterol metabolism, blood lipids, inflammation, and other factors associated with cardiovascular disease. Although laboratory measurements cannot independently determine the condition of the heart or blood vessels, they can help identify risk factors, evaluate metabolic processes, and provide information useful in long-term cardiovascular care.
My cardiovascular history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm. Because of these conditions, understanding cardiovascular laboratory markers is particularly important. These measurements complement blood pressure monitoring, cardiac imaging, heart rhythm evaluations, and the clinical assessments performed by my cardiologist.
This subsection explains the major cardiovascular laboratory markers, their clinical significance, and their relevance to my health history. The actual measurements and their dates are preserved in Section 7.1 — Laboratory Library. Changes in these measurements over time will be examined separately in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Total Cholesterol
Total cholesterol represents the combined cholesterol carried by different types of lipoproteins in the bloodstream. Cholesterol is essential for cell membranes, hormone production, and other biological functions. However, elevated concentrations of certain cholesterol-carrying particles can contribute to atherosclerosis.
Total cholesterol is most useful when interpreted alongside LDL cholesterol, HDL cholesterol, triglycerides, and, when available, apolipoprotein B.
Clinical significance: Total cholesterol provides a general overview of cholesterol levels but does not independently establish cardiovascular risk.
2. LDL Cholesterol (LDL-C)
Low-density lipoprotein cholesterol measures the amount of cholesterol carried by LDL particles. LDL particles can enter artery walls and contribute to the development of atherosclerotic plaque.
Higher LDL-C levels are associated with increased risk of atherosclerotic cardiovascular disease, particularly when elevations persist over time.
Clinical significance: LDL-C is an important marker for assessing and managing cardiovascular risk. Its interpretation depends on overall risk, other lipid measurements, and medical history.
3. HDL Cholesterol (HDL-C)
High-density lipoprotein cholesterol measures cholesterol carried by HDL particles. HDL participates in cholesterol transport and other biological processes.
Although higher HDL-C concentrations are often associated with lower cardiovascular risk in population studies, HDL-C alone does not reliably measure HDL function or guarantee protection from cardiovascular disease.
Clinical significance: HDL-C contributes to cardiovascular risk assessment but should not be interpreted independently of LDL-C, ApoB, triglycerides, and other risk factors.
4. Triglycerides
Triglycerides are a form of fat transported in the bloodstream and used for energy storage. Their concentrations are influenced by diet, metabolic health, genetics, alcohol consumption, and other factors.
Elevated triglycerides may accompany insulin resistance and other metabolic abnormalities. Very high concentrations can also increase the risk of pancreatitis.
Clinical significance: Triglycerides provide useful information about lipid metabolism and metabolic health. They are particularly informative when considered alongside HDL-C and glucose-related measurements.
5. Non-HDL Cholesterol
Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It represents cholesterol carried by lipoproteins that can contribute to atherosclerosis, including LDL and remnant particles.
Clinical significance: Non-HDL cholesterol offers a broader measure of atherogenic cholesterol than LDL-C alone and can be useful when triglyceride levels are elevated.
6. Apolipoprotein B (ApoB)
Apolipoprotein B is a structural protein found on major atherogenic lipoproteins. Each LDL particle contains one ApoB molecule, and ApoB is also present on other potentially atherogenic particles.
An ApoB measurement therefore provides an estimate of the number of these particles circulating in the bloodstream.
Clinical significance: ApoB can improve cardiovascular risk assessment, especially when LDL-C and particle concentrations do not agree. Elevated ApoB indicates a greater number of atherogenic particles.
7. Lipoprotein(a) — Lp(a)
Lipoprotein(a) is a genetically influenced lipoprotein associated with increased risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis.
Lp(a) concentrations are generally more stable over a person’s lifetime than many other lipid measurements.
Clinical significance: Elevated Lp(a) can represent an additional cardiovascular risk factor even when other lipid measurements appear favorable. It is not a direct measure of an ascending aortic aneurysm.
8. LDL Particle Number and Particle Size
Advanced lipid testing may measure the number and size distribution of LDL particles.
LDL particle number estimates how many LDL particles are circulating, while particle size describes their physical characteristics. A greater concentration of LDL particles can indicate increased atherosclerotic risk.
Clinical significance: Particle number can provide additional information in selected circumstances. Particle size alone is less useful for risk assessment and should not replace established measurements such as LDL-C or ApoB.
9. High-Sensitivity C-Reactive Protein (hs-CRP)
High-sensitivity C-reactive protein is a measurement of low concentrations of CRP, a protein produced by the liver in response to inflammation.
Elevated hs-CRP may indicate inflammatory activity associated with increased cardiovascular risk. However, infections, autoimmune conditions, injuries, and other inflammatory processes can also raise CRP.
Clinical significance: hs-CRP may contribute to cardiovascular risk assessment, but an elevated result does not establish that inflammation originates in the cardiovascular system.
10. B-Type Natriuretic Peptide (BNP) and NT-proBNP
BNP and NT-proBNP are substances released in response to increased stress or stretching of the heart’s chambers.
They are commonly used when evaluating possible heart failure and may provide information about cardiac strain.
Clinical significance: Elevated concentrations can suggest increased cardiac stress but are not specific to heart failure. Age, kidney function, atrial fibrillation, and other conditions can influence these measurements.
BNP and NT-proBNP are related but different tests, and their values and reference limits should not be used interchangeably.
Relevance to My Health History
Hypertension
Hypertension increases the workload placed on the heart and blood vessels and is an established risk factor for cardiovascular disease.
Laboratory lipid measurements help assess additional cardiovascular risk, while kidney function and electrolyte testing provide information relevant to blood pressure management.
Blood pressure itself is not measured through laboratory testing, so home and office blood pressure records remain essential.
Hyperlipidemia
My history of hyperlipidemia makes LDL-C, non-HDL cholesterol, ApoB, triglycerides, and related lipid measurements particularly relevant.
Because these measurements describe different aspects of lipid metabolism, no single result should be used to characterize overall cardiovascular health.
The objective is to understand the complete lipid profile and its relationship to my other cardiovascular risk factors.
History of Atrial Fibrillation
Atrial fibrillation is an electrical rhythm disorder of the heart. Lipid measurements do not diagnose atrial fibrillation or directly measure its severity.
However, kidney function, electrolytes, thyroid function, and selected cardiac biomarkers may be relevant when evaluating cardiovascular status or managing treatment.
My history of atrial fibrillation and Watchman device implantation makes ongoing clinical follow-up important even when laboratory measurements are satisfactory.
Ascending Aortic Aneurysm
An ascending aortic aneurysm involves enlargement of a portion of the aorta. Its assessment depends primarily on imaging, measurements of aortic diameter, the rate of enlargement, blood pressure, and other clinical factors.
There is no routine blood test that reliably determines the size or stability of an ascending aortic aneurysm.
The important distinction is that favorable cardiovascular laboratory results do not establish that an aortic aneurysm is stable. Imaging and cardiovascular follow-up remain necessary.
Dietary Considerations
My carnivore diet, followed since January 2024, may influence several laboratory measurements, particularly cholesterol, triglycerides, and metabolic markers.
The effects of a very-low-carbohydrate, animal-based diet can differ among individuals. Improvements in triglycerides, glucose, or HDL-C do not necessarily offset the cardiovascular risk associated with substantially elevated LDL-C or ApoB.
For this reason, the complete cardiovascular laboratory profile should be evaluated rather than relying on one favorable measurement.
Important Considerations
Cardiovascular laboratory results should be interpreted in the context of the complete medical history. Several considerations are especially important:
- Laboratory measurements are only one part of cardiovascular evaluation. Blood pressure, cardiac rhythm, imaging, symptoms, and physical examination remain essential.
- Atherosclerotic risk and other cardiovascular conditions are not identical. Lipid markers are particularly relevant to atherosclerosis, while atrial fibrillation and ascending aortic aneurysm require additional forms of evaluation.
- Laboratory reference ranges are not always equivalent to clinical treatment goals. An LDL-C value within a laboratory’s reference range may still exceed an individualized treatment target.
- Changes in laboratory methods may affect comparisons. Results from different laboratories should be compared carefully, especially when advanced lipid measurements or calculated values are involved.
- Age and medical conditions influence interpretation. Cardiovascular management at age 90 requires consideration of overall health, treatment tolerance, competing risks, and personal priorities.
- Medication decisions require individualized evaluation. Previous medication reactions and treatment limitations are relevant when discussing cardiovascular risk management with my cardiologist.
Summary of Understanding
Cardiovascular laboratory testing provides valuable information about cholesterol metabolism, atherogenic lipoproteins, inflammation, and selected indicators of cardiac stress. LDL cholesterol, non-HDL cholesterol, ApoB, triglycerides, HDL cholesterol, and Lp(a) are particularly important when evaluating lipid-related cardiovascular risk.
Because my medical history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm, these measurements must be considered alongside clinical evaluations, blood pressure records, heart rhythm assessments, and cardiovascular imaging.
The purpose of this subsection is to understand what the measurements mean and how they relate to my health. Section 7.1 preserves the actual laboratory results, while Section 7.3 will examine their historical trends.
Central Understanding: Cardiovascular health cannot be determined by any single laboratory measurement. The most useful assessment combines laboratory results with cardiovascular history, clinical findings, and appropriate ongoing monitoring.
7.2.2 — Kidney Function and Electrolytes
Overview
The kidneys perform several essential functions that help maintain the body’s internal balance. They filter waste products from the bloodstream, regulate fluid and electrolyte concentrations, participate in blood pressure control, maintain acid-base balance, and produce hormones involved in red blood cell formation and bone health.
Laboratory testing provides important information about how effectively the kidneys perform these functions. Measurements such as blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), sodium, potassium, chloride, and bicarbonate help evaluate kidney function and electrolyte balance.
My medical history includes hypertension, cardiovascular conditions, and previous episodes of abnormal laboratory measurements involving kidney-related markers and electrolytes. Because kidney function and cardiovascular health influence one another, understanding these measurements is particularly important.
This subsection explains the principal kidney function and electrolyte markers, their clinical significance, and their relevance to my health history. The actual laboratory measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Blood Urea Nitrogen (BUN)
Blood urea nitrogen measures the amount of nitrogen in the bloodstream derived from urea, a waste product formed when the body metabolizes protein. Urea is produced by the liver and removed primarily through the kidneys.
BUN concentrations can be influenced by kidney function, hydration, dietary protein intake, gastrointestinal bleeding, and certain medical conditions.
Clinical significance: Elevated BUN may reflect reduced kidney filtration, dehydration, or increased protein metabolism. Because several factors influence BUN, an elevated measurement does not independently establish kidney disease.
2. Creatinine
Creatinine is a waste product generated primarily through normal muscle metabolism. It is removed from the bloodstream by the kidneys.
Blood creatinine concentration is commonly used to evaluate kidney filtration, although its interpretation depends partly on muscle mass, age, diet, and other individual factors.
Clinical significance: An increase in creatinine may indicate reduced kidney filtration. However, relatively low muscle mass can produce a lower creatinine concentration and make kidney function appear better than it actually is.
3. Estimated Glomerular Filtration Rate (eGFR)
Estimated glomerular filtration rate is a calculated estimate of how effectively the kidneys filter blood.
Most routine eGFR calculations use serum creatinine together with age and sex. Some methods incorporate cystatin C, another blood marker that can help refine estimates of kidney function.
Clinical significance: eGFR is one of the principal measurements used to assess kidney filtration. A persistently reduced eGFR may indicate chronic kidney disease, but diagnosis requires consideration of duration and other evidence of kidney damage.
A single eGFR measurement should not be used to establish a long-term diagnosis.
4. BUN-to-Creatinine Ratio
The BUN-to-creatinine ratio compares two measurements that are influenced by kidney function and other physiological processes.
A higher ratio can occur with dehydration, increased protein intake, gastrointestinal bleeding, or other conditions. A lower ratio may occur in different nutritional or medical circumstances.
Clinical significance: The ratio can provide additional context when interpreting BUN and creatinine, but it is not a reliable standalone measure of kidney function or hydration.
5. Cystatin C
Cystatin C is a protein produced by many cells in the body and filtered by the kidneys. It can be used to estimate kidney filtration, either independently or in combination with creatinine.
Cystatin C is generally less dependent on muscle mass than creatinine, although inflammation, thyroid function, and other factors may influence its concentration.
Clinical significance: Cystatin C may be particularly useful when creatinine-based eGFR is potentially inaccurate because of reduced muscle mass or other individual characteristics.
6. Sodium
Sodium is an essential electrolyte involved in fluid balance, nerve transmission, muscle function, and blood pressure regulation.
Blood sodium concentration reflects the relationship between sodium and water in the body rather than simply the amount of sodium consumed.
Low blood sodium is called hyponatremia, while high blood sodium is called hypernatremia.
Clinical significance: Abnormal sodium concentrations can affect neurological function and may become serious, particularly when changes are substantial or rapid. Sodium results must be interpreted in relation to fluid balance, medications, kidney function, and other medical conditions.
7. Potassium
Potassium is an essential mineral required for normal nerve transmission, muscle contraction, and electrical activity of the heart.
The kidneys play a major role in maintaining appropriate potassium concentrations in the bloodstream.
Both low potassium and high potassium can interfere with normal cardiac electrical activity.
Clinical significance: Potassium is particularly important in individuals with cardiovascular conditions or a history of heart rhythm abnormalities. Significant potassium abnormalities may require prompt medical evaluation.
8. Chloride
Chloride is an electrolyte that works closely with sodium and bicarbonate to maintain fluid distribution and acid-base balance.
Abnormal chloride concentrations may occur with changes in hydration, kidney function, or acid-base status.
Clinical significance: Chloride helps provide a more complete understanding of electrolyte and acid-base balance, especially when interpreted alongside sodium and bicarbonate.
9. Carbon Dioxide (CO₂) / Bicarbonate
The carbon dioxide measurement included in a routine metabolic panel primarily reflects the amount of bicarbonate in the bloodstream.
Bicarbonate helps regulate the body’s acid-base balance.
Low bicarbonate may occur with metabolic acidosis, while elevated bicarbonate may occur with metabolic alkalosis or compensation for certain respiratory conditions.
Clinical significance: This measurement helps evaluate acid-base balance. Abnormal values may warrant additional testing to determine their cause.
10. Calcium
Calcium is essential for bone health, muscle contraction, nerve function, and blood clotting.
The kidneys participate in calcium regulation through their effects on vitamin D activation and mineral balance.
Blood calcium measurements are influenced by several factors, including albumin concentration and hormonal regulation.
Clinical significance: Abnormal calcium measurements may indicate disturbances involving kidney function, parathyroid activity, vitamin D metabolism, or other conditions.
Total calcium and ionized calcium are different measurements and may require different interpretations.
11. Magnesium
Magnesium supports numerous biological processes, including muscle function, nerve signaling, energy metabolism, and normal cardiac electrical activity.
The kidneys help regulate magnesium by adjusting how much is excreted in urine.
Clinical significance: Magnesium abnormalities may contribute to muscle symptoms and cardiac rhythm disturbances. A normal serum magnesium measurement does not always exclude inadequate magnesium stores elsewhere in the body.
12. Phosphorus / Phosphate
Phosphorus is important for bone structure, cellular energy production, and normal cellular function.
The kidneys regulate phosphate balance through filtration and excretion.
Clinical significance: Abnormal phosphate concentrations may occur with kidney dysfunction, hormonal disturbances, nutritional factors, or changes in vitamin D metabolism.
13. Urine Albumin-to-Creatinine Ratio (uACR)
The urine albumin-to-creatinine ratio measures the amount of albumin in urine relative to urine creatinine.
Healthy kidneys ordinarily prevent substantial amounts of albumin from passing into the urine. Increased urinary albumin can be an early indicator of kidney damage.
Clinical significance: uACR provides information about kidney health that blood creatinine and eGFR may not reveal. Persistent albuminuria is important in evaluating chronic kidney disease and cardiovascular risk.
Relevance to My Health History
Hypertension and Kidney Function
My history of hypertension makes kidney monitoring particularly important.
High blood pressure can damage the small blood vessels within the kidneys over time. Conversely, impaired kidney function can contribute to elevated blood pressure through changes in fluid balance and hormonal regulation.
For this reason, kidney function measurements and blood pressure records should be considered together.
History of Elevated BUN
My laboratory history includes an elevated BUN measurement of approximately 40 mg/dL in June 2024, with an accompanying reported eGFR of approximately 81 mL/min/1.73 m².
This illustrates why BUN should not be interpreted independently.
An elevated BUN with a relatively preserved eGFR may reflect factors other than reduced kidney filtration, including hydration status and dietary protein intake. However, the combination does not establish a particular cause.
Previous Hyponatremia
My laboratory history also includes a sodium concentration of approximately 129 mmol/L during the systemic inflammatory illness in 2021.
This represents hyponatremia and is an important historical finding.
Low sodium can occur for many reasons, including changes in fluid regulation, medications, acute illness, and hormonal or kidney-related disturbances.
The historical measurement does not establish whether sodium regulation remains abnormal today. Later measurements and clinical circumstances are necessary to determine whether the condition resolved or recurred.
History of Atrial Fibrillation
Potassium and magnesium are important for normal cardiac electrical activity.
Because of my history of atrial fibrillation, electrolyte abnormalities deserve particular attention. However, normal electrolyte values do not rule out atrial fibrillation, and abnormal values do not necessarily explain an episode.
Heart rhythm evaluation remains a separate and essential part of cardiovascular care.
Carnivore Diet and Protein Metabolism
My carnivore diet, followed since January 2024, includes substantial animal protein intake.
Higher protein consumption may increase urea production and contribute to elevated BUN without necessarily indicating impaired kidney filtration.
Creatinine measurements may also be affected by recent meat consumption, muscle mass, and other factors.
For this reason, BUN, creatinine, eGFR, and urine albumin measurements should be interpreted together, considering dietary intake, hydration, and laboratory trends.
Electrolyte Supplementation
My dietary routine has included electrolyte supplementation containing sodium, potassium, and magnesium.
These minerals are essential for normal physiological function, but the appropriate amount depends on kidney function, blood pressure, medications, dietary intake, and other medical considerations.
Potassium supplementation deserves particular attention because excessive potassium can be dangerous, especially when kidney function is impaired or when certain medications are used.
Laboratory monitoring can help identify abnormalities, but supplementation decisions should also account for the complete clinical picture.
Age and Muscle Mass
At age 90, changes in muscle mass can affect the interpretation of creatinine-based kidney function measurements.
Lower muscle mass may produce relatively low creatinine concentrations even when kidney filtration is reduced.
In selected circumstances, cystatin C testing or a combined creatinine-cystatin C estimate may provide a more accurate assessment.
This is an important consideration when interpreting apparently favorable eGFR measurements.
Important Considerations
- Kidney function cannot be evaluated from BUN alone. Creatinine, eGFR, urine albumin, and clinical circumstances provide a more complete assessment.
- Hydration and protein intake influence laboratory results. Changes in BUN or creatinine do not always represent changes in kidney function.
- Normal creatinine does not guarantee normal kidney function. This is particularly relevant in older adults with reduced muscle mass.
- Electrolyte balance is essential for cardiovascular health. Sodium, potassium, magnesium, and calcium abnormalities may have important consequences, particularly when heart rhythm disorders are present.
- Chronic kidney disease requires evidence of persistent abnormalities. A diagnosis generally depends on kidney abnormalities lasting at least three months, including reduced eGFR or markers of kidney damage.
- Blood and urine measurements provide complementary information. eGFR estimates filtration, while urine albumin testing helps detect kidney damage.
- Reference ranges and laboratory methods matter. Comparisons across different laboratories and testing dates should account for possible methodological differences.
- Supplementation should be individualized. Sodium, potassium, and magnesium requirements cannot be determined solely from dietary patterns or one laboratory result.
- Significant electrolyte abnormalities may require urgent attention. Symptoms such as marked weakness, confusion, fainting, or new palpitations warrant prompt medical assessment, particularly when accompanied by abnormal potassium or sodium results.
Summary of Understanding
Kidney function and electrolyte testing provide important information about filtration, waste removal, fluid balance, acid-base regulation, and the electrical activity of the heart.
BUN, creatinine, and eGFR are central measurements for evaluating kidney filtration, while urine albumin testing helps identify kidney damage that may not be apparent from blood measurements alone.
Sodium, potassium, chloride, bicarbonate, calcium, magnesium, and phosphorus provide additional information about the body’s internal balance.
Because my medical history includes hypertension, atrial fibrillation, previous hyponatremia, and a high-protein carnivore diet, these measurements are particularly relevant to my ongoing health assessment.
The purpose of this subsection is to understand the meaning of these laboratory markers and their relationship to my health. Section 7.1 preserves the actual measurements, while Section 7.3 will examine their historical patterns.
Central Understanding: Kidney health is best evaluated through several complementary measurements considered together. Changes in laboratory values must be interpreted in relation to hydration, diet, muscle mass, medications, age, and the overall medical history.
7.2.3 — Thyroid Function
Overview
The thyroid gland is a small, butterfly-shaped organ located in the front of the neck. It produces hormones that help regulate metabolism, energy production, body temperature, heart rate, digestion, and many other physiological processes.
Thyroid function is controlled through a feedback system involving the hypothalamus, pituitary gland, and thyroid gland. The pituitary produces thyroid-stimulating hormone (TSH), which signals the thyroid to produce primarily thyroxine (T4) and smaller amounts of triiodothyronine (T3). Much of the body’s active T3 is produced by converting T4 into T3 in peripheral tissues.
Laboratory testing helps evaluate whether the thyroid is producing appropriate amounts of hormone and whether the body’s regulatory system is functioning normally. The principal measurements include TSH, Free T4, and Free T3. Additional tests may evaluate thyroid antibodies or other aspects of thyroid function.
My medical history includes hypothyroidism treated with levothyroxine. Previous laboratory testing has also shown a low Free T3 measurement despite TSH and Free T4 measurements being within their respective reference ranges. Understanding the relationship among these markers is therefore particularly important.
This subsection explains the major thyroid laboratory markers, their clinical significance, and their relevance to my health history. The actual laboratory measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Thyroid-Stimulating Hormone (TSH)
Thyroid-stimulating hormone is produced by the pituitary gland and regulates thyroid hormone production.
When circulating thyroid hormone levels decrease, the pituitary generally increases TSH production to stimulate the thyroid. When thyroid hormone levels increase, TSH production usually decreases.
This feedback relationship makes TSH one of the most useful measurements for evaluating thyroid function.
Clinical significance: Elevated TSH may indicate an underactive thyroid, while suppressed TSH may indicate excessive thyroid hormone activity or thyroid hormone replacement. However, TSH must be interpreted alongside Free T4 and the clinical circumstances.
For most individuals receiving levothyroxine for primary hypothyroidism, TSH is the principal laboratory measurement used to guide treatment.
2. Free Thyroxine (Free T4)
Thyroxine, or T4, is the principal hormone produced by the thyroid gland.
Most circulating T4 is attached to transport proteins. Free T4 measures the small portion that is not protein-bound and is available for biological activity and conversion to T3.
T4 serves largely as a circulating supply of thyroid hormone that can be converted into the more biologically active T3.
Clinical significance: Free T4 helps evaluate thyroid hormone availability and is especially useful when TSH is abnormal or when pituitary-related thyroid dysfunction is suspected.
In individuals taking levothyroxine, Free T4 may also help assess thyroid hormone replacement.
3. Free Triiodothyronine (Free T3)
Triiodothyronine, or T3, is the more biologically active thyroid hormone at many cellular receptors.
Although the thyroid produces some T3 directly, much of the body’s T3 is generated by converting T4 into T3 in other tissues.
Free T3 measures the unbound portion of circulating T3.
Clinical significance: Free T3 can provide additional information in selected clinical situations, but it is not generally recommended as a routine test for adjusting levothyroxine treatment in primary hypothyroidism.
Low Free T3 may occur during illness, reduced caloric intake, fasting, or other physiological stresses without necessarily indicating inadequate thyroid hormone replacement.
4. Total Thyroxine (Total T4)
Total T4 measures both protein-bound and unbound thyroxine circulating in the bloodstream.
Because most T4 is attached to transport proteins, total T4 concentrations can be influenced by changes in these proteins.
Clinical significance: Total T4 may be useful in selected circumstances, but Free T4 is generally preferred when evaluating thyroid hormone availability.
5. Total Triiodothyronine (Total T3)
Total T3 measures both bound and unbound triiodothyronine.
It can be useful in certain thyroid disorders, particularly when evaluating suspected hyperthyroidism.
Clinical significance: Total T3 is not ordinarily used as the primary measurement for monitoring levothyroxine replacement in hypothyroidism.
6. Thyroid Peroxidase Antibodies (TPOAb)
Thyroid peroxidase is an enzyme involved in thyroid hormone production.
Thyroid peroxidase antibodies are immune proteins directed against this enzyme. Elevated concentrations are commonly associated with autoimmune thyroid disease, particularly Hashimoto thyroiditis.
Clinical significance: Positive TPO antibodies support an autoimmune cause of thyroid dysfunction but do not independently establish the degree of thyroid hormone deficiency.
Antibody concentrations are not generally used to adjust thyroid hormone replacement doses.
7. Thyroglobulin Antibodies (TgAb)
Thyroglobulin is a protein produced by the thyroid gland and used in thyroid hormone synthesis.
Thyroglobulin antibodies are directed against this protein and may be present in autoimmune thyroid disorders.
Clinical significance: TgAb can provide additional information about thyroid autoimmunity. Their presence alone does not establish that thyroid function is abnormal.
8. Thyroid-Stimulating Immunoglobulins (TSI) and TSH Receptor Antibodies (TRAb)
These antibodies interact with the thyroid-stimulating hormone receptor.
Some stimulate thyroid hormone production and are associated with Graves disease, a common cause of hyperthyroidism.
Other TSH receptor antibodies may interfere with thyroid stimulation.
Clinical significance: These tests are primarily useful when investigating suspected Graves disease or particular forms of autoimmune thyroid dysfunction. They are not routine monitoring tests for uncomplicated hypothyroidism.
9. Reverse T3 (rT3)
Reverse T3 is an inactive metabolite produced during thyroid hormone metabolism.
Its concentration can change during illness, fasting, and other physiological conditions.
Clinical significance: Reverse T3 testing is not generally recommended for diagnosing hypothyroidism or determining levothyroxine dosage. An abnormal reverse T3 result does not independently establish impaired thyroid hormone action in tissues.
Relevance to My Health History
Hypothyroidism
My medical history includes hypothyroidism, a condition in which the body has insufficient thyroid hormone activity.
Thyroid hormone influences metabolism, energy levels, temperature regulation, cardiovascular function, digestion, and many other physiological processes.
Symptoms of hypothyroidism can include fatigue, cold intolerance, constipation, dry skin, and reduced energy. However, these symptoms are not specific to thyroid disease and may have other causes, particularly in older adults.
TSH and Free T4 measurements provide important information when evaluating thyroid hormone replacement.
Levothyroxine Treatment
My prescribed thyroid replacement medication has been levothyroxine 75 micrograms daily.
Levothyroxine is a synthetic form of T4. The body converts some of this T4 into active T3 according to physiological requirements.
For most individuals with primary hypothyroidism, treatment is monitored primarily through TSH, with Free T4 providing additional information when needed.
Medication absorption can be affected by food, calcium, iron supplements, and certain other medications.
An important consideration is consistency: taking levothyroxine under similar conditions each day helps reduce variations in absorption and laboratory measurements.
Previous Low Free T3 Measurement
My laboratory history includes a low Free T3 measurement in 2025 while TSH and Free T4 were reported within their reference ranges.
This combination deserves careful interpretation.
Low Free T3 may occur during illness, fasting, changes in energy intake, or other physiological conditions. It can also reflect differences in laboratory testing methods.
A low Free T3 measurement does not automatically mean that levothyroxine treatment is inadequate.
The significance of this finding depends on symptoms, the actual measurements, the timing of testing, and the broader medical history.
History of Systemic Inflammation
My medical history includes a significant systemic inflammatory illness in 2021 and subsequent autoimmune investigations.
Acute and chronic illnesses can influence thyroid hormone metabolism, particularly the conversion of T4 to T3.
During significant illness, T3 concentrations may decrease without the thyroid gland itself being the primary cause.
This phenomenon is sometimes called nonthyroidal illness syndrome.
Clinical importance: Thyroid measurements obtained during illness may require different interpretation from measurements obtained during stable health.
Cardiovascular Health and Atrial Fibrillation
Thyroid hormones influence heart rate, cardiac contraction, and the body’s response to circulating stress hormones.
Excessive thyroid hormone activity can contribute to tachycardia and increase the likelihood of atrial fibrillation.
Because my medical history includes atrial fibrillation and other cardiovascular conditions, avoiding excessive thyroid hormone replacement is particularly important.
In older adults, excessive thyroid hormone exposure can also contribute to bone loss and other complications.
Thyroid replacement decisions must therefore balance adequate treatment of hypothyroidism against the risks of overtreatment.
Age and Thyroid Function
At age 90, thyroid laboratory results require particular attention to age, symptoms, cardiovascular history, and medication tolerance.
TSH concentrations may increase somewhat with advancing age, even in otherwise healthy individuals.
For this reason, the most appropriate TSH target may differ from that used for younger adults.
A mildly elevated TSH does not always require an increase in medication, especially when Free T4 is normal and there are concerns about cardiovascular complications.
Treatment targets should be individualized by the prescribing physician.
Diet and Fasting
My dietary pattern includes a carnivore diet and periods of fasting.
Prolonged fasting, reduced energy intake, and significant dietary changes can influence thyroid hormone metabolism, particularly circulating T3 concentrations.
These changes may represent physiological adaptations rather than primary thyroid dysfunction.
Consequently, thyroid laboratory results should be interpreted with consideration of recent fasting, illness, weight changes, and overall nutritional intake.
Important Considerations
- TSH is generally the principal marker for monitoring primary hypothyroidism. Free T4 provides additional information, while Free T3 has a more limited routine role.
- A low Free T3 measurement does not automatically indicate inadequate treatment. Illness, fasting, reduced caloric intake, and other factors may influence T3 concentrations.
- Thyroid hormone replacement must be individualized. Age, symptoms, cardiovascular conditions, and medication tolerance all influence appropriate treatment.
- Excessive thyroid hormone replacement can be harmful. In older adults, overtreatment may increase the risk of atrial fibrillation, bone loss, and other complications.
- Consistency in medication administration matters. Food, supplements, and certain medications can interfere with levothyroxine absorption.
- Thyroid antibodies help identify autoimmune causes. They do not necessarily indicate the current severity of thyroid dysfunction.
- Laboratory results obtained during illness may be misleading. Significant illness can temporarily alter thyroid hormone concentrations without indicating a permanent change in thyroid function.
- Symptoms and laboratory values must be evaluated together. Fatigue, weakness, and other symptoms may have causes unrelated to thyroid disease.
- Changes in medication should be guided by the prescribing physician. A single abnormal thyroid measurement should not automatically lead to a dosage adjustment.
Summary of Understanding
Thyroid function testing provides important information about hormone production, regulation, metabolism, and the adequacy of thyroid hormone replacement.
TSH, Free T4, and Free T3 are the principal measurements used to understand thyroid physiology, although their clinical roles differ. TSH is generally the most useful marker for monitoring primary hypothyroidism treated with levothyroxine.
My history of hypothyroidism, previous low Free T3, systemic inflammatory illness, fasting, and atrial fibrillation makes careful interpretation particularly important.
At age 90, thyroid treatment must balance adequate hormone replacement with the risks of excessive thyroid hormone exposure, especially cardiovascular complications.
The purpose of this subsection is to understand the meaning of thyroid laboratory markers and their relationship to my health. Section 7.1 preserves the actual measurements, while Section 7.3 will examine their historical patterns.
Central Understanding: Thyroid health is best evaluated by considering TSH, Free T4, clinical symptoms, and the overall medical history together. A low Free T3 measurement alone does not establish inadequate thyroid replacement, and avoiding overtreatment is especially important in older adults with cardiovascular conditions.
7.2.4 — Inflammation and Autoimmune Health
Overview
Inflammation is a natural protective response of the immune system to infection, injury, and other forms of tissue damage. When properly regulated, inflammation helps the body eliminate harmful substances, repair damaged tissues, and restore normal function. However, inflammation that becomes excessive, persistent, or misdirected can contribute to tissue injury and chronic illness.
Autoimmune conditions occur when the immune system mistakenly reacts against components of the body’s own tissues. These reactions may involve joints, muscles, blood vessels, skin, kidneys, or other organs. Autoimmune laboratory testing helps identify antibodies and inflammatory patterns that may be associated with these conditions.
Laboratory measurements such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), antinuclear antibodies (ANA), rheumatoid factor (RF), and other specialized antibodies provide information about inflammatory activity and possible autoimmune processes.
My medical history includes a significant systemic inflammatory illness in 2021, with severe joint and muscle symptoms, markedly elevated inflammatory markers, and subsequent investigations for autoimmune disease. Later laboratory testing identified positive autoimmune serology, including an ANA titer of 1:320 with a homogeneous staining pattern.
These findings make inflammation and autoimmune testing especially important in understanding my health history. However, laboratory abnormalities must be distinguished from confirmed clinical diagnoses, since positive antibodies do not always indicate active autoimmune disease.
This subsection explains the major inflammatory and autoimmune laboratory markers, their clinical significance, and their relevance to my health history. The actual measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. C-Reactive Protein (CRP)
C-reactive protein is produced primarily by the liver in response to inflammatory signals, particularly interleukin-6.
CRP concentrations can increase rapidly during infection, tissue injury, inflammatory disease, and other conditions involving immune activation.
CRP is a nonspecific marker, meaning that it can indicate inflammation without identifying its cause or location.
Clinical significance: Elevated CRP supports the presence of an inflammatory process but does not independently establish an autoimmune diagnosis. Serial measurements can help evaluate changes in inflammatory activity when interpreted alongside symptoms and clinical findings.
2. High-Sensitivity C-Reactive Protein (hs-CRP)
High-sensitivity CRP measures the same protein as conventional CRP but uses a method designed to detect lower concentrations more precisely.
It is commonly used in cardiovascular risk assessment when an individual is otherwise clinically stable.
Clinical significance: hs-CRP can provide information about low-grade inflammation and cardiovascular risk. However, an elevated result may reflect infection, autoimmune activity, injury, or other inflammatory conditions rather than cardiovascular inflammation specifically.
Conventional CRP and hs-CRP should be interpreted according to their testing purpose and laboratory reporting methods.
3. Erythrocyte Sedimentation Rate (ESR)
The erythrocyte sedimentation rate measures how quickly red blood cells settle in a vertical tube during a specified period.
Inflammatory proteins in the blood can cause red blood cells to aggregate and settle more rapidly.
ESR may increase with inflammatory disease, infection, certain cancers, anemia, and other conditions.
Clinical significance: ESR provides a general indication of inflammation but is less specific than many other laboratory measurements. Age, anemia, and other physiological factors can influence the result.
ESR and CRP are often considered together because they respond differently to inflammatory processes.
4. Antinuclear Antibodies (ANA)
Antinuclear antibodies are immune proteins that react with components found within the nuclei of cells.
ANA testing is commonly used when evaluating possible systemic autoimmune diseases, including systemic lupus erythematosus and certain connective tissue disorders.
ANA results may be reported as positive or negative and may include a titer and staining pattern.
Clinical significance: A positive ANA indicates the presence of detectable antinuclear antibodies but does not independently establish autoimmune disease.
Positive ANA results may occur in otherwise healthy individuals, particularly with advancing age.
5. ANA Titer
The ANA titer describes the degree to which a blood sample can be diluted while antibodies remain detectable.
A result such as 1:320 indicates that ANA reactivity was detectable at that dilution.
Higher titers may increase the likelihood that an ANA result is clinically relevant, but the relationship is not absolute.
Clinical significance: ANA titer helps characterize antibody findings. It does not directly measure disease severity, inflammatory activity, or the amount of tissue damage.
6. ANA Staining Pattern
ANA testing by indirect immunofluorescence may produce patterns such as homogeneous, speckled, centromere, or nucleolar.
These patterns can provide clues about the types of antibodies present and may help guide additional testing.
A homogeneous pattern can occur with antibodies directed against nuclear components, including chromatin, histones, or double-stranded DNA.
Clinical significance: An ANA staining pattern is not diagnostic by itself. Its meaning depends on specific antibody testing and the clinical presentation.
7. Rheumatoid Factor (RF)
Rheumatoid factor is an antibody directed against part of another antibody molecule.
It is frequently measured when evaluating possible rheumatoid arthritis and certain other inflammatory conditions.
However, rheumatoid factor may also be positive in infections, other autoimmune diseases, and some otherwise healthy older adults.
Clinical significance: Positive rheumatoid factor can support a diagnosis of rheumatoid arthritis when compatible clinical findings are present, but it does not establish the diagnosis independently.
8. Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)
Anti-CCP antibodies recognize proteins that have undergone a process called citrullination.
These antibodies are associated with rheumatoid arthritis and are generally more specific for that condition than rheumatoid factor.
Clinical significance: Positive anti-CCP antibodies can strengthen suspicion of rheumatoid arthritis, particularly when persistent inflammatory joint symptoms are present.
A negative result does not completely exclude rheumatoid arthritis.
9. Anti-Double-Stranded DNA Antibodies (Anti-dsDNA)
Anti-dsDNA antibodies react against double-stranded DNA.
They are associated with systemic lupus erythematosus and may provide useful information when that condition is suspected.
In some patients with lupus, changes in anti-dsDNA concentrations may correlate with disease activity, particularly kidney involvement.
Clinical significance: Anti-dsDNA testing is most meaningful when considered alongside symptoms, ANA results, complement levels, urine testing, and other clinical findings.
10. Extractable Nuclear Antigen Antibodies (ENA Panel)
The extractable nuclear antigen panel evaluates antibodies directed against several specific cellular proteins.
Depending on the laboratory, the panel may include:
- Anti-Sm antibodies
- Anti-RNP antibodies
- Anti-SSA/Ro antibodies
- Anti-SSB/La antibodies
- Anti-Scl-70 antibodies
- Anti-Jo-1 antibodies
These antibodies may be associated with lupus, Sjögren disease, systemic sclerosis, inflammatory muscle diseases, and other autoimmune conditions.
Clinical significance: ENA testing helps characterize possible autoimmune disorders after clinical evaluation and, frequently, a positive ANA result.
Individual antibodies differ substantially in their diagnostic significance.
11. Complement C3 and C4
Complement proteins are components of the immune system that participate in inflammation and the removal of pathogens and immune complexes.
C3 and C4 concentrations may decrease when complement is consumed during certain immune-mediated processes.
Clinical significance: Low complement levels may support evidence of immune-complex activity in selected autoimmune diseases, particularly lupus.
Normal complement levels do not exclude autoimmune disease.
12. Creatine Kinase (CK)
Creatine kinase is an enzyme found primarily in skeletal muscle, heart muscle, and other tissues.
CK concentrations may rise when muscle cells are injured.
Elevated CK can occur with inflammatory muscle diseases, strenuous physical activity, trauma, medications, and other causes of muscle injury.
Clinical significance: CK is useful when evaluating muscle injury or suspected inflammatory muscle disease. Muscle pain alone does not necessarily produce an elevated CK measurement.
13. Aldolase
Aldolase is an enzyme involved in energy metabolism and is present in skeletal muscle and other tissues.
Its concentration may increase in certain conditions involving muscle injury or inflammation.
Clinical significance: Aldolase may provide additional information when inflammatory muscle disease is suspected, particularly when considered alongside CK, symptoms, and other testing.
14. Immunoglobulins (IgG, IgA, and IgM)
Immunoglobulins are antibodies produced by immune cells.
The principal classes commonly measured in blood include IgG, IgA, and IgM.
Abnormal concentrations may occur with immune deficiency, chronic inflammation, autoimmune conditions, liver disease, and certain blood disorders.
Clinical significance: Immunoglobulin measurements help evaluate immune system function but do not independently diagnose a specific autoimmune condition.
15. White Blood Cell Count and Differential
White blood cells participate in immune defense and inflammatory responses.
The differential identifies the relative or absolute numbers of neutrophils, lymphocytes, monocytes, eosinophils, and basophils.
Changes may occur during infection, inflammation, allergic reactions, medication exposure, or other medical conditions.
Clinical significance: White blood cell measurements provide supporting information about immune activity but cannot independently identify the cause of inflammation.
A more complete explanation of these measurements appears in Section 7.2.5 — Complete Blood Count and Immune Cells.
Relevance to My Health History
Severe Systemic Inflammatory Illness in 2021
My medical history includes a period of severe systemic inflammation in 2021, accompanied by substantial joint and muscle symptoms.
Laboratory measurements during that period included an ESR of approximately 71 mm/hr and CRP of approximately 32 mg/L.
These findings supported the presence of significant inflammation but did not independently establish its underlying cause.
The combination of symptoms and inflammatory laboratory findings remains an important part of my medical history.
Positive ANA and Autoimmune Serology
Subsequent laboratory testing identified a positive ANA titer of 1:320 with a homogeneous staining pattern.
This finding indicates detectable antinuclear antibodies and may be relevant to investigations of systemic autoimmune disease.
However, ANA positivity is not equivalent to a diagnosis of lupus, rheumatoid arthritis, or another specific autoimmune disorder.
Its significance depends on the complete clinical picture, including symptoms, physical examination, other antibody measurements, and evidence of organ involvement.
History of Joint and Muscle Pain
My history includes substantial joint and muscle discomfort during the earlier inflammatory illness.
Inflammatory joint and muscle symptoms can occur in autoimmune disease, infection-related conditions, medication reactions, and other disorders.
CRP and ESR may help characterize systemic inflammation, while CK and aldolase can provide additional information when muscle injury is suspected.
Normal inflammatory markers do not necessarily exclude localized or ongoing inflammatory disease.
Family History of Rheumatoid Arthritis
My maternal grandmother had severe rheumatoid arthritis.
Family history can influence the likelihood of certain autoimmune diseases because genetic factors contribute to susceptibility.
However, a family history of rheumatoid arthritis does not establish that my previous inflammatory illness was rheumatoid arthritis.
Rheumatoid factor, anti-CCP antibodies, joint findings, and clinical history must be considered together.
Improvement in Symptoms and Dietary Changes
My health history includes substantial improvement in joint and muscle symptoms following the period of severe inflammation.
I subsequently adopted a strict carnivore diet beginning January 1, 2024, and have reported continued improvement in my general inflammatory symptoms.
This personal experience is important to document.
However, improvement occurring during or after dietary changes does not independently establish that the diet caused the improvement or that an underlying autoimmune process has resolved.
Changes in medication use, disease activity, other lifestyle factors, and the natural course of illness may also contribute.
Laboratory trends can provide additional information about inflammatory activity, but they cannot by themselves determine the cause of improvement.
Autoimmune Monitoring
Because of my history of systemic inflammation and positive autoimmune serology, ongoing clinical assessment remains important.
Changes in symptoms, physical examination findings, inflammatory markers, and selected autoimmune tests may help determine whether additional evaluation is appropriate.
ANA titers alone are generally not useful for routine monitoring of autoimmune disease activity.
The most informative monitoring approach depends on whether a specific autoimmune diagnosis has been established.
Age and Interpretation of Inflammatory Markers
At age 90, inflammatory laboratory measurements require consideration of age-related changes, chronic medical conditions, medications, and other possible causes.
ESR may be higher in older adults even without a specific inflammatory disease.
Positive autoantibodies may also be found in individuals who do not have a clinically significant autoimmune disorder.
Consequently, laboratory abnormalities should not be interpreted independently of symptoms and medical evaluation.
Important Considerations
- Inflammation and autoimmunity are not identical. Inflammation can occur without autoimmune disease, and some autoimmune conditions may be present without markedly elevated inflammatory markers.
- CRP and ESR identify inflammatory activity but not its cause. Elevated results require interpretation in the context of symptoms, examination findings, and other investigations.
- A positive ANA is not a diagnosis. ANA titers and patterns provide information about antibody activity but do not independently establish a specific autoimmune condition.
- Autoimmune antibodies may persist after symptoms improve. Persistent antibody positivity does not necessarily indicate ongoing tissue injury or active disease.
- Normal inflammatory markers do not exclude autoimmune disease. Some autoimmune conditions may remain clinically active despite relatively normal CRP or ESR measurements.
- Family history provides context, not certainty. A family history of rheumatoid arthritis increases the importance of appropriate evaluation but does not establish a diagnosis.
- Dietary associations should be distinguished from proven causes. Symptom improvement is meaningful, but laboratory trends and clinical assessment are necessary to evaluate possible changes in disease activity.
- Repeated ANA testing is not always useful. Changes in ANA titer generally do not provide a reliable measure of treatment response or disease activity.
- Organ-specific findings may be more important than antibody levels. Kidney function, urinalysis, blood counts, muscle enzymes, and other tests may be relevant when evaluating suspected systemic autoimmune disease.
- Clinical monitoring should be individualized. The most useful laboratory measurements depend on symptoms, established diagnoses, medication exposure, and the assessment of the treating specialist.
Summary of Understanding
Inflammation and autoimmune laboratory testing provide valuable information about immune activity, inflammatory responses, and possible immune-mediated disorders.
CRP and ESR help identify systemic inflammation, while ANA, rheumatoid factor, anti-CCP, anti-dsDNA, ENA antibodies, and complement measurements may contribute to the evaluation of specific autoimmune conditions.
My medical history includes severe systemic inflammation in 2021, markedly elevated inflammatory markers, significant joint and muscle symptoms, and subsequent positive autoimmune serology.
These findings are important but must be distinguished from a confirmed diagnosis of a particular autoimmune disease.
My reported improvement in symptoms is also an important part of the history. However, the relationship between symptom improvement, dietary changes, laboratory measurements, and underlying immune activity requires careful interpretation.
The purpose of this subsection is to understand what inflammatory and autoimmune laboratory measurements mean and how they relate to my health history. Section 7.1 preserves the actual results, while Section 7.3 will examine their historical patterns.
Central Understanding: Inflammatory markers reveal evidence of inflammation, while autoimmune antibodies may identify immune-system reactions against the body’s own tissues. Neither type of measurement establishes a diagnosis independently. The most meaningful assessment combines laboratory findings with symptoms, medical history, examination findings, and appropriate specialist evaluation.
7.2.5 — Complete Blood Count and Immune Cells
Overview
The complete blood count (CBC) is one of the most frequently performed laboratory tests. It provides information about the three principal cellular components of blood: red blood cells, white blood cells, and platelets. These cells perform essential functions involving oxygen transport, immune defense, and blood clotting.
Red blood cells transport oxygen from the lungs to the body’s tissues. White blood cells help protect against infections and participate in inflammatory and immune responses. Platelets contribute to the formation of blood clots and the prevention of excessive bleeding.
A CBC with differential provides additional information about the different types of white blood cells, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Changes in these measurements may reflect nutritional deficiencies, inflammation, infection, medication effects, bone marrow disorders, or other medical conditions.
My medical history includes a period of anemia during the systemic inflammatory illness in 2021 and a later laboratory finding of elevated eosinophils in 2024. These findings make the CBC and white blood cell differential particularly relevant to understanding my health history.
This subsection explains the principal blood cell measurements, their clinical significance, and their relationship to my medical history. The actual measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Red Blood Cell Count (RBC)
The red blood cell count measures the number of red blood cells circulating in a specified volume of blood.
Red blood cells contain hemoglobin, the protein responsible for carrying oxygen from the lungs to tissues throughout the body.
A reduced RBC count may occur with anemia, blood loss, nutritional deficiencies, chronic illness, or bone marrow disorders. An elevated count may occur with dehydration, chronic low oxygen levels, or certain blood disorders.
Clinical significance: RBC count helps evaluate the body’s oxygen-carrying system but must be interpreted alongside hemoglobin, hematocrit, and red blood cell indices.
2. Hemoglobin (Hgb)
Hemoglobin is the iron-containing protein within red blood cells that transports oxygen.
Hemoglobin concentration is one of the principal measurements used to identify anemia.
Low hemoglobin may result from blood loss, iron deficiency, vitamin deficiencies, chronic inflammation, kidney disease, or other conditions.
Clinical significance: Hemoglobin is a central marker of anemia. The severity and significance of a low result depend on its degree, duration, associated symptoms, and underlying cause.
3. Hematocrit (Hct)
Hematocrit represents the percentage of blood volume occupied by red blood cells.
It generally changes in the same direction as hemoglobin but is also influenced by hydration and plasma volume.
Clinical significance: Hematocrit helps evaluate anemia, elevated red blood cell concentrations, and changes in blood volume. It should be considered alongside hemoglobin and RBC count.
4. Mean Corpuscular Volume (MCV)
Mean corpuscular volume measures the average size of red blood cells.
It is commonly used to classify anemia into three general categories:
- Microcytic anemia — red blood cells are smaller than normal.
- Normocytic anemia — red blood cells are approximately normal in size.
- Macrocytic anemia — red blood cells are larger than normal.
These categories help guide further investigation.
Clinical significance: MCV provides clues about possible causes of anemia but does not independently establish a diagnosis.
5. Mean Corpuscular Hemoglobin (MCH)
Mean corpuscular hemoglobin estimates the average amount of hemoglobin contained within each red blood cell.
MCH is influenced by red blood cell size and hemoglobin content.
Clinical significance: MCH contributes to the characterization of anemia and is most useful when interpreted alongside MCV and MCHC.
6. Mean Corpuscular Hemoglobin Concentration (MCHC)
Mean corpuscular hemoglobin concentration measures the average concentration of hemoglobin within red blood cells.
Reduced MCHC may occur in conditions involving inadequate hemoglobin production, including some forms of iron deficiency.
Clinical significance: MCHC provides additional information about red blood cell characteristics and may help distinguish among types of anemia.
7. Red Cell Distribution Width (RDW)
Red cell distribution width describes the degree of variation in red blood cell size.
An elevated RDW indicates greater variation among circulating red blood cells.
This may occur with nutritional deficiencies, mixed causes of anemia, recovery from blood loss, or other conditions affecting red blood cell production.
Clinical significance: RDW can help characterize anemia, particularly when interpreted alongside MCV, hemoglobin, and iron or vitamin measurements.
8. White Blood Cell Count (WBC)
The white blood cell count measures the total number of circulating white blood cells.
White blood cells participate in immune defense, inflammation, and the body’s response to infection.
Elevated WBC counts may occur with infections, inflammation, stress, medications, or certain blood disorders.
Reduced WBC counts may occur with viral illnesses, medication effects, autoimmune conditions, nutritional deficiencies, or bone marrow disorders.
Clinical significance: WBC count provides a general assessment of circulating immune cells but does not identify the cause of an abnormality without additional information.
9. Neutrophils
Neutrophils are white blood cells that play a major role in defending the body against bacterial and fungal infections.
Their numbers may increase during bacterial infections, inflammation, physical stress, or corticosteroid treatment.
Reduced neutrophil counts may increase susceptibility to certain infections.
Clinical significance: The absolute neutrophil count (ANC) is generally more informative than the neutrophil percentage when evaluating neutropenia and infection risk.
10. Lymphocytes
Lymphocytes include T cells, B cells, and natural killer cells, which participate in adaptive and innate immune responses.
They are involved in recognizing pathogens, producing antibodies, and regulating immune activity.
Lymphocyte counts may change with infections, immune disorders, medications, and other conditions.
Clinical significance: Absolute lymphocyte counts help evaluate immune cell populations, but abnormalities require interpretation in relation to the complete clinical picture.
11. Monocytes
Monocytes are white blood cells that participate in immune defense, inflammation, and the removal of damaged cells.
After entering tissues, monocytes can develop into macrophages and other specialized immune cells.
Clinical significance: Elevated monocyte counts may occur during recovery from infection, chronic inflammation, and certain blood disorders. Mild isolated abnormalities are often nonspecific.
12. Eosinophils
Eosinophils are white blood cells involved in allergic responses, defense against certain parasites, and some inflammatory and immune processes.
Elevated eosinophils may occur with allergic conditions, medication reactions, parasitic infections, autoimmune or inflammatory disorders, and certain blood diseases.
Clinical significance: Eosinophilia is best assessed using the absolute eosinophil count rather than the percentage alone.
Persistent or substantial eosinophilia may require further investigation, particularly when accompanied by symptoms or evidence of organ involvement.
13. Basophils
Basophils are a relatively uncommon type of white blood cell involved in allergic and inflammatory responses.
They contain substances such as histamine that participate in immune signaling.
Clinical significance: Basophil abnormalities are often nonspecific. Persistent elevations may occasionally provide clues to allergic, inflammatory, or hematologic conditions.
14. Platelet Count
Platelets are small cell fragments produced in the bone marrow that help form blood clots when blood vessels are injured.
Low platelet counts, called thrombocytopenia, may increase bleeding risk.
High platelet counts, called thrombocytosis, may occur in response to inflammation, iron deficiency, infection, or certain bone marrow disorders.
Clinical significance: Platelet count helps evaluate clotting-related risk and may provide additional information about inflammation or bone marrow function.
Platelet count does not directly measure how effectively platelets function.
15. Mean Platelet Volume (MPV)
Mean platelet volume measures the average size of circulating platelets.
Larger platelets are often younger and may reflect changes in platelet production or turnover.
Clinical significance: MPV can provide supplementary information about platelet characteristics, but its clinical interpretation is limited by differences in laboratory methods and other factors.
16. Reticulocyte Count
Reticulocytes are immature red blood cells recently released from the bone marrow.
The reticulocyte count provides information about the rate of red blood cell production.
An increased count may occur when the bone marrow responds to blood loss or red blood cell destruction. A reduced or inappropriately normal count in someone with anemia may indicate inadequate production.
Clinical significance: Reticulocyte measurements help distinguish anemia caused by insufficient red blood cell production from anemia involving blood loss or increased destruction.
Relevance to My Health History
Anemia During the 2021 Inflammatory Illness
My laboratory history includes a hemoglobin measurement of approximately 11.4 g/dL during the systemic inflammatory illness in 2021.
The anemia was described as normocytic, indicating that the average size of the red blood cells was within the expected range.
Normocytic anemia may occur with inflammation, chronic illness, kidney dysfunction, blood loss, or other conditions.
The simultaneous presence of significant inflammation makes anemia associated with inflammation one possible explanation, but the laboratory measurements alone do not establish the cause.
Inflammation and Red Blood Cell Production
Inflammation can interfere with normal red blood cell production and iron metabolism.
Inflammatory signaling may increase hepcidin, a hormone that reduces the availability of iron for red blood cell production.
This can contribute to anemia even when total body iron stores are not severely depleted.
Because of my history of systemic inflammation, hemoglobin trends should be considered alongside inflammatory markers and iron studies.
Elevated Eosinophils in 2024
My laboratory history includes an eosinophil percentage of approximately 19% in June 2024.
This is an elevated percentage, but its clinical significance depends on the total white blood cell count and the calculated absolute eosinophil count.
A high eosinophil percentage does not necessarily indicate a severely elevated absolute eosinophil count.
Possible explanations for eosinophilia include allergic conditions, medication reactions, certain infections, and immune-related disorders.
The historical result deserves consideration alongside later differential counts and any associated symptoms.
History of Medication Reactions
My medical history includes adverse reactions to several medications.
Certain medications can cause changes in blood cell counts, including eosinophilia, neutropenia, anemia, or thrombocytopenia.
Drug-related eosinophilia may sometimes occur as part of a broader hypersensitivity reaction.
However, an elevated eosinophil measurement does not establish that a medication caused the abnormality.
The timing of medication exposure, symptoms, and laboratory changes is important when considering this possibility.
Autoimmune and Inflammatory History
Autoimmune and inflammatory conditions can affect blood cell production, destruction, and distribution.
Some conditions may contribute to anemia, reduced white blood cell counts, or platelet abnormalities.
Because my medical history includes positive autoimmune serology and previous systemic inflammation, CBC findings provide useful supporting information when considered with inflammatory markers and clinical symptoms.
A normal CBC does not exclude autoimmune disease.
Nutritional Considerations
Iron, vitamin B12, folate, and other nutrients are required for normal blood cell production.
Deficiencies may contribute to anemia or other blood count abnormalities.
My carnivore diet includes animal foods that provide substantial amounts of iron and vitamin B12, but dietary intake alone does not guarantee adequate absorption or exclude nutritional deficiencies.
Laboratory testing may be useful when unexplained changes in blood counts occur.
Age and Blood Cell Production
At age 90, changes in blood counts require careful evaluation.
Anemia is not an inevitable or normal consequence of aging and should not automatically be attributed to age.
Potential causes include nutritional deficiencies, kidney disease, chronic inflammation, blood loss, medication effects, and bone marrow disorders.
Persistent or progressive abnormalities deserve appropriate medical assessment.
Aspirin and Bleeding Considerations
My medication history includes low-dose aspirin.
Aspirin affects platelet function rather than ordinarily reducing platelet count.
Although a normal platelet count may be reassuring regarding platelet numbers, it does not eliminate aspirin-associated bleeding risk.
If hemoglobin declines unexpectedly, possible blood loss is one of several causes that may need consideration.
My history of atrial fibrillation and Watchman device implantation also makes accurate documentation of current antithrombotic treatment important.
Important Considerations
- Hemoglobin is a principal measurement for identifying anemia. RBC count, hematocrit, and red blood cell indices help characterize the abnormality and guide further evaluation.
- Anemia should not automatically be attributed to aging. Persistent low hemoglobin deserves consideration of possible underlying causes.
- MCV helps classify anemia but does not establish its cause. Iron studies, vitamin measurements, reticulocyte count, kidney function, and other tests may be needed.
- White blood cell percentages can be misleading when considered alone. Absolute neutrophil, lymphocyte, and eosinophil counts often provide more clinically useful information.
- Elevated eosinophils have several possible causes. Allergic conditions, medication reactions, infections, and immune disorders may all contribute.
- Inflammation can influence multiple blood cell measurements. Anemia, elevated platelets, and changes in white blood cells may accompany inflammatory conditions.
- Normal blood counts do not exclude illness. Some autoimmune, infectious, and other disorders may be present despite a CBC within reference ranges.
- Medication effects are important. Aspirin influences platelet function, while certain other medications can alter blood cell production or survival.
- Trends are often more informative than isolated results. Persistent, progressive, or recurrent abnormalities may be more significant than a single mildly abnormal measurement.
- Laboratory findings must be interpreted alongside symptoms. Unexplained fatigue, breathlessness, bleeding, bruising, recurrent infections, or other concerning symptoms may warrant further evaluation.
Summary of Understanding
The complete blood count provides essential information about oxygen transport, immune defense, and blood clotting.
Hemoglobin, hematocrit, RBC count, and red blood cell indices help evaluate anemia and red blood cell production. WBC count and the differential provide information about circulating immune cells, while platelet measurements contribute to the assessment of blood clotting and bone marrow activity.
My medical history includes normocytic anemia during the systemic inflammatory illness in 2021 and an elevated eosinophil percentage in 2024. These findings are important historical observations but do not independently establish their underlying causes.
Because of my inflammatory history, medication reactions, cardiovascular conditions, and age, blood count measurements should be evaluated as part of the broader medical picture.
The purpose of this subsection is to understand what the CBC measurements mean and how they relate to my health. Section 7.1 preserves the actual laboratory results, while Section 7.3 will examine their historical trends.
Central Understanding: The complete blood count provides a broad picture of blood cell production and function. The greatest value comes from interpreting related measurements together, considering absolute cell counts when appropriate, and evaluating changes over time rather than relying on a single laboratory result.
7.2.6 — Metabolic Health
Overview
Metabolic health describes how effectively the body obtains, processes, stores, and uses energy. It involves the regulation of blood glucose, insulin activity, fat metabolism, and the body’s ability to adapt to changing nutritional conditions.
Glucose is an important energy source for many tissues, while fatty acids and ketones can provide alternative fuels. Hormones such as insulin and glucagon help regulate the movement and use of these energy sources.
Laboratory testing provides valuable information about glucose regulation, insulin sensitivity, long-term blood sugar exposure, and selected aspects of metabolic function. Important measurements include fasting glucose, hemoglobin A1c (HbA1c), fasting insulin, C-peptide, and other markers associated with metabolic regulation.
My laboratory history includes HbA1c measurements extending back to 2015, as well as more recent glucose and ketone measurements obtained during fasting. Since January 1, 2024, I have followed a strict carnivore diet consisting primarily of animal foods, with very limited carbohydrate intake.
These dietary and fasting practices make it particularly important to distinguish normal metabolic adaptations from laboratory abnormalities that may indicate disease.
This subsection explains the principal metabolic laboratory markers, their clinical significance, and their relationship to my health history. The actual laboratory measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Fasting Blood Glucose
Fasting blood glucose measures the concentration of glucose in the bloodstream after a period without caloric intake, usually at least eight hours.
Blood glucose is regulated primarily through the actions of insulin, glucagon, the liver, and other metabolic processes.
In individuals without diabetes, fasting glucose generally remains within a relatively narrow range.
Common diagnostic categories for fasting plasma glucose are:
- Normal: below 100 mg/dL
- Prediabetes: 100–125 mg/dL
- Diabetes range: 126 mg/dL or higher, generally requiring confirmation in the absence of unequivocal hyperglycemia
Clinical significance: Fasting glucose provides a snapshot of blood sugar regulation. A single measurement may be influenced by fasting duration, illness, stress, medications, and other factors.
2. Hemoglobin A1c (HbA1c)
Hemoglobin A1c measures the percentage of hemoglobin that has glucose attached to it.
Because red blood cells circulate for approximately 120 days, HbA1c reflects average blood glucose exposure over roughly the preceding two to three months, with greater influence from more recent weeks.
Common diagnostic categories are:
- Normal: below 5.7%
- Prediabetes: 5.7–6.4%
- Diabetes range: 6.5% or higher, generally requiring confirmation unless the clinical circumstances establish the diagnosis
Clinical significance: HbA1c is useful for evaluating long-term glucose regulation and identifying possible prediabetes or diabetes.
However, anemia, altered red blood cell lifespan, recent blood loss, and certain other conditions can affect its accuracy.
3. Fasting Insulin
Insulin is a hormone produced by the beta cells of the pancreas.
Its principal functions include helping glucose enter insulin-sensitive tissues, suppressing excessive glucose production by the liver, and regulating the storage and use of nutrients.
Fasting insulin measures the amount of circulating insulin after a period without food.
Clinical significance: Elevated fasting insulin may accompany insulin resistance, although there is no universally accepted fasting insulin cutoff for diagnosing insulin resistance.
Low fasting insulin can occur normally during prolonged fasting or very-low-carbohydrate eating.
4. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
HOMA-IR is a calculated estimate of insulin resistance based on fasting glucose and fasting insulin.
When glucose is expressed in mg/dL, a commonly used calculation is:
HOMA-IR = Fasting Insulin (µIU/mL) × Fasting Glucose (mg/dL) ÷ 405
Higher values may suggest greater insulin resistance, but interpretation varies with the population and laboratory methods.
Clinical significance: HOMA-IR is primarily a research and supplementary assessment tool. It is not a definitive diagnostic test, and its interpretation can be limited during prolonged fasting or carbohydrate restriction.
5. C-Peptide
C-peptide is released by the pancreas when the body produces insulin.
Unlike injected insulin, naturally produced insulin is accompanied by C-peptide release.
Measuring C-peptide can therefore help estimate the body’s own insulin production.
Clinical significance: C-peptide is useful in selected evaluations of diabetes, unexplained low blood glucose, or suspected abnormalities of insulin secretion.
Its interpretation depends on the glucose concentration at the time of testing and kidney function.
6. Ketones — Beta-Hydroxybutyrate (BHB)
Beta-hydroxybutyrate is one of the principal ketone bodies produced by the liver when carbohydrate availability is reduced and fatty acid metabolism increases.
Ketone production commonly rises during fasting, carbohydrate restriction, or prolonged exercise.
Ketones can provide an alternative energy source for the brain and other tissues.
Clinical significance: Elevated BHB may indicate nutritional ketosis or fasting-related ketosis.
However, ketone concentration alone does not establish metabolic health. Markedly elevated ketones must be interpreted alongside glucose, acid-base status, symptoms, and the clinical circumstances.
Nutritional ketosis and diabetic ketoacidosis are different physiological states.
7. Glucose Ketone Index (GKI)
The glucose ketone index compares blood glucose concentration with blood beta-hydroxybutyrate concentration.
The calculation is:
GKI = Glucose (mmol/L) ÷ Beta-Hydroxybutyrate (mmol/L)
When glucose is measured in mg/dL, it is first converted to mmol/L by dividing by approximately 18.
A lower GKI generally indicates a greater relative concentration of ketones compared with glucose.
Clinical significance: GKI describes the relationship between glucose and ketones at a particular moment.
It is not an established diagnostic measure of metabolic health, disease prevention, or longevity, and there is no universally accepted clinical target for healthy individuals.
8. Fructosamine
Fructosamine measures glucose-related changes to circulating blood proteins, primarily albumin.
Because these proteins have a shorter lifespan than red blood cells, fructosamine generally reflects glucose exposure over approximately two to three weeks.
Clinical significance: Fructosamine may provide useful supplementary information when HbA1c is unreliable or when a shorter-term assessment is needed.
Its interpretation can be affected by abnormal protein concentrations or protein turnover.
9. Glycated Albumin
Glycated albumin measures the proportion of albumin that has undergone glycation.
Like fructosamine, it reflects glucose exposure over a shorter period than HbA1c.
Clinical significance: Glycated albumin may be useful when HbA1c does not accurately reflect glucose regulation, although changes in albumin metabolism can affect the result.
10. Leptin
Leptin is a hormone produced primarily by fat tissue.
It helps communicate information about stored energy to the brain and participates in the regulation of appetite, energy expenditure, and reproductive function.
Leptin concentrations are influenced by body fat, energy intake, fasting, and other physiological factors.
Clinical significance: Leptin can provide information about energy regulation, but it is not routinely used to diagnose metabolic health or determine dietary treatment.
11. Adiponectin
Adiponectin is a hormone produced by fat tissue that participates in glucose and fatty acid metabolism.
Higher adiponectin concentrations are often associated with greater insulin sensitivity in population studies.
However, its relationship with health outcomes is complex and may differ in older adults or individuals with chronic illness.
Clinical significance: Adiponectin is primarily a supplementary or research-oriented metabolic marker rather than a routine diagnostic test.
12. Uric Acid
Uric acid is produced during the metabolism of purines and is removed primarily through the kidneys.
Elevated uric acid may occur with reduced kidney excretion, certain dietary patterns, medications, dehydration, or increased purine metabolism.
High uric acid is associated with gout and may accompany several metabolic conditions.
Clinical significance: Uric acid is useful when evaluating gout risk and certain metabolic or kidney-related conditions, but it is not a standalone measure of insulin resistance or cardiovascular health.
13. Triglyceride-to-HDL Cholesterol Ratio
The triglyceride-to-HDL cholesterol ratio compares two common lipid measurements.
In some populations, a higher ratio is associated with insulin resistance and increased cardiometabolic risk.
However, its interpretation varies by population, measurement units, and metabolic circumstances.
Clinical significance: This ratio may provide supplementary information about metabolic patterns but should not replace established glucose measurements, lipid assessment, or clinical evaluation.
Relevance to My Health History
Historical HbA1c Measurements
My laboratory history includes the following previously recorded HbA1c values:
- 2015 — 5.7%
- 2016 — 5.1%
- 2019 — 5.5%
- February 2021 — 5.6%
These measurements illustrate variation in long-term glucose exposure over several years.
The 2015 value of 5.7% falls at the lower threshold of the commonly used prediabetes range, while the other listed measurements fall below that threshold.
These historical results do not establish my present glucose status. More recent measurements and the complete clinical picture are needed.
Carnivore Diet and Glucose Regulation
Since January 1, 2024, I have followed a strict carnivore diet with very limited carbohydrate intake.
Reducing dietary carbohydrates often lowers the amount of glucose entering the bloodstream from food and may reduce the insulin required to manage post-meal glucose.
This can produce lower glucose and insulin measurements in some individuals.
However, favorable glucose measurements do not by themselves establish that all aspects of metabolic or cardiovascular health are optimal.
Lipid measurements, kidney function, nutritional status, and other clinical findings remain important.
Fasting Glucose and Ketone Measurements
On January 4, 2026, after approximately 24 hours of fasting, I recorded:
- Blood glucose — 78 mg/dL
- Blood ketones — 4.7 mmol/L
- Glucose Ketone Index — approximately 0.9
These measurements indicate substantial ketone production relative to circulating glucose at that time.
The glucose measurement was within the usual fasting reference range, while the elevated ketone concentration was consistent with a fasting-related ketogenic state.
However, these results do not establish a particular level of health, predict longevity, or prove that prolonged fasting is beneficial.
A ketone measurement of 4.7 mmol/L is substantial and should be interpreted in the context of symptoms, hydration, medications, glucose, and acid-base status.
Fasting and Metabolic Adaptation
During fasting, insulin concentrations generally decrease while the body increases its use of stored energy.
The liver produces glucose through glycogen breakdown and gluconeogenesis, while fatty acids and ketones become increasingly important energy sources.
These adaptations allow the body to maintain energy availability when food is not being consumed.
However, prolonged fasting may also affect hydration, electrolytes, blood pressure, medication requirements, and nutritional intake.
At age 90, these considerations are particularly important because reduced physiological reserves can increase vulnerability to dehydration, weakness, and other complications.
Body Weight and Nutritional Status
My reported height is approximately 5 feet 10 inches, and my weight has been approximately 147 pounds.
Body weight provides some information about nutritional status, but it does not independently establish whether muscle mass, protein intake, or overall nutrition is adequate.
In older adults, maintaining strength, muscle mass, and functional ability is especially important.
A dietary pattern that produces favorable glucose measurements should also provide sufficient energy and nutrients to support physical function.
Previous Inflammatory Illness
My history includes severe systemic inflammation during 2021.
Inflammation and acute illness can influence glucose regulation through stress hormones, changes in insulin sensitivity, and alterations in metabolism.
Medication exposure, including corticosteroids, can also affect glucose measurements.
Consequently, historical glucose and HbA1c results should be interpreted in relation to the medical circumstances present at the time.
Relationship Between Metabolic and Cardiovascular Health
Glucose regulation is one component of cardiovascular risk assessment.
Insulin resistance, diabetes, elevated blood pressure, and abnormal lipid measurements may contribute to cardiovascular disease.
However, normal glucose and HbA1c values do not eliminate cardiovascular risk.
Because my medical history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm, metabolic measurements should be considered alongside the broader cardiovascular assessment.
Important Considerations
- Metabolic health cannot be determined by glucose alone. HbA1c, insulin, lipid measurements, blood pressure, nutritional status, and other clinical factors provide additional information.
- HbA1c reflects average glucose exposure rather than individual fluctuations. It may be affected by anemia, altered red blood cell lifespan, and certain medical conditions.
- Fasting insulin and HOMA-IR have limitations. Neither provides a definitive diagnosis of insulin resistance, particularly during prolonged fasting or substantial carbohydrate restriction.
- Nutritional ketosis is not the same as diabetic ketoacidosis. Ketones must be interpreted alongside glucose, symptoms, medications, and acid-base status. Significant illness or symptoms such as vomiting, abdominal pain, or rapid breathing require urgent evaluation, even when glucose is not markedly elevated.
- GKI is a descriptive calculation, not a validated health score. A low GKI does not independently demonstrate improved longevity or reduced disease risk.
- Dietary effects vary among individuals. A carnivore diet may influence glucose, insulin, ketones, cholesterol, and other measurements differently in different people.
- Fasting may affect hydration and electrolytes. This is especially relevant when blood pressure is low or when kidney and cardiovascular conditions are present.
- Muscle preservation is important in older adults. Favorable laboratory measurements should not come at the expense of adequate nutrition, strength, or physical function.
- Laboratory trends are generally more informative than isolated measurements. Changes over time can provide useful context, although they do not independently establish cause and effect.
- Metabolic findings must be interpreted in relation to the complete medical history. Cardiovascular conditions, medications, age, dietary practices, and symptoms all influence their significance.
Summary of Understanding
Metabolic laboratory testing provides important information about glucose regulation, insulin activity, energy metabolism, and the body’s response to dietary intake and fasting.
Fasting glucose and HbA1c are principal measurements for evaluating blood sugar regulation. Fasting insulin, C-peptide, and selected supplementary markers may provide additional information in appropriate clinical circumstances.
Ketone measurements describe the body’s use of alternative energy sources during fasting or carbohydrate restriction, while the glucose ketone index expresses the relationship between circulating glucose and ketones.
My laboratory history includes several HbA1c measurements, a long-term carnivore diet beginning in 2024, and fasting measurements demonstrating substantial ketone production.
These observations are useful for understanding my metabolic history, but no single measurement establishes overall metabolic health or predicts long-term outcomes.
The purpose of this subsection is to explain what metabolic laboratory markers mean and how they relate to my health. Section 7.1 preserves the recorded results, while Section 7.3 will examine their historical trends.
Central Understanding: Metabolic health involves more than maintaining low blood glucose or producing ketones. The most meaningful assessment considers glucose regulation, insulin activity, cardiovascular risk, nutritional adequacy, physical function, and changes in laboratory measurements over time.
7.2.7 — Liver Function and Protein Chemistry
Overview
The liver is one of the body’s most important metabolic organs. It processes nutrients absorbed from the digestive system, produces essential blood proteins, participates in cholesterol and fat metabolism, regulates aspects of blood glucose, and helps process medications, hormones, and other substances.
The liver also produces bile, which assists in the digestion and absorption of dietary fats. In addition, it converts ammonia, a byproduct of protein metabolism, into urea that can be removed through the kidneys.
Laboratory testing provides valuable information about liver-cell injury, bile flow, protein production, and other aspects of liver-related physiology. Important measurements include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, albumin, and total protein.
Although these measurements are often collectively called liver function tests, they do not all measure liver function directly. Some primarily identify liver-cell injury, while others provide information about bile duct abnormalities or the liver’s ability to produce proteins.
My medical history includes a significant systemic inflammatory illness, long-term medication exposure, and a carnivore diet beginning January 1, 2024. These factors provide important context when interpreting liver-related laboratory measurements.
This subsection explains the principal liver and protein chemistry markers, their clinical significance, and their relevance to my health history. The actual measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Alanine Aminotransferase (ALT)
Alanine aminotransferase is an enzyme found primarily in liver cells.
When liver cells are injured, ALT may be released into the bloodstream, causing its concentration to increase.
Elevated ALT may occur with fatty liver disease, viral hepatitis, medication-related liver injury, and other conditions affecting the liver.
Clinical significance: ALT is an important marker of liver-cell injury. However, an elevated ALT does not independently establish the cause or severity of liver disease.
A normal ALT also does not completely exclude significant liver disease.
2. Aspartate Aminotransferase (AST)
Aspartate aminotransferase is an enzyme found in the liver, skeletal muscles, heart, and several other tissues.
AST may increase when liver cells are injured, but it can also rise following muscle injury or other tissue damage.
Clinical significance: AST helps evaluate possible liver injury but is less specific to the liver than ALT.
When AST is elevated, other measurements such as ALT, creatine kinase, and clinical findings may help identify the source.
3. AST-to-ALT Ratio
The AST-to-ALT ratio compares the concentrations of these two enzymes.
Certain patterns may provide clues about possible causes of liver injury, including alcohol-associated liver disease or advanced liver fibrosis.
However, substantial overlap exists among different conditions.
Clinical significance: The ratio may provide supplementary information but should not be used independently to diagnose liver disease or determine its severity.
4. Alkaline Phosphatase (ALP)
Alkaline phosphatase is an enzyme found in several tissues, particularly the liver and bones.
Within the liver, ALP is associated with the bile ducts.
Elevated ALP may occur when bile flow is impaired, but it may also result from increased bone activity or certain other conditions.
Clinical significance: ALP helps evaluate possible bile duct abnormalities. Additional testing may be needed to determine whether an elevated result originates from the liver or another tissue.
5. Gamma-Glutamyl Transferase (GGT)
Gamma-glutamyl transferase is an enzyme found in the liver and several other organs.
GGT often increases in conditions involving liver or bile duct injury. Certain medications and alcohol exposure can also affect its concentration.
Clinical significance: GGT is particularly useful when ALP is elevated because a concurrent elevation may support a liver or bile duct source.
GGT is sensitive to several forms of liver-related disturbance but is not specific enough to establish a diagnosis independently.
6. Total Bilirubin
Bilirubin is produced primarily during the breakdown of hemoglobin from aging red blood cells.
The liver processes bilirubin and excretes it into bile.
Total bilirubin measures both unconjugated and conjugated bilirubin circulating in the bloodstream.
Clinical significance: Elevated bilirubin may occur with increased red blood cell breakdown, impaired liver processing, or reduced bile excretion.
The pattern of bilirubin elevation and accompanying laboratory findings helps determine possible causes.
7. Direct Bilirubin
Direct bilirubin, also called conjugated bilirubin, is bilirubin that has been processed by the liver.
It is normally excreted into bile and ultimately eliminated through the digestive system.
Clinical significance: Elevated direct bilirubin may indicate impaired bile excretion or certain liver disorders.
It is most useful when interpreted alongside total bilirubin, ALP, GGT, and other findings.
8. Indirect Bilirubin
Indirect bilirubin represents the portion of bilirubin that has not yet been conjugated by the liver.
It is generally calculated by subtracting direct bilirubin from total bilirubin.
Elevated indirect bilirubin may occur with increased red blood cell destruction, reduced bilirubin processing, or inherited conditions such as Gilbert syndrome.
Clinical significance: Indirect bilirubin helps characterize the cause of elevated total bilirubin but does not independently establish a diagnosis.
9. Albumin
Albumin is the most abundant protein in blood plasma and is produced primarily by the liver.
It helps maintain fluid balance within blood vessels and transports hormones, medications, fatty acids, and other substances.
Low albumin may occur with chronic liver disease, inflammation, kidney protein loss, inadequate nutritional intake, or other medical conditions.
Clinical significance: Albumin provides information about protein metabolism and, in some circumstances, the liver’s protein-producing capacity.
However, albumin is influenced by many factors and is not a specific measure of nutritional adequacy or liver function.
10. Total Protein
Total protein measures the combined concentration of albumin and globulins in the bloodstream.
These proteins contribute to fluid balance, transport functions, immune defense, and other biological processes.
Abnormal total protein concentrations may occur with dehydration, inflammation, liver disease, kidney disorders, or changes in immunoglobulin production.
Clinical significance: Total protein provides a general assessment of circulating proteins but must be interpreted alongside albumin and globulin measurements.
11. Globulin
Globulin represents a group of blood proteins that includes immunoglobulins and other proteins involved in transport and immune function.
In routine chemistry panels, globulin is commonly calculated by subtracting albumin from total protein.
Clinical significance: Elevated globulin may occur with chronic inflammation, immune activation, certain liver disorders, or abnormal immunoglobulin production.
Low globulin may occur in some immune deficiencies or protein-loss conditions.
12. Albumin-to-Globulin Ratio (A/G Ratio)
The albumin-to-globulin ratio compares the concentration of albumin with that of globulin.
Changes in the ratio may reflect decreased albumin, increased globulin, or both.
Clinical significance: The A/G ratio can help identify patterns of altered blood proteins but is not a standalone diagnostic measurement.
13. Prothrombin Time (PT) and International Normalized Ratio (INR)
Prothrombin time measures how long blood takes to clot under standardized laboratory conditions.
The international normalized ratio standardizes PT results, particularly for monitoring warfarin treatment.
Because the liver produces several important clotting factors, PT and INR may provide information about liver synthetic function in appropriate circumstances.
Clinical significance: An elevated INR may indicate reduced clotting-factor production in significant liver disease, but vitamin K deficiency, anticoagulant medications, and other factors can also influence the result.
INR is not a reliable measure of the anticoagulant effect of all blood-thinning medications.
14. Lactate Dehydrogenase (LDH)
Lactate dehydrogenase is an enzyme found in many tissues, including the liver, muscles, blood cells, and kidneys.
Its concentration may rise when cells are damaged.
Clinical significance: LDH can provide evidence of tissue injury but is not specific to the liver. Interpretation requires consideration of other laboratory measurements and clinical findings.
15. Ammonia
Ammonia is produced during protein metabolism and by intestinal microorganisms.
The liver normally converts much of this ammonia into urea for elimination through the kidneys.
Ammonia concentrations may become elevated in certain severe liver disorders or other metabolic conditions.
Clinical significance: Ammonia testing is useful in selected clinical situations but is not a routine screening test for liver health.
Blood ammonia concentration does not reliably indicate the severity of liver-related neurological dysfunction.
Relevance to My Health History
History of Systemic Inflammation
My medical history includes a significant systemic inflammatory illness in 2021.
Systemic inflammation can influence liver-related laboratory measurements through changes in protein production, immune signaling, and metabolism.
Albumin may decrease during substantial inflammation, while certain globulin proteins may increase.
These changes do not necessarily indicate that the liver itself is the primary source of the illness.
For this reason, liver enzymes and protein measurements should be interpreted alongside inflammatory markers and the clinical circumstances present at the time.
Medication History and Liver Monitoring
My medical history includes exposure to several medications, including treatments used during the earlier inflammatory illness.
Some medications can affect liver enzymes or, less commonly, cause clinically significant liver injury.
My history also includes adverse reactions to multiple medications.
However, a medication reaction does not necessarily involve liver injury, and abnormal liver enzymes do not independently establish that a medication was responsible.
The relationship between medication exposure and laboratory changes depends on timing, the pattern of abnormalities, symptoms, and other possible causes.
Carnivore Diet and Liver Metabolism
Since January 1, 2024, I have followed a strict carnivore diet consisting primarily of animal foods.
The liver plays an important role in processing dietary protein and fat, producing glucose when needed, and generating ketones during carbohydrate restriction or fasting.
Changes in diet and body weight may influence certain liver-related measurements.
However, normal liver enzymes do not establish that a particular dietary pattern is harmless, and abnormal enzymes do not necessarily indicate that the diet is responsible.
The complete clinical picture remains important.
Protein Intake and Urea Production
My dietary pattern includes substantial animal protein intake.
The liver converts nitrogen generated during protein metabolism into urea, which is then removed through the kidneys.
This process helps explain why dietary protein intake may influence blood urea nitrogen measurements.
However, BUN is not a direct measurement of liver health, and elevated BUN should not automatically be attributed to high protein intake.
The relationship between liver metabolism and kidney excretion is an important part of understanding these measurements.
Inflammation and Blood Protein Measurements
My history of positive autoimmune serology and systemic inflammation makes albumin, globulin, and total protein potentially informative.
Chronic inflammation or immune activation may increase certain globulin proteins.
Albumin may decrease during inflammatory illness even when the liver retains adequate protein-producing capacity.
These findings can provide useful supporting information but do not independently establish a specific autoimmune or liver disorder.
Age and Liver Function
At age 90, changes in body composition, blood flow, medication metabolism, and physiological reserves may affect how the liver responds to illness and medications.
Older adults may experience medication-related complications even when routine liver enzymes are within reference ranges.
Therefore, liver chemistry results should be considered alongside medication history, nutritional status, symptoms, and other medical conditions.
Relationship to Cardiovascular and Metabolic Health
The liver participates in cholesterol production, lipoprotein metabolism, glucose regulation, and ketone production.
Because my medical history includes hyperlipidemia and other cardiovascular conditions, liver metabolism is relevant to my broader health assessment.
However, liver enzyme measurements do not directly measure cardiovascular risk.
Lipid measurements and cardiovascular evaluations remain necessary for that purpose.
Important Considerations
- Not all liver function tests measure liver function directly. ALT and AST primarily indicate possible cell injury, while albumin and PT/INR may provide information about protein production in appropriate circumstances.
- Normal liver enzymes do not exclude liver disease. Some chronic liver conditions may be present despite relatively normal ALT and AST measurements.
- Elevated liver enzymes do not establish the cause of injury. Medications, infections, metabolic conditions, muscle injury, and other factors may contribute.
- AST is not specific to the liver. Muscle injury and other tissue damage can increase AST.
- ALP and GGT help evaluate possible bile duct abnormalities. Their combined pattern may provide more information than either measurement alone.
- Albumin is influenced by inflammation and protein loss. A low albumin result does not automatically indicate liver failure or inadequate dietary protein.
- Total protein and globulin provide information about immune and protein metabolism. Abnormalities may reflect inflammation, dehydration, or other conditions.
- Laboratory trends are generally more informative than isolated values. Persistent or progressive abnormalities may warrant greater attention than a single mild elevation.
- Medication history is essential. Liver-related abnormalities should be evaluated in relation to prescription medications, supplements, and other exposures.
- Symptoms remain important. New jaundice, dark urine, pale stools, significant abdominal pain, or unexplained confusion may require prompt medical evaluation.
Summary of Understanding
Liver function and protein chemistry testing provides valuable information about liver-cell injury, bile flow, protein metabolism, and selected aspects of the liver’s synthetic capacity.
ALT and AST help identify possible liver-cell injury. ALP and GGT provide information about potential bile duct abnormalities. Bilirubin measurements help evaluate the processing and elimination of products from red blood cell breakdown.
Albumin, total protein, globulin, and the albumin-to-globulin ratio provide additional information about circulating proteins, inflammation, and other physiological processes.
My medical history includes systemic inflammation, medication exposures, cardiovascular conditions, and a carnivore diet. These factors provide important context when interpreting liver-related laboratory measurements.
The purpose of this subsection is to understand what these laboratory markers mean and how they relate to my health. Section 7.1 preserves the actual measurements, while Section 7.3 will examine their historical patterns.
Central Understanding: Liver-related laboratory measurements evaluate different aspects of liver and protein metabolism. Their greatest value comes from interpreting patterns of results together, considering medical history and medications, and recognizing that normal liver enzymes do not necessarily establish normal liver health.
7.2.8 — Nutritional Health
Overview
Nutritional health involves obtaining, absorbing, and using the vitamins, minerals, proteins, fats, and other nutrients necessary for normal physiological function. Adequate nutrition supports energy production, blood cell formation, immune function, muscle strength, bone health, neurological activity, and tissue repair.
Laboratory testing can help identify certain nutritional deficiencies, excesses, and disturbances in nutrient metabolism. Important measurements include iron, ferritin, transferrin saturation, vitamin B12, folate, vitamin D, magnesium, zinc, and selected additional vitamins and minerals.
However, nutritional status cannot be determined from laboratory measurements alone. Dietary intake, digestion, absorption, body composition, medical conditions, medications, and physical function also influence nutritional health.
My medical history includes a period of anemia during the systemic inflammatory illness in 2021, a strict carnivore diet beginning January 1, 2024, and the use of selected electrolyte supplements. At age 90, maintaining adequate nutrition, muscle mass, strength, and functional independence is particularly important.
This subsection explains the principal nutritional laboratory markers, their clinical significance, and their relevance to my health history. The actual laboratory measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Serum Iron
Serum iron measures the amount of iron circulating in the bloodstream, primarily attached to the transport protein transferrin.
Iron is essential for hemoglobin production, oxygen transport, energy metabolism, and several cellular processes.
Serum iron concentrations can vary throughout the day and may be influenced by recent food intake, inflammation, and other factors.
Clinical significance: Serum iron contributes to the evaluation of iron status but should not be interpreted independently. Ferritin, transferrin saturation, total iron-binding capacity, and the complete blood count provide additional information.
2. Ferritin
Ferritin is a protein that stores iron within cells. Blood ferritin concentrations generally provide information about the body’s iron reserves.
Low ferritin is a useful indicator of depleted iron stores.
However, ferritin is also an acute-phase reactant, meaning that its concentration may increase during inflammation, infection, liver disease, or other medical conditions.
Clinical significance: Low ferritin strongly supports iron deficiency, while normal or elevated ferritin does not always exclude iron deficiency when significant inflammation is present.
3. Total Iron-Binding Capacity (TIBC)
Total iron-binding capacity estimates the blood’s capacity to transport iron through transferrin.
TIBC may increase when iron stores are depleted and decrease during inflammation or certain other medical conditions.
Clinical significance: TIBC helps distinguish patterns of iron deficiency from changes associated with inflammation or chronic illness.
It is most useful when considered alongside serum iron, ferritin, and transferrin saturation.
4. Transferrin Saturation
Transferrin saturation measures the percentage of transferrin’s iron-binding sites occupied by iron.
It is generally calculated using serum iron and total iron-binding capacity.
Low transferrin saturation may indicate inadequate iron availability for red blood cell production.
Elevated transferrin saturation may occur with excessive iron absorption or certain iron-overload conditions.
Clinical significance: Transferrin saturation helps evaluate both iron deficiency and possible iron overload. Its interpretation should include ferritin and the clinical circumstances.
5. Transferrin
Transferrin is a protein produced primarily by the liver that transports iron through the bloodstream.
Its concentration may increase during iron deficiency and decrease during inflammation, inadequate protein intake, or certain liver conditions.
Clinical significance: Transferrin provides additional information about iron transport but is influenced by factors beyond nutritional iron status.
6. Vitamin B12 (Cobalamin)
Vitamin B12 is essential for normal red blood cell production, DNA synthesis, and neurological function.
It is found naturally in animal-derived foods, including meat, fish, eggs, and dairy products.
Vitamin B12 absorption depends on several digestive processes, including the production of intrinsic factor in the stomach and absorption in the small intestine.
Clinical significance: Vitamin B12 deficiency may cause anemia, neurological symptoms, or both.
A normal or borderline serum B12 measurement does not always exclude functional deficiency, particularly when symptoms or blood count abnormalities are present.
7. Methylmalonic Acid (MMA)
Methylmalonic acid is a substance that may accumulate when vitamin B12-dependent metabolic processes are impaired.
Elevated MMA can provide additional evidence of functional vitamin B12 deficiency.
However, kidney dysfunction and other factors may also increase MMA.
Clinical significance: MMA is useful when serum vitamin B12 results are borderline or inconsistent with clinical findings.
It should be interpreted alongside kidney function and other laboratory measurements.
8. Folate (Vitamin B9)
Folate is necessary for DNA synthesis, normal cell division, and red blood cell production.
It is found in a variety of foods, particularly leafy vegetables, legumes, and certain animal foods such as liver.
Folate deficiency may contribute to macrocytic anemia and other abnormalities involving rapidly dividing cells.
Clinical significance: Folate testing helps evaluate certain types of anemia and nutritional deficiency.
Folate and vitamin B12 status should be considered together because their deficiencies can produce overlapping blood count abnormalities.
9. Vitamin D — 25-Hydroxyvitamin D
Vitamin D supports calcium absorption, bone mineralization, and several other physiological processes.
The principal laboratory measurement used to evaluate vitamin D status is serum 25-hydroxyvitamin D, often abbreviated 25(OH)D.
Vitamin D can be obtained through certain foods and supplements and is also produced in the skin following ultraviolet light exposure.
Clinical significance: Low vitamin D may contribute to impaired bone mineralization and muscle-related problems.
However, there is no universally agreed optimal concentration for every individual, and higher vitamin D levels do not necessarily produce better health outcomes.
10. Calcium
Calcium is essential for bone structure, muscle contraction, nerve transmission, and blood clotting.
Most calcium in the body is stored in bones and teeth, while only a small amount circulates in the bloodstream.
Blood calcium concentration is tightly regulated by hormones and does not directly indicate dietary calcium intake or total body calcium stores.
Clinical significance: Abnormal calcium measurements may reflect disturbances involving parathyroid function, vitamin D metabolism, kidney function, or other conditions.
Total calcium may require interpretation in relation to albumin, while ionized calcium measures the biologically active fraction more directly.
11. Magnesium
Magnesium participates in hundreds of enzyme-related processes, including energy metabolism, muscle contraction, nerve signaling, and normal cardiac electrical activity.
The kidneys regulate magnesium balance by adjusting urinary excretion.
Only a small proportion of the body’s magnesium is present in the bloodstream.
Clinical significance: Serum magnesium testing can identify certain abnormalities, but a normal serum concentration does not always exclude inadequate magnesium stores.
Magnesium measurements are especially relevant when evaluating muscle symptoms, electrolyte disturbances, or cardiac rhythm concerns.
12. Zinc
Zinc is an essential trace mineral involved in immune function, wound healing, protein synthesis, and numerous enzyme reactions.
Zinc is found in several animal foods, including beef and other meats.
Blood zinc concentrations may be influenced by inflammation, albumin levels, recent food intake, and the timing of sample collection.
Clinical significance: Low zinc may support suspicion of deficiency when compatible symptoms or dietary risks are present.
However, serum or plasma zinc is not a perfect measure of total body zinc status.
13. Copper
Copper is an essential trace mineral involved in iron metabolism, connective tissue formation, neurological function, and antioxidant enzyme activity.
Copper deficiency may cause anemia, reduced white blood cell counts, or neurological abnormalities.
Excessive zinc supplementation can interfere with copper absorption.
Clinical significance: Copper testing may be useful when unexplained anemia, neutropenia, neurological symptoms, or possible trace mineral imbalance is present.
14. Selenium
Selenium is a trace mineral required for several antioxidant enzymes and proteins involved in thyroid hormone metabolism.
Both inadequate and excessive selenium intake can cause health problems.
Clinical significance: Selenium testing is generally reserved for selected circumstances involving suspected deficiency, excess, or unusual nutritional exposure.
Routine testing is not necessary for most individuals.
15. Vitamin B6
Vitamin B6 participates in amino acid metabolism, neurotransmitter synthesis, and hemoglobin production.
Deficiency may contribute to anemia, neurological symptoms, or other abnormalities.
Excessive vitamin B6 supplementation can also cause peripheral neuropathy.
Clinical significance: Vitamin B6 testing may be useful when deficiency or toxicity is suspected, particularly when neurological symptoms are present.
16. Vitamin A
Vitamin A supports vision, immune function, and normal cell differentiation.
It is found in animal foods as preformed vitamin A and in certain plant foods as provitamin A carotenoids.
Because vitamin A is fat-soluble, excessive intake of preformed vitamin A can accumulate and cause toxicity.
Clinical significance: Vitamin A testing may be appropriate when deficiency, malabsorption, or excessive intake is suspected.
A diet that includes substantial liver consumption or high-dose supplements deserves particular consideration because of the possibility of excess vitamin A.
17. Vitamin E
Vitamin E is a fat-soluble vitamin involved in protecting cell membranes from oxidative damage.
Deficiency is uncommon in individuals with normal fat absorption but may occur with certain malabsorption disorders.
Clinical significance: Vitamin E testing is usually reserved for selected clinical circumstances rather than routine nutritional screening.
18. Albumin and Total Protein
Albumin and total protein are frequently included in routine blood chemistry panels.
Although these measurements are sometimes discussed in relation to nutrition, they are strongly influenced by inflammation, liver function, kidney protein loss, hydration, and other medical conditions.
Clinical significance: Albumin and total protein should not be used alone to diagnose protein-calorie malnutrition.
Assessment of nutritional adequacy requires consideration of dietary intake, weight changes, muscle mass, strength, and overall physical function.
Relevance to My Health History
Anemia During the 2021 Inflammatory Illness
My laboratory history includes a hemoglobin measurement of approximately 11.4 g/dL during the systemic inflammatory illness in 2021.
The anemia was described as normocytic, indicating that the average red blood cell size was within the expected range.
Inflammation can interfere with iron availability and red blood cell production, producing anemia even when iron stores are not completely depleted.
However, iron deficiency, vitamin deficiencies, kidney dysfunction, blood loss, and other causes may also contribute.
Ferritin, transferrin saturation, vitamin B12, folate, and related measurements may help clarify the cause when anemia is present.
Carnivore Diet and Nutritional Adequacy
Since January 1, 2024, I have followed a strict carnivore diet consisting primarily of beef, eggs, butter, salt, and raw whole milk.
These foods provide substantial amounts of protein and several important nutrients, including vitamin B12, iron, zinc, and certain fat-soluble vitamins.
However, dietary variety is limited, and the amounts of other nutrients depend on food selection, quantity, and individual absorption.
Potential concerns may include folate, vitamin C, magnesium, and other nutrients, depending on the exact dietary pattern.
Laboratory testing can help evaluate selected nutrients, but it cannot establish complete nutritional adequacy.
Iron and Vitamin B12 Intake
Beef and other animal foods provide heme iron, which is generally absorbed more efficiently than non-heme iron from plant foods.
Animal foods also provide vitamin B12.
However, adequate dietary intake does not guarantee normal iron or B12 status.
Absorption can be affected by age-related digestive changes, medications, gastrointestinal disorders, and other factors.
For this reason, unexplained anemia or neurological symptoms may warrant evaluation even when dietary intake appears adequate.
Electrolyte Supplementation
My nutritional routine has included supplementation with sodium, potassium, and magnesium.
These minerals support fluid balance, nerve function, muscle activity, and cardiovascular physiology.
However, the appropriate amounts depend on kidney function, blood pressure, dietary intake, medications, and other medical factors.
Potassium supplementation is particularly important to evaluate carefully because excessive potassium can cause dangerous cardiac rhythm disturbances.
Vitamin D, Calcium, and Bone Health
Maintaining bone and muscle health is especially important at age 90.
Vitamin D supports calcium absorption, while calcium is essential for bone mineralization.
However, normal blood calcium does not establish that bone density or dietary calcium intake is adequate.
Vitamin D measurements may provide useful information, but bone health also depends on physical activity, hormonal factors, nutritional intake, and other clinical considerations.
Muscle Mass and Healthy Aging
My reported height is approximately 5 feet 10 inches, and my weight has been approximately 147 pounds.
At age 90, maintaining muscle mass and physical strength is an important component of nutritional health.
Age-related muscle loss can occur even when laboratory measurements appear normal.
Adequate protein and energy intake, appropriate physical activity, and functional assessments are therefore important.
A stable body weight alone does not establish that muscle mass is being preserved.
Inflammation and Nutritional Markers
My history of systemic inflammation and positive autoimmune serology is relevant when interpreting several nutritional laboratory measurements.
Inflammation may increase ferritin while reducing circulating iron and transferrin concentrations.
It may also lower albumin and affect serum zinc measurements.
Consequently, abnormal nutritional markers do not always indicate inadequate dietary intake.
The relationship between inflammation and nutrient metabolism must be considered.
Food Safety and Nutritional Health
My dietary history includes consumption of raw whole milk.
Raw milk may contain disease-causing microorganisms, including organisms that can cause serious infection.
Older adults are at increased risk of severe complications from foodborne illness.
Pasteurized milk provides a safer alternative while retaining its major nutritional components.
This consideration is relevant to overall nutritional health even though it is not directly evaluated through routine nutrient measurements.
Important Considerations
- Nutritional health cannot be determined from laboratory results alone. Dietary intake, weight changes, muscle mass, strength, and physical function are essential parts of the assessment.
- Ferritin is influenced by inflammation. A normal or elevated ferritin concentration does not always exclude iron deficiency when inflammatory activity is present.
- Vitamin B12 deficiency can occur despite animal-food consumption. Age-related absorption difficulties and other medical conditions may contribute.
- Serum mineral measurements have limitations. Normal magnesium, calcium, or zinc concentrations do not necessarily establish adequate total body stores or dietary intake.
- Excessive supplementation can be harmful. Fat-soluble vitamins and certain minerals may cause toxicity when consumed in excessive amounts.
- A restricted diet requires attention to nutritional completeness. Adequate protein intake does not automatically ensure sufficient intake of every vitamin and mineral.
- Inflammation can alter nutritional laboratory measurements. Changes in ferritin, albumin, transferrin, and zinc may reflect illness rather than dietary deficiency alone.
- Bone and muscle health require more than laboratory testing. Strength, balance, activity, and appropriate clinical assessments remain important.
- Kidney function influences mineral balance. Magnesium, potassium, calcium, and phosphorus measurements should be considered alongside kidney function when appropriate.
- Trends are more useful than isolated measurements. Persistent or progressive abnormalities may warrant additional evaluation, particularly when accompanied by symptoms or changes in physical function.
Summary of Understanding
Nutritional laboratory testing provides valuable information about selected vitamins, minerals, iron metabolism, and other substances essential for normal physiological function.
Iron studies help evaluate iron availability and storage, while vitamin B12 and folate measurements contribute to the assessment of red blood cell production and neurological health.
Vitamin D, calcium, magnesium, zinc, copper, and other micronutrients support bone health, muscle function, immune activity, and numerous metabolic processes.
My medical history includes previous anemia, systemic inflammation, a long-term carnivore diet, and electrolyte supplementation. These factors make nutritional assessment particularly relevant.
At age 90, maintaining adequate energy intake, muscle mass, physical strength, and functional independence is at least as important as obtaining favorable individual laboratory measurements.
The purpose of this subsection is to understand what nutritional laboratory markers mean and how they relate to my health. Section 7.1 preserves the actual measurements, while Section 7.3 will examine their historical patterns.
Central Understanding: Nutritional health depends on adequate nutrient intake, absorption, metabolism, and physical function. Laboratory measurements can identify selected deficiencies or excesses, but the most meaningful assessment combines those results with dietary history, muscle strength, body composition, and overall health.
7.2.9 — Hormones and Male Health
Overview
Hormones are chemical messengers that regulate many essential functions throughout the body. They influence metabolism, muscle maintenance, bone strength, reproductive function, stress responses, energy regulation, and the activity of numerous organs.
In men, important hormonal systems include the hypothalamic-pituitary-gonadal axis, which regulates testosterone production, and the hypothalamic-pituitary-adrenal axis, which helps coordinate the body’s response to physical and psychological stress.
Laboratory measurements such as total testosterone, free testosterone, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, and cortisol provide information about different aspects of hormonal regulation.
Prostate-specific antigen (PSA), although not a hormone, is also included in this subsection because of its relevance to male health and prostate evaluation.
Hormonal measurements require careful interpretation because concentrations may change with age, illness, medications, nutritional status, and the time of day. An abnormal laboratory result does not necessarily indicate a hormonal disorder requiring treatment.
At age 90, the primary importance of hormonal evaluation is understanding whether a measurement helps explain a specific medical concern or contributes meaningfully to health assessment. Maintaining strength, mobility, bone health, and overall function is more important than attempting to achieve hormone concentrations typical of younger men.
This subsection explains the principal hormonal and male health laboratory markers, their clinical significance, and their relevance to my medical history. The actual measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Total Testosterone
Testosterone is the principal androgen hormone produced by the testes, with smaller contributions from the adrenal glands.
It supports male sexual development, reproductive function, muscle and bone maintenance, red blood cell production, and other physiological processes.
Total testosterone measures both protein-bound and unbound testosterone circulating in the bloodstream.
Testosterone concentrations commonly decrease with advancing age, although the degree of change varies considerably among individuals.
Clinical significance: Low total testosterone may support a diagnosis of testosterone deficiency when compatible symptoms are present and low concentrations are confirmed through appropriate repeat testing.
A single low result does not establish testosterone deficiency.
2. Free Testosterone
Free testosterone represents the small portion of circulating testosterone that is not bound to transport proteins.
Most testosterone is attached to SHBG or albumin, while only a small fraction circulates freely.
Free testosterone may be measured directly using specialized methods or calculated from total testosterone, SHBG, and albumin.
Clinical significance: Free testosterone can provide additional information when total testosterone is borderline or when SHBG concentrations are abnormal.
The accuracy of the measurement depends on the laboratory method. Some commonly used direct free testosterone assays are less reliable than equilibrium dialysis or validated calculations.
3. Sex Hormone-Binding Globulin (SHBG)
Sex hormone-binding globulin is a protein produced primarily by the liver.
It binds testosterone and estradiol, influencing the amount of these hormones that circulates in an unbound form.
SHBG concentrations may be affected by age, thyroid function, liver conditions, body composition, and certain medications.
Clinical significance: SHBG helps explain differences between total testosterone and free testosterone.
An elevated SHBG concentration may be associated with lower free testosterone even when total testosterone appears satisfactory.
4. Luteinizing Hormone (LH)
Luteinizing hormone is produced by the pituitary gland and stimulates testosterone production in the testes.
Its secretion is regulated through feedback involving testosterone and other hormones.
Clinical significance: LH helps distinguish between different causes of low testosterone.
Elevated LH with low testosterone may suggest impaired testicular hormone production, while low or inappropriately normal LH may indicate a problem involving pituitary or hypothalamic regulation.
5. Follicle-Stimulating Hormone (FSH)
Follicle-stimulating hormone is produced by the pituitary gland.
In men, FSH acts primarily on Sertoli cells within the testes and participates in the regulation of sperm production.
FSH concentrations are influenced by feedback signals from the testes, including inhibin B.
Clinical significance: FSH is useful when evaluating reproductive function and certain forms of testicular dysfunction.
Elevated FSH may indicate reduced testicular function, but it does not independently establish a specific diagnosis.
6. Estradiol (E2)
Estradiol is an estrogen hormone present in both men and women.
In men, much of the circulating estradiol is produced through the conversion of testosterone by an enzyme called aromatase.
Estradiol contributes to bone health, hormonal feedback, and other physiological functions.
Clinical significance: Estradiol testing may be useful in selected circumstances involving testosterone treatment, breast enlargement, or suspected hormonal imbalance.
Routine estradiol testing is not necessary for every older man.
7. Dihydrotestosterone (DHT)
Dihydrotestosterone is a potent androgen produced when testosterone is converted by the enzyme 5-alpha-reductase.
DHT plays important roles in androgen-related tissues, including the prostate and skin.
Clinical significance: DHT testing is generally reserved for selected clinical situations. It is not a routine measure of overall male health or testosterone adequacy.
8. Dehydroepiandrosterone Sulfate (DHEA-S)
DHEA-S is a hormone produced primarily by the adrenal glands.
It serves as a precursor for the production of certain androgens and estrogens.
DHEA-S concentrations generally decline substantially with advancing age.
Clinical significance: DHEA-S may help evaluate selected adrenal or androgen-related disorders.
A low concentration in an older adult does not automatically indicate disease or a need for supplementation.
9. Cortisol
Cortisol is a glucocorticoid hormone produced by the adrenal glands.
It participates in the regulation of blood glucose, metabolism, blood pressure, inflammation, and the body’s response to stress.
Cortisol normally follows a daily rhythm, with concentrations generally highest in the morning and lower later in the day.
Clinical significance: Cortisol testing is useful when evaluating suspected adrenal insufficiency or excessive cortisol production.
A single cortisol measurement must be interpreted according to the time of collection, the testing method, medications, and the clinical circumstances.
10. Adrenocorticotropic Hormone (ACTH)
Adrenocorticotropic hormone is produced by the pituitary gland and stimulates cortisol production by the adrenal glands.
ACTH and cortisol participate in a feedback system that helps regulate adrenal function.
Clinical significance: ACTH can help distinguish among causes of abnormal cortisol production.
It is most useful when interpreted together with appropriately timed cortisol measurements and other endocrine testing.
11. Prolactin
Prolactin is a hormone produced by the pituitary gland.
Although best known for its role in milk production, prolactin also influences reproductive hormonal regulation in men.
Elevated prolactin can suppress gonadotropin signaling and contribute to reduced testosterone production.
Clinical significance: Prolactin testing may be useful when low testosterone is accompanied by findings suggesting pituitary dysfunction or when certain medications or symptoms raise concern.
Mild elevations may be temporary or medication-related.
12. Insulin-Like Growth Factor 1 (IGF-1)
Insulin-like growth factor 1 is produced primarily by the liver in response to growth hormone.
It participates in growth, tissue maintenance, and several metabolic processes.
IGF-1 concentrations generally decrease with age.
Clinical significance: IGF-1 is useful when evaluating suspected growth hormone disorders.
A low value in an older adult does not independently establish a deficiency requiring treatment.
13. Prostate-Specific Antigen (PSA)
Prostate-specific antigen is a protein produced by cells of the prostate gland.
PSA is not a hormone. It is measured because changes in its concentration may provide information about prostate conditions.
PSA can increase with benign prostate enlargement, inflammation, infection, and prostate cancer.
Clinical significance: PSA is a prostate-related marker, not a cancer-specific test.
An elevated PSA does not establish prostate cancer, and a normal PSA does not completely exclude it.
At age 90, routine PSA screening generally offers little benefit because of the long time required for screening to prevent prostate cancer deaths and the potential harms of further testing and treatment. Evaluation for symptoms or a specific clinical concern is a separate matter.
14. Free PSA and Percent Free PSA
PSA circulates in several forms, including protein-bound and unbound PSA.
Free PSA measures the unbound portion, while percent free PSA compares free PSA with total PSA.
Clinical significance: Percent free PSA may provide supplementary information in selected evaluations of an elevated total PSA.
It is not ordinarily useful as an independent screening test.
Relevance to My Health History
Age and Hormonal Changes
At age 90, age-related changes in testosterone, SHBG, DHEA-S, and other hormones are expected.
However, a laboratory measurement outside a reference range does not automatically indicate a condition that requires treatment.
The significance of a hormonal result depends on symptoms, functional status, medical conditions, and whether treatment would offer a meaningful benefit.
My health goals include maintaining strength, independence, and physical function as I continue aging.
These goals provide a practical framework for interpreting hormonal measurements.
Testosterone and Muscle Maintenance
Testosterone contributes to muscle protein synthesis and the maintenance of lean body mass.
Lower testosterone concentrations may be associated with reduced muscle mass or strength, although aging, physical activity, nutrition, illness, and neurological factors also influence these outcomes.
My reported weight has been approximately 147 pounds at a height of 5 feet 10 inches.
Maintaining adequate nutrition, muscle strength, balance, and physical activity remains important regardless of testosterone concentration.
Testosterone treatment is not routinely recommended solely to counter normal aging or improve longevity.
Thyroid Function and SHBG
My medical history includes hypothyroidism treated with levothyroxine.
Thyroid hormone influences SHBG production in the liver.
Excessive thyroid hormone activity may increase SHBG, while hypothyroidism may reduce it.
Consequently, thyroid status can affect the interpretation of total and free testosterone measurements.
This is one reason hormonal results should be considered together rather than independently.
History of Systemic Inflammation
My medical history includes a severe systemic inflammatory illness in 2021.
Significant illness and inflammation can temporarily affect the hypothalamic-pituitary-gonadal axis, sometimes reducing testosterone concentrations.
Corticosteroid exposure and other medications may also influence hormonal regulation.
A hormone measurement obtained during illness may therefore differ from one obtained during stable health.
Diet, Fasting, and Hormonal Regulation
Since January 1, 2024, I have followed a strict carnivore diet and have periodically practiced fasting.
Energy intake, body composition, nutritional status, and prolonged fasting can influence several hormonal measurements.
Inadequate energy intake may suppress reproductive hormone production, while changes in insulin and thyroid function can influence SHBG.
However, a particular dietary pattern does not guarantee favorable hormone concentrations.
Hormonal measurements should be interpreted in relation to nutritional adequacy, symptoms, and overall health.
Cortisol and Previous Corticosteroid Treatment
My medical history includes corticosteroid treatment during the earlier inflammatory illness.
Corticosteroid medications can suppress the body’s natural cortisol-producing system, particularly when used for prolonged periods.
Recovery of normal adrenal function depends on the medication, dose, duration of treatment, and individual circumstances.
This historical exposure is relevant if symptoms or laboratory findings raise concern about adrenal function.
However, previous corticosteroid use does not establish that adrenal suppression is present today.
Cardiovascular Health and Hormonal Treatment
My medical history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm.
These conditions are important considerations when evaluating possible hormonal treatments.
Testosterone therapy can increase hematocrit and may affect blood pressure and other cardiovascular-related measurements.
Treatment decisions require individualized evaluation of potential benefits, risks, and monitoring requirements.
Hormonal treatment should not be initiated solely because a laboratory value is lower than that typically observed in younger men.
Prostate Health
PSA testing may provide information about certain prostate conditions, but its usefulness depends on age, symptoms, medical history, and the purpose of testing.
At age 90, the potential harms of routine prostate cancer screening generally outweigh the expected benefits.
However, urinary symptoms, unexplained bleeding, or other concerning findings may warrant clinical evaluation regardless of whether routine screening is appropriate.
The distinction between screening an asymptomatic person and investigating symptoms is important.
Family History
My family history has not identified a known pattern of prostate cancer.
This provides useful background but does not eliminate the possibility of prostate disease.
Family history is only one component of clinical risk assessment.
Important Considerations
- Hormonal measurements must be interpreted in relation to age and symptoms. A concentration outside a laboratory reference range does not automatically establish a disorder requiring treatment.
- Testosterone deficiency generally requires compatible symptoms and confirmed low measurements. A single low testosterone result is insufficient for diagnosis.
- SHBG influences testosterone interpretation. Total testosterone and free testosterone may provide different information when SHBG is unusually high or low.
- The timing of laboratory collection matters. Testosterone and cortisol have daily rhythms, although these patterns may change with age.
- Illness and medications can affect hormone concentrations. Inflammation, corticosteroids, thyroid treatment, and other medications may alter endocrine measurements.
- Low age-related hormone concentrations do not necessarily require replacement. Treatment should be based on demonstrated clinical need and a favorable balance of benefits and risks.
- Testosterone therapy requires careful monitoring. Hematocrit, blood pressure, symptoms, and other factors may need evaluation, particularly in individuals with cardiovascular conditions.
- PSA is not specific for prostate cancer. Benign prostate enlargement, inflammation, and other conditions may affect the result.
- Routine prostate cancer screening is generally not recommended at age 90. Symptom-directed evaluation remains appropriate when clinically indicated.
- Physical function is a central measure of healthy aging. Strength, mobility, balance, and nutritional adequacy may be more meaningful than attempts to optimize individual hormone concentrations.
Summary of Understanding
Hormonal laboratory testing provides information about testosterone production, reproductive regulation, adrenal activity, and other endocrine processes.
Total testosterone, free testosterone, SHBG, LH, and FSH help evaluate different aspects of male reproductive hormone function. Cortisol, ACTH, DHEA-S, and related measurements provide information about adrenal and broader endocrine activity.
PSA and free PSA are included because of their relevance to prostate health, although they are not hormones.
My medical history includes hypothyroidism, previous systemic inflammation, corticosteroid exposure, cardiovascular conditions, and a long-term carnivore diet. These factors may influence hormonal measurements and their interpretation.
At age 90, hormonal assessment should focus on clinically meaningful concerns rather than attempting to restore hormone concentrations associated with younger adulthood.
The purpose of this subsection is to understand what hormonal and male health laboratory markers mean and how they relate to my health. Section 7.1 preserves the actual measurements, while Section 7.3 will examine their historical patterns.
Central Understanding: Hormonal health is best evaluated by considering laboratory measurements together with symptoms, age, medical conditions, medications, and physical function. An abnormal hormone result does not automatically require treatment, and maintaining strength, independence, and overall health remains the primary objective.
7.2.10 — Specialized Laboratory Testing
Overview
Specialized laboratory testing provides information about particular organs, metabolic pathways, environmental exposures, inherited characteristics, and medical conditions that may not be fully evaluated through routine blood chemistry or complete blood count measurements.
Unlike standard laboratory panels, specialized tests are generally selected to investigate a particular clinical question. Some help evaluate kidney and urinary tract health, while others assess pancreatic function, fatty acid composition, immune activity, toxic exposures, or inherited biological characteristics.
These measurements may be useful when routine laboratory findings are unexplained, when symptoms suggest a particular disorder, or when a physician needs additional information to guide diagnosis or treatment.
Specialized testing requires careful interpretation. Some measurements have well-established clinical applications, while others are primarily supplementary or research-oriented. An abnormal result may indicate the need for further investigation without necessarily establishing disease.
My medical history includes cardiovascular conditions, a previous systemic inflammatory illness, positive autoimmune serology, medication reactions, and a long-term carnivore diet. These circumstances provide context for understanding why certain specialized tests may be relevant.
This subsection explains important categories of specialized laboratory testing, their clinical significance, and their relationship to my health history. The actual measurements are preserved in Section 7.1 — Laboratory Library, while their historical changes will be examined in Section 7.3 — Laboratory Trends and Health Assessment.
Important Laboratory Markers and Their Meaning
1. Urinalysis
Urinalysis examines the physical, chemical, and microscopic characteristics of urine.
A routine urinalysis may evaluate urine color, appearance, specific gravity, pH, protein, glucose, ketones, blood, bilirubin, and other substances.
Microscopic examination may identify red blood cells, white blood cells, casts, crystals, and microorganisms.
Clinical significance: Urinalysis provides useful information about kidney function, urinary tract conditions, hydration, and certain metabolic abnormalities.
Abnormal findings should be interpreted in relation to symptoms, blood chemistry, and other clinical information.
2. Urine Specific Gravity
Urine specific gravity measures the concentration of dissolved substances in urine relative to water.
It provides information about how concentrated or dilute the urine is.
Higher values may occur with dehydration or increased urinary solutes, while lower values may occur with high fluid intake or impaired urine-concentrating ability.
Clinical significance: Specific gravity helps assess urine concentration but does not independently establish hydration status or kidney disease.
3. Urine pH
Urine pH measures the acidity or alkalinity of urine.
It is influenced by dietary composition, kidney acid regulation, medications, and certain medical conditions.
Animal-protein-rich diets may produce more acidic urine because of their dietary acid load.
Clinical significance: Urine pH can provide information relevant to kidney stone formation and selected metabolic or urinary conditions.
A single urine pH measurement does not establish an acid-base disorder.
4. Urine Protein
Urine protein testing evaluates whether abnormal amounts of protein are present in urine.
Healthy kidneys normally prevent most large proteins from entering the urine.
Protein may appear in urine because of kidney disorders, temporary physiological changes, or other conditions.
Clinical significance: Persistent proteinuria may indicate kidney damage and warrants appropriate evaluation.
A routine urine dipstick may miss smaller amounts of albumin, making more specific testing useful in selected circumstances.
5. Urine Albumin-to-Creatinine Ratio (UACR)
The urine albumin-to-creatinine ratio compares urinary albumin with urinary creatinine.
It helps estimate albumin loss while accounting for differences in urine concentration.
An elevated UACR may indicate kidney damage even when estimated glomerular filtration rate remains relatively preserved.
Clinical significance: UACR is an important measurement for evaluating kidney health, particularly in individuals with hypertension, diabetes, or other kidney risk factors.
Persistent abnormalities are generally more meaningful than a single elevated result.
6. Urine Blood and Red Blood Cells
Urinalysis may detect blood through a chemical dipstick test or identify red blood cells through microscopic examination.
Blood in urine may result from urinary tract infection, stones, kidney disorders, prostate conditions, or other causes.
A positive dipstick result does not always indicate intact red blood cells because the test may also react to hemoglobin or myoglobin.
Clinical significance: Persistent or unexplained blood in urine requires appropriate evaluation, particularly in older adults.
7. Urine White Blood Cells and Nitrites
White blood cells in urine may indicate inflammation or infection within the urinary tract.
Nitrites may be produced when certain bacteria convert urinary nitrates into nitrites.
However, not all urinary infections produce positive nitrite results.
Clinical significance: These measurements may support evaluation for urinary tract infection but should be interpreted alongside symptoms and, when indicated, urine culture.
The presence of bacteria or white blood cells without symptoms does not always require antibiotic treatment.
8. Urine Ketones
Urine ketone testing detects certain ketone bodies eliminated through the kidneys.
Standard urine ketone strips primarily detect acetoacetate rather than beta-hydroxybutyrate, the principal ketone commonly measured in blood during ketosis.
Urine ketone concentrations are influenced by hydration, kidney excretion, and the body’s adaptation to carbohydrate restriction.
Clinical significance: Urine ketones may provide general information about ketone production but are less useful than blood beta-hydroxybutyrate for assessing the current degree of ketosis.
Urine ketones alone cannot distinguish nutritional ketosis from dangerous ketoacidosis.
9. Amylase
Amylase is an enzyme involved in carbohydrate digestion.
It is produced primarily by the pancreas and salivary glands.
Blood amylase may increase with pancreatic inflammation, salivary gland disorders, and certain other conditions.
Clinical significance: Amylase may contribute to the evaluation of suspected pancreatic disease but is not specific to the pancreas.
An elevated amylase measurement does not independently establish pancreatitis.
10. Lipase
Lipase is an enzyme produced primarily by the pancreas that helps digest dietary fats.
Blood lipase concentrations may increase substantially during acute pancreatic inflammation.
Clinical significance: Lipase is generally preferred over amylase when evaluating suspected acute pancreatitis.
However, lipase must be interpreted alongside symptoms and other diagnostic findings.
11. Omega-3 Index
The omega-3 index measures the proportion of the omega-3 fatty acids EPA and DHA in red blood cell membranes.
It reflects aspects of longer-term omega-3 fatty acid exposure and incorporation into cell membranes.
EPA and DHA are found primarily in fatty fish, seafood, and certain supplements.
Clinical significance: The omega-3 index provides information about fatty acid composition.
Although associations with cardiovascular outcomes have been reported, the index is not a universally established diagnostic test or treatment target for preventing cardiovascular disease.
12. Omega-6 to Omega-3 Fatty Acid Ratio
This ratio compares selected omega-6 and omega-3 fatty acids.
Both categories contain essential fatty acids that participate in cell membrane structure and physiological signaling.
The biological effects depend on the specific fatty acids involved rather than the ratio alone.
Clinical significance: The omega-6 to omega-3 ratio may provide supplementary dietary and metabolic information, but there is no universally accepted clinical target that establishes optimal health.
13. Arachidonic Acid to EPA Ratio
The arachidonic acid-to-EPA ratio compares an omega-6 fatty acid with an omega-3 fatty acid.
Both participate in the production of signaling molecules involved in inflammation and other physiological processes.
Clinical significance: This ratio may be included in specialized fatty acid panels, but it should not be treated as a direct or definitive measure of systemic inflammation.
Established inflammatory markers and clinical findings remain important.
14. Heavy Metals — Lead, Mercury, Arsenic, and Cadmium
Heavy metal testing evaluates exposure to selected toxic elements.
Different metals affect different organs and physiological systems.
For example, lead may affect neurological, cardiovascular, and blood-forming systems, while mercury exposure may affect the nervous system and kidneys.
The appropriate specimen depends on the metal and suspected exposure. Blood, urine, or other samples may be used.
Clinical significance: Heavy metal testing is most useful when a credible exposure history or compatible clinical findings justify investigation.
An abnormal concentration does not automatically establish poisoning, and results must be interpreted using appropriate methods and reference standards.
15. Environmental Chemical Exposure Testing
Certain specialized tests measure chemicals or metabolites associated with occupational, household, dietary, or environmental exposures.
Examples may include selected pesticides, industrial compounds, and other environmental substances.
The clinical significance depends on the substance measured, the exposure route, and the timing of sample collection.
Clinical significance: Environmental testing should generally be guided by a specific exposure concern.
Broad screening without a clear clinical question may produce findings that are difficult to interpret.
16. Genetic Testing
Genetic testing examines inherited variations in DNA that may influence disease risk, biological characteristics, or responses to certain medications.
Different genetic tests have different purposes.
Some identify variants associated with established inherited disorders, while others estimate susceptibility to common conditions.
Clinical significance: A genetic variant does not necessarily mean that a person has or will develop a particular disease.
The usefulness of a result depends on the strength of the scientific evidence, the type of variant, family history, and whether the information can guide meaningful medical decisions.
17. Pharmacogenetic Testing
Pharmacogenetic testing examines genetic variations that may influence how certain medications are metabolized or how the body responds to them.
Some genetic variants affect enzymes responsible for drug metabolism.
In selected situations, these findings can help guide medication selection or dosing.
Clinical significance: Pharmacogenetic testing may be useful for certain medications with established gene-drug relationships.
However, it cannot predict every adverse reaction, allergy, or medication intolerance.
18. Specialized Immune Testing
Specialized immune investigations may include measurements of immunoglobulin subclasses, complement activity, lymphocyte populations, or antibodies directed against particular tissues.
These tests may provide additional information when immune deficiency, autoimmune disease, or unusual inflammatory activity is suspected.
Clinical significance: Specialized immune tests are most useful when selected to answer a specific clinical question.
An isolated abnormality does not necessarily establish immune dysfunction or autoimmune disease.
19. Serum Protein Electrophoresis (SPEP)
Serum protein electrophoresis separates circulating blood proteins into groups according to their electrical characteristics.
It may identify patterns associated with inflammation, reduced immunoglobulin production, or the presence of a monoclonal protein.
Clinical significance: SPEP may be useful when unexplained anemia, abnormal globulin concentrations, certain kidney abnormalities, or other findings raise concern about a plasma cell disorder.
Additional tests may be required to characterize an abnormal result.
20. Serum Free Light Chains
Serum free light chain testing measures circulating kappa and lambda immunoglobulin light chains.
It may be used alongside serum protein electrophoresis and immunofixation when evaluating selected plasma cell disorders.
Kidney function can influence free light chain concentrations.
Clinical significance: An abnormal light chain measurement or ratio requires interpretation in relation to kidney function, other protein studies, and the clinical circumstances.
21. Cardiac Troponin
Cardiac troponin is a protein released into the bloodstream when heart muscle cells are injured.
High-sensitivity troponin assays can detect relatively small amounts of cardiac injury.
Troponin may increase during a heart attack, but elevations may also occur with other cardiovascular and systemic conditions.
Clinical significance: Troponin is important in the evaluation of suspected acute cardiac injury.
An elevated result does not independently establish a heart attack; symptoms, electrocardiographic findings, serial measurements, and other clinical information are essential.
22. B-Type Natriuretic Peptide (BNP) and NT-proBNP
BNP and NT-proBNP are substances released in response to increased pressure or stretching of the heart’s chambers.
They are commonly used in the evaluation of suspected heart failure.
Concentrations may also be influenced by age, kidney function, atrial fibrillation, and other factors.
Clinical significance: BNP and NT-proBNP provide useful information about cardiac stress but are not specific to one cardiovascular condition.
Their interpretation requires consideration of the patient’s age and medical history.
Relevance to My Health History
Kidney and Urinary Tract Monitoring
My medical history includes hypertension and laboratory measurements used to monitor kidney function.
Urinalysis and urine albumin measurements may provide information that is not available from blood creatinine or estimated glomerular filtration rate alone.
Persistent urinary protein or albumin may indicate kidney damage even when filtration measurements remain relatively stable.
These tests may therefore contribute to a more complete understanding of kidney health.
Carnivore Diet and Urinary Chemistry
Since January 1, 2024, I have followed a strict carnivore diet.
Dietary composition can influence urine pH, urinary solute excretion, and certain factors involved in kidney stone formation.
A diet rich in animal protein may increase dietary acid load and influence urinary calcium, citrate, and uric acid handling.
However, these effects vary among individuals.
Urine chemistry measurements may be useful if kidney stones, unexplained urinary abnormalities, or other specific concerns arise.
Ketone Production During Fasting
My history includes fasting-related blood glucose and ketone measurements.
Urine ketone testing and blood beta-hydroxybutyrate testing measure different aspects of ketone metabolism.
Consequently, the results are not directly interchangeable.
Blood ketone measurements generally provide a more useful indication of current beta-hydroxybutyrate concentration.
The clinical importance of ketones depends on glucose, symptoms, medications, and the broader metabolic circumstances.
Cardiovascular Health
My medical history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm.
Specialized cardiovascular markers such as troponin and BNP or NT-proBNP may be relevant when a specific clinical concern arises.
However, these measurements are not substitutes for cardiovascular examinations, imaging, or other established monitoring.
Fatty acid testing may provide additional information about dietary exposure but does not replace standard cardiovascular risk assessment.
History of Medication Reactions
My medical history includes adverse reactions to several medications.
Pharmacogenetic testing may occasionally help explain differences in medication metabolism or response.
However, many adverse reactions arise through mechanisms that are not predictable through genetic testing.
A normal pharmacogenetic result would not establish that a medication is safe for me.
My documented medication history remains essential.
Autoimmune and Inflammatory History
My medical history includes positive autoimmune serology and a previous severe systemic inflammatory illness.
Specialized immune tests may help investigate particular abnormalities when clinically indicated.
However, a positive antibody result or an unusual immune measurement does not necessarily establish an active autoimmune disorder.
The relationship between laboratory findings, symptoms, physical examination, and disease-specific diagnostic criteria remains important.
Blood Proteins and Previous Anemia
My history includes normocytic anemia during the inflammatory illness in 2021.
Serum protein electrophoresis and related tests may be appropriate in selected evaluations of unexplained anemia, abnormal globulin concentrations, kidney abnormalities, or other concerning findings.
These tests are not necessary for every case of anemia.
Their usefulness depends on the results of the initial evaluation and the clinical circumstances.
Age and the Value of Specialized Testing
At age 90, the value of specialized laboratory testing should be considered in relation to whether the information is likely to influence medical care.
A test may identify a biological variation without revealing a condition that requires treatment.
The most useful specialized tests are those that help answer a specific question, clarify an unexplained finding, or guide a meaningful medical decision.
Avoiding unnecessary testing is also part of responsible health assessment.
Important Considerations
- Specialized tests should answer specific clinical questions. Testing is most valuable when the result can clarify a diagnosis, guide treatment, or contribute meaningfully to health assessment.
- Urinalysis provides information beyond blood chemistry. Protein, blood, urinary cells, and other findings may reveal abnormalities not apparent from serum measurements alone.
- Abnormal urine findings may be temporary. Hydration, illness, exercise, and sample contamination can influence certain results.
- Fatty acid measurements are supplementary. They describe aspects of fatty acid composition but do not independently establish cardiovascular or inflammatory health.
- Environmental testing requires appropriate context. A detectable substance does not necessarily indicate toxic exposure or clinically significant harm.
- Genetic findings describe susceptibility rather than certainty. Many genetic variants have limited predictive value, particularly for complex conditions influenced by multiple factors.
- Pharmacogenetic testing has important limitations. It cannot identify every possible medication reaction or guarantee medication safety.
- Specialized immune results require careful interpretation. An abnormal antibody or immune measurement does not automatically establish autoimmune disease.
- Cardiac biomarkers must be interpreted clinically. Troponin and natriuretic peptides are useful in selected circumstances but are not substitutes for comprehensive cardiovascular assessment.
- More testing does not necessarily produce better health outcomes. The greatest value comes from selecting clinically meaningful tests and understanding their limitations.
Summary of Understanding
Specialized laboratory testing extends beyond routine blood chemistry and complete blood count measurements to evaluate particular organs, metabolic pathways, environmental exposures, inherited characteristics, and immune processes.
Urinalysis provides information about kidney and urinary tract health, while pancreatic enzymes assist in selected evaluations of pancreatic disease.
Fatty acid measurements describe aspects of dietary fatty acid exposure and metabolism. Environmental testing may help investigate suspected toxic exposures, while genetic and pharmacogenetic testing can provide useful information in selected clinical circumstances.
Specialized immune investigations and serum protein studies may help clarify unexplained abnormalities when supported by clinical findings.
My medical history includes cardiovascular conditions, previous systemic inflammation, medication reactions, and a long-term carnivore diet. These factors provide context for understanding why certain specialized tests may be relevant.
At age 90, the usefulness of specialized laboratory testing depends not simply on how much information can be collected, but on whether the results can meaningfully improve understanding or medical decision-making.
The purpose of this subsection is to explain the meaning and limitations of specialized laboratory measurements. Section 7.1 preserves the actual results, while Section 7.3 will examine the historical patterns of the measurements available in my laboratory records.
Central Understanding: Specialized laboratory tests are most valuable when they address a specific medical question. Their results must be interpreted in relation to symptoms, medical history, other laboratory measurements, and the likelihood that the information will contribute meaningfully to health assessment or treatment decisions.
Section 7.3 — Laboratory Trends and Health Assessment
| Subsection | Title | Description |
| 7.3.1 | Cardiovascular Health Trends | Cholesterol, LDL, HDL, triglycerides, ApoB, and cardiovascular risk markers. |
| 7.3.2 | Kidney Function and Electrolyte Trends | BUN, creatinine, eGFR, electrolytes, and kidney-related measurements. |
| 7.3.3 | Thyroid Function Trends | TSH, free T4, free T3, thyroid antibodies, and thyroid regulation. |
| 7.3.4 | Inflammation and Autoimmune Trends | CRP, ESR, ANA, autoimmune markers, and inflammatory activity. |
| 7.3.5 | Complete Blood Count and Immune Cell Trends | Hemoglobin, red blood cells, white blood cells, platelets, and immune cell measurements. |
| 7.3.6 | Metabolic Health Trends | Glucose, A1c, insulin, ketones, uric acid, and metabolic regulation. |
| 7.3.7 | Liver Function and Protein Chemistry Trends | ALT, AST, alkaline phosphatase, bilirubin, albumin, and protein chemistry. |
| 7.3.8 | Nutritional Health Trends | Iron, ferritin, vitamins, minerals, fatty acids, and nutritional status. |
| 7.3.9 | Hormones and Male Health Trends | Testosterone, SHBG, DHEA sulfate, estradiol, PSA, and hormonal health. |
| 7.3.10 | Specialized Laboratory Markers and Additional Health Trends | Pancreatic enzymes, environmental toxins, urinalysis, and additional specialized measurements. |
7.3.1 — Cardiovascular Trends
Overview
Cardiovascular laboratory trends provide important information about changes in cholesterol, lipoproteins, and other measurements associated with cardiovascular health. Unlike the educational explanations in Section 7.2, this subsection examines my actual laboratory results and identifies patterns that have developed over time.
My cardiovascular history includes hypertension, hyperlipidemia, atrial fibrillation, implantation of a Watchman device, and an ascending aortic aneurysm. These conditions make the evaluation of cardiovascular risk particularly important.
My laboratory records extend from 2013 through November 2026. The most clearly documented recent cardiovascular trend involves changes in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides between June 2024 and November 2026.
Advanced lipid testing in June 2026 also provides additional information about the number of cholesterol-carrying particles in the bloodstream.
The purpose of this subsection is to identify significant changes, distinguish potentially favorable findings from continuing concerns, and consider what these measurements mean in the context of my cardiovascular history.
The complete historical laboratory record remains available in Section 7.1 — Laboratory Library. This subsection concentrates on interpretation rather than reproducing the entire laboratory archive.
Important Laboratory Trends and Their Significance
1. Standard Lipid Panel — June 2024 Through November 2026
The following table summarizes the recent lipid measurements documented in my laboratory history.
All values are expressed in mg/dL.
| Date | Total Cholesterol | LDL-C | HDL-C | Triglycerides |
|---|---|---|---|---|
| June 2024 | 220 | 136 | 75 | 50 |
| November 2024 | 243 | 141 | 94 | 52 |
| December 2025 | 256 | 151 | 89 | 60 |
| June 2026 | 284 | 183 | 82 | 85 |
| September 2026 | 252 | 168 | 73 | 54 |
| November 2026 | 249 | 157 | 78 | 45 |
Trend interpretation:
The measurements reveal two distinct phases.
The first phase, from June 2024 through June 2026, shows increasing total cholesterol and LDL cholesterol.
The second phase, from June through November 2026, shows a decline in both measurements.
During the same period, HDL cholesterol remained relatively high, while triglycerides remained comparatively low.
These findings provide a useful picture of my changing lipid profile, but the individual measurements must be considered together rather than interpreting any one result as a complete assessment of cardiovascular risk.
2. Total Cholesterol Trend
Total cholesterol increased from 220 mg/dL in June 2024 to 284 mg/dL in June 2026.
This represents an increase of 64 mg/dL, or approximately 29%.
By September 2026, total cholesterol had decreased to 252 mg/dL.
The November 2026 measurement was 249 mg/dL, representing a further small decline.
Overall, total cholesterol decreased by 35 mg/dL between June and November 2026, approximately 12%.
Clinical interpretation:
The recent decline is a measurable change in a favorable direction relative to the June 2026 peak.
However, total cholesterol remains above the conventional desirable range.
Total cholesterol alone does not distinguish among different cholesterol-carrying particles and is therefore less informative than LDL cholesterol, non-HDL cholesterol, and apolipoprotein B when evaluating atherosclerotic cardiovascular risk.
3. LDL Cholesterol Trend
LDL cholesterol increased from 136 mg/dL in June 2024 to 183 mg/dL in June 2026.
This represents an increase of 47 mg/dL, approximately 35%.
The subsequent measurements were:
- September 2026 — 168 mg/dL
- November 2026 — 157 mg/dL
Between June and November 2026, LDL cholesterol decreased by 26 mg/dL, approximately 14%.
Clinical interpretation:
The reduction from the June peak is encouraging as a trend, but the November LDL cholesterol concentration of 157 mg/dL remains elevated.
LDL particles contribute to the development of atherosclerotic plaque. Prolonged exposure to elevated LDL cholesterol and other apolipoprotein B-containing particles is an established contributor to atherosclerotic cardiovascular disease.
My relatively high HDL cholesterol and low triglycerides do not eliminate the risk associated with elevated LDL cholesterol.
At age 90, decisions about lipid-lowering treatment require individualized consideration of cardiovascular history, medication tolerance, life expectancy, functional status, and treatment preferences.
4. HDL Cholesterol Trend
HDL cholesterol measurements were:
- June 2024 — 75 mg/dL
- November 2024 — 94 mg/dL
- December 2025 — 89 mg/dL
- June 2026 — 82 mg/dL
- September 2026 — 73 mg/dL
- November 2026 — 78 mg/dL
HDL cholesterol remained relatively high throughout the period.
The highest recorded value in this series was 94 mg/dL in November 2024.
Clinical interpretation:
HDL cholesterol participates in cholesterol transport and is associated with cardiovascular risk patterns in population studies.
However, higher HDL cholesterol does not necessarily provide progressively greater protection.
HDL cholesterol concentration does not directly measure HDL function, and a high HDL result does not neutralize the potential risk associated with elevated LDL cholesterol or ApoB.
The sustained HDL pattern is useful information but should not be interpreted as proof of cardiovascular protection.
5. Triglyceride Trend
Triglyceride measurements were:
- June 2024 — 50 mg/dL
- November 2024 — 52 mg/dL
- December 2025 — 60 mg/dL
- June 2026 — 85 mg/dL
- September 2026 — 54 mg/dL
- November 2026 — 45 mg/dL
All six measurements were below the commonly used threshold of 150 mg/dL.
Triglycerides increased between June 2024 and June 2026, then declined to their lowest measurement in this series in November 2026.
Clinical interpretation:
These measurements do not indicate hypertriglyceridemia.
Low triglycerides are frequently associated with favorable aspects of metabolic regulation, particularly when accompanied by normal glucose measurements.
However, low triglycerides do not independently establish low cardiovascular risk.
6. Advanced Lipid Testing — June 2026
The June 2026 laboratory record includes two particularly important advanced lipid measurements.
| Measurement | June 2026 Result |
|---|---|
| Apolipoprotein B (ApoB) | 139 mg/dL |
| LDL Particle Number (LDL-P) | 2,483 nmol/L |
Apolipoprotein B:
ApoB is a structural protein present on atherogenic lipoprotein particles, including LDL and certain triglyceride-rich lipoproteins.
Because each of these particles generally contains one ApoB molecule, ApoB provides an estimate of the number of circulating atherogenic particles.
The June 2026 ApoB result of 139 mg/dL is elevated and represents an important cardiovascular risk finding.
LDL Particle Number:
LDL-P measures the concentration of LDL particles rather than the total cholesterol carried within them.
The June 2026 result of 2,483 nmol/L is also elevated.
Clinical interpretation:
The combination of elevated LDL cholesterol, ApoB, and LDL particle number indicates that the June 2026 lipid pattern involved a substantial concentration of atherogenic particles.
This finding is important because low triglycerides and high HDL cholesterol do not necessarily indicate a low number of LDL particles.
The September and November 2026 standard lipid measurements show declining LDL cholesterol, but without repeat advanced testing, the corresponding changes in ApoB and LDL-P cannot be determined directly.
7. Non-HDL Cholesterol
Non-HDL cholesterol represents total cholesterol minus HDL cholesterol.
It includes cholesterol carried by LDL and other potentially atherogenic lipoproteins.
Using the available measurements:
| Date | Calculated Non-HDL Cholesterol |
|---|---|
| June 2024 | 145 mg/dL |
| November 2024 | 149 mg/dL |
| December 2025 | 167 mg/dL |
| June 2026 | 202 mg/dL |
| September 2026 | 179 mg/dL |
| November 2026 | 171 mg/dL |
These values are calculated from the recorded total cholesterol and HDL cholesterol measurements.
Clinical interpretation:
Non-HDL cholesterol increased substantially between June 2024 and June 2026, then declined through November 2026.
The November value of 171 mg/dL remains elevated.
This pattern reinforces the finding that atherogenic cholesterol exposure increased during the earlier period and subsequently decreased, although it remains an area of cardiovascular concern.
8. Cholesterol-to-HDL Ratio
The total cholesterol-to-HDL ratio provides a comparison between total cholesterol and HDL cholesterol.
A lower ratio has traditionally been associated with a more favorable cardiovascular risk pattern.
However, this ratio may appear favorable when HDL is high even if LDL cholesterol and ApoB remain elevated.
Clinical interpretation:
The cholesterol-to-HDL ratio can provide supplementary information but should not replace direct evaluation of LDL cholesterol, non-HDL cholesterol, and ApoB.
In my case, the advanced lipid findings demonstrate why relying on cholesterol ratios alone could underestimate an important aspect of cardiovascular risk.
Relevance to My Cardiovascular Health History
Hyperlipidemia
My medical history includes hyperlipidemia.
The laboratory trends confirm that LDL cholesterol and non-HDL cholesterol have remained elevated during the recent observation period.
Although the measurements improved after June 2026, the November values do not establish normalization of the lipid profile.
The June 2026 ApoB and LDL-P results provide additional evidence of elevated atherogenic particle burden at that time.
Hypertension
Hypertension is an established cardiovascular risk factor.
When elevated blood pressure and elevated atherogenic lipoproteins occur together, they may contribute to cumulative vascular risk.
My blood pressure history must therefore be considered alongside the lipid measurements.
I previously discontinued amlodipine because of low blood pressure, illustrating the importance of individualized cardiovascular management.
Atrial Fibrillation and Watchman Device
My history includes atrial fibrillation and implantation of a Watchman device.
Atrial fibrillation is primarily an electrical rhythm disorder, while elevated LDL cholesterol and ApoB are most directly associated with atherosclerotic cardiovascular risk.
These are different cardiovascular concerns.
The Watchman device addresses selected stroke-prevention considerations associated with atrial fibrillation but does not treat elevated cholesterol or eliminate all cardiovascular risk.
Ascending Aortic Aneurysm
My medical history includes an ascending aortic aneurysm.
Monitoring this condition depends primarily on cardiovascular imaging, aortic measurements, blood pressure management, and clinical assessment.
Lipid measurements contribute to the broader cardiovascular risk picture but do not indicate whether the aneurysm is enlarging or stable.
Carnivore Diet
I began following a strict carnivore diet on January 1, 2024.
The recent lipid series therefore largely reflects the period during which I have followed this dietary pattern.
The increase in LDL cholesterol from June 2024 through June 2026 occurred during this period.
However, the available laboratory measurements do not establish that the diet was the sole cause of the increase.
Dietary fat composition, body weight, genetics, thyroid status, medications, and other factors may influence cholesterol concentrations.
The subsequent decline in LDL cholesterol during 2026 is also documented, but its cause cannot be determined from the laboratory values alone.
Medication Tolerance
My medical history includes adverse reactions to several medications, including previous cholesterol-lowering treatment.
This history is relevant when considering cardiovascular risk management.
The potential benefits of reducing atherogenic lipoproteins must be weighed against treatment tolerability, other medical conditions, and my personal health goals.
The laboratory trends provide useful information for these discussions but do not independently determine which treatment is appropriate.
Important Considerations
- The LDL cholesterol trend improved after June 2026. The decrease from 183 to 157 mg/dL is meaningful, but the most recent concentration remains elevated.
- ApoB and LDL particle number are important findings. Their elevated June 2026 values identify a substantial atherogenic particle burden at that time.
- High HDL does not cancel elevated LDL risk. HDL cholesterol should not be interpreted as a guarantee of cardiovascular protection.
- Low triglycerides are favorable in one respect but are not a complete risk assessment. They do not eliminate the significance of elevated LDL cholesterol or ApoB.
- The cause of lipid changes cannot be established from timing alone. Diet, medications, weight, thyroid function, and other factors may contribute.
- Advanced lipid trends remain incomplete. Repeat ApoB or LDL-P measurements would be needed to determine whether their concentrations declined alongside LDL cholesterol.
- Cardiovascular laboratory results do not measure every cardiovascular condition. Atrial fibrillation and ascending aortic aneurysm require separate clinical evaluation.
- Age and medication tolerance are important. Cardiovascular management at age 90 should consider overall health, functional status, treatment burden, and individual priorities.
- The November 2026 results provide an important recent comparison. They show continued improvement from June 2026 without demonstrating complete resolution of the elevated lipid measurements.
- Longitudinal assessment is more informative than isolated results. The pattern of rising measurements followed by partial improvement is more useful than any single cholesterol result.
Summary of Cardiovascular Trends
The cardiovascular laboratory record reveals an important pattern between June 2024 and November 2026.
Total cholesterol and LDL cholesterol increased through June 2026, reaching 284 mg/dL and 183 mg/dL, respectively.
Both subsequently declined, with November 2026 measurements of 249 mg/dL for total cholesterol and 157 mg/dL for LDL cholesterol.
HDL cholesterol remained relatively high, and triglycerides remained low throughout the observation period.
The June 2026 advanced lipid measurements—ApoB of 139 mg/dL and LDL particle number of 2,483 nmol/L—are particularly important because they demonstrate elevated atherogenic particle concentrations despite the favorable triglyceride pattern.
The most recent standard lipid measurements show improvement, but elevated LDL cholesterol and non-HDL cholesterol remain concerns.
These findings must be considered alongside my history of hypertension, atrial fibrillation, ascending aortic aneurysm, medication intolerance, and dietary practices.
The purpose of this subsection is to identify the important patterns and their clinical significance without repeating the complete laboratory archive maintained in Section 7.1.
Central Understanding: My cardiovascular laboratory trends show a substantial increase in atherogenic cholesterol measurements through June 2026, followed by partial improvement through November 2026. High HDL cholesterol and low triglycerides are notable features of my lipid profile, but they do not eliminate the significance of elevated LDL cholesterol, ApoB, and LDL particle number. Continued assessment should focus on the overall cardiovascular picture rather than any single favorable or unfavorable measurement.
7.3.2 — Kidney Function and Electrolyte Trends
Overview
Kidney function and electrolyte measurements provide important information about the body’s ability to filter waste products, regulate fluid balance, maintain appropriate mineral concentrations, and preserve normal physiological function.
Unlike Section 7.2, which explained the meaning of individual laboratory markers, this subsection examines changes in my actual laboratory measurements and considers their significance over time.
My medical history includes hypertension, a severe systemic inflammatory illness in 2021, and a strict carnivore diet beginning January 1, 2024. These circumstances are relevant because blood pressure, illness, hydration, dietary protein, and other factors may influence kidney-related laboratory measurements.
The recent laboratory record includes measurements from September and November 2026 that permit direct comparison of creatinine, estimated glomerular filtration rate (eGFR), sodium, potassium, chloride, and calcium.
Earlier documented findings provide additional historical context, including an elevated BUN in June 2024 and low sodium during the systemic inflammatory illness in 2021.
The purpose of this subsection is to identify important changes, distinguish temporary variations from findings that may require continued observation, and consider what these results mean for my overall health.
The complete laboratory archive remains available in Section 7.1 — Laboratory Library. This subsection focuses on the trends that can be established from the documented results.
Important Laboratory Trends and Their Significance
1. Kidney Function — Recent Measurements
The following table compares the kidney function measurements available for September and November 2026.
| Measurement | September 2026 | November 2026 |
|---|---|---|
| Creatinine | 0.90 mg/dL | 1.09 mg/dL |
| Estimated GFR | 81.64 | 64 |
| BUN | 32 mg/dL | Not established in the available matrix |
| BUN/Creatinine Ratio | Not established | 34 |
Trend interpretation:
Between September and November 2026, creatinine increased by 0.19 mg/dL, approximately 21%.
During the same period, reported eGFR decreased from 81.64 to 64 mL/min/1.73 m², a reduction of approximately 22%.
These measurements indicate a change in estimated kidney filtration during the interval.
However, the two results were reported by different laboratories, and differences in calculation methods, assay calibration, and other factors may contribute to variation.
A two-point comparison is insufficient to establish progressive kidney disease.
2. Blood Urea Nitrogen (BUN)
BUN measures the concentration of nitrogen derived from urea, a substance produced during protein metabolism.
My documented history includes the following findings:
- June 2024 — BUN 40 mg/dL
- September 2026 — BUN 32 mg/dL
The September measurement was 8 mg/dL lower than the June 2024 measurement, a reduction of 20%.
Clinical interpretation:
Although the later value was lower, both measurements were elevated relative to many commonly used laboratory reference intervals.
BUN can increase with high dietary protein intake, dehydration, gastrointestinal bleeding, certain medications, and reduced kidney filtration.
Because I follow a diet composed primarily of animal products, dietary protein intake is a relevant consideration.
However, elevated BUN alone does not establish kidney dysfunction.
The September 2026 BUN of 32 mg/dL occurred alongside creatinine of 0.90 mg/dL and reported eGFR of 81.64.
This combination suggests that the elevated BUN should not automatically be interpreted as evidence of substantially impaired kidney filtration.
3. Creatinine Trend
Creatinine is produced through normal muscle metabolism and eliminated primarily through the kidneys.
The recent measurements were:
- September 2026 — 0.90 mg/dL
- November 2026 — 1.09 mg/dL
The increase was 0.19 mg/dL.
Clinical interpretation:
The November result is higher than the September measurement.
Creatinine is influenced by kidney filtration, muscle mass, dietary intake, hydration, and laboratory variation.
Because creatinine is derived partly from muscle metabolism, its interpretation can be especially important in older adults, whose muscle mass may differ substantially from that of younger individuals.
A change in creatinine may reflect altered kidney filtration, but a single increase does not establish the cause.
The most useful next comparison would be another measurement obtained under reasonably similar circumstances.
4. Estimated Glomerular Filtration Rate (eGFR)
eGFR estimates the kidneys’ ability to filter blood.
The recent results were:
- September 2026 — 81.64 mL/min/1.73 m²
- November 2026 — 64 mL/min/1.73 m²
The decrease was 17.64 mL/min/1.73 m².
Clinical interpretation:
The September measurement was in the G2 category of mildly decreased eGFR, while the November measurement also remained in G2.
An eGFR between 60 and 89 does not independently establish chronic kidney disease. Evidence of kidney damage or another qualifying abnormality is also required.
The decline is worth observing, particularly in view of my hypertension history.
However, the measurements alone do not establish whether the change represents temporary variation, altered hydration, laboratory differences, or a persistent reduction in filtration.
If uncertainty remains about creatinine-based eGFR, a cystatin C measurement or combined creatinine-cystatin C estimate may provide additional information when clinically appropriate.
5. BUN-to-Creatinine Ratio
The BUN-to-creatinine ratio compares two substances associated with kidney function and protein metabolism.
The November 2026 laboratory matrix records a ratio of 34.
Clinical interpretation:
An elevated ratio may occur with dehydration, increased urea production, high protein intake, or certain medical conditions.
Because my dietary pattern contains substantial animal protein, this is a possible contributing factor.
However, the ratio is nonspecific.
It cannot independently distinguish dietary influences from dehydration or kidney-related conditions.
The interpretation should consider BUN and creatinine separately, along with fluid intake, symptoms, and other clinical findings.
6. Sodium Trend
Sodium is essential for fluid balance, nerve signaling, and muscle function.
My recent measurements were:
| Date | Sodium |
|---|---|
| September 2026 | 140 mmol/L |
| November 2026 | 137 mmol/L |
Both results fall within commonly used reference intervals.
The November measurement was 3 mmol/L lower than September.
Historical context:
During my severe inflammatory illness in 2021, sodium was documented at approximately 129 mmol/L.
That earlier result represented hyponatremia.
Clinical interpretation:
The recent sodium measurements are reassuring compared with the historical low value.
They indicate that the previously documented hyponatremia was not present in either of these two recent laboratory reports.
However, the historical illness and recent measurements occurred under different clinical circumstances.
The available information does not establish the cause of the 2021 hyponatremia or prove that the underlying circumstances could never recur.
7. Potassium Trend
Potassium is important for normal heart rhythm, nerve transmission, and muscle contraction.
The recent results were:
| Date | Potassium |
|---|---|
| September 2026 | 4.4 mmol/L |
| November 2026 | 4.3 mmol/L |
The difference was 0.1 mmol/L.
Clinical interpretation:
Both measurements fall within commonly used reference intervals.
The change is small and does not suggest a significant potassium disturbance.
This is particularly relevant to my cardiovascular history, including atrial fibrillation.
Abnormal potassium concentrations can affect cardiac electrical activity, although normal potassium does not eliminate the possibility of arrhythmias.
Continued observation is reasonable because potassium balance can be influenced by kidney function, medications, and electrolyte intake.
8. Chloride Trend
Chloride works with sodium and other electrolytes to maintain fluid and acid-base balance.
The recent measurements were:
| Date | Chloride |
|---|---|
| September 2026 | 102 mmol/L |
| November 2026 | 102 mmol/L |
Clinical interpretation:
Chloride remained unchanged.
Both measurements fall within commonly used reference intervals.
This is a stable finding in the recent electrolyte record.
However, chloride alone does not provide a complete assessment of acid-base balance.
Carbon dioxide or bicarbonate measurements are also useful for that purpose.
9. Calcium Trend
Calcium contributes to bone structure, muscle contraction, nerve signaling, and other physiological processes.
The recent measurements were:
| Date | Calcium |
|---|---|
| September 2026 | 9.8 mg/dL |
| November 2026 | 9.5 mg/dL |
Calcium decreased by 0.3 mg/dL.
Clinical interpretation:
Both measurements are within commonly used reference intervals.
The difference is modest and does not establish an abnormal calcium trend.
Total serum calcium is influenced partly by albumin concentration.
My recent albumin measurements were also within their reported reference intervals, providing useful context for interpreting total calcium.
10. Magnesium Trend
Magnesium is important for muscle function, nerve transmission, cardiac electrical activity, and numerous enzyme reactions.
My health history includes magnesium supplementation.
However, the recent 40-report matrix does not provide September and November 2026 serum or red blood cell magnesium values from which to establish a direct trend.
Clinical interpretation:
No recent magnesium trend can be determined from these two reports.
Supplementation does not establish that blood magnesium concentrations are normal or abnormal.
If magnesium monitoring becomes clinically important, the actual laboratory measurements should be evaluated rather than assuming a particular effect from supplement intake.
11. Carbon Dioxide and Acid-Base Balance
Serum total carbon dioxide, which largely reflects bicarbonate, contributes to the evaluation of acid-base balance.
Dietary composition, kidney function, respiratory conditions, and certain illnesses can influence acid-base regulation.
My carnivore diet makes this measurement relevant to the broader metabolic assessment.
However, the recent matrix does not provide a paired September and November carbon dioxide series.
Clinical interpretation:
A recent trend cannot be established from the available values.
A high-animal-protein diet may influence dietary acid load, but it does not automatically establish an abnormal blood acid-base state.
12. Urine Albumin and Kidney Damage
Urine albumin and the urine albumin-to-creatinine ratio can help identify kidney damage that may not be apparent from serum creatinine alone.
These measurements are particularly relevant in individuals with hypertension.
The recent laboratory matrix does not contain values establishing a urine albumin trend.
Clinical interpretation:
Without these measurements, the laboratory record cannot fully assess whether albumin leakage is present or absent.
The available serum creatinine and eGFR results provide information about estimated filtration, but they do not independently establish the complete status of kidney health.
Relevance to My Health History
Hypertension and Kidney Function
My medical history includes hypertension.
Blood pressure and kidney function are closely related.
Long-standing hypertension may contribute to kidney damage, while impaired kidney function may also influence blood pressure regulation.
The recent change in creatinine and eGFR therefore deserves attention.
However, the two measurements do not establish hypertension-related kidney disease.
Blood pressure history, repeated laboratory measurements, and urine albumin testing may provide additional context.
Previous Systemic Inflammatory Illness
In 2021, I experienced a severe systemic inflammatory illness accompanied by multiple laboratory abnormalities.
These included a sodium concentration of approximately 129 mmol/L.
The more recent sodium measurements of 140 and 137 mmol/L demonstrate a substantially different electrolyte pattern.
This comparison is useful because it distinguishes an important historical abnormality from the current laboratory findings.
Carnivore Diet and Protein Metabolism
Since January 1, 2024, I have followed a strict carnivore diet.
High dietary protein intake can influence BUN, and meat intake may also affect creatinine measurements.
Consequently, BUN and creatinine should be interpreted with awareness of my dietary practices.
The diet may help explain some laboratory characteristics, but it should not be assumed to account for every abnormal result.
A high BUN concentration does not necessarily indicate kidney damage, and a change in eGFR should not automatically be dismissed as dietary.
Hydration and Electrolyte Balance
Fluid intake and hydration can influence BUN, creatinine, sodium, and other measurements.
Dehydration may temporarily increase BUN and creatinine, while excessive water intake under certain circumstances may contribute to low sodium.
My laboratory results should therefore be interpreted with attention to hydration, recent illness, and the conditions surrounding sample collection.
The available records do not establish whether hydration contributed to the November 2026 creatinine increase.
Cardiovascular Health
My history of atrial fibrillation makes electrolyte balance particularly relevant.
Potassium and magnesium participate in normal cardiac electrical activity.
The recent potassium measurements are stable and within commonly used reference intervals.
However, electrolyte measurements are only one part of cardiovascular assessment and cannot determine whether atrial fibrillation is present or adequately controlled.
Age and Kidney Function
At age 90, kidney function assessment requires consideration of age-related physiological changes, muscle mass, nutrition, and other medical conditions.
Creatinine-based eGFR is an estimate rather than a direct measurement of filtration.
An isolated eGFR result should therefore not be interpreted without considering the broader clinical picture.
Persistent changes over time are generally more informative than a single result.
Important Considerations
- Creatinine increased between September and November 2026. The increase from 0.90 to 1.09 mg/dL deserves follow-up comparison but does not independently establish progressive kidney disease.
- Reported eGFR decreased during the same interval. The decline from 81.64 to 64 is important, although both measurements remain in the G2 category.
- Elevated BUN may have several explanations. High dietary protein, hydration status, and kidney-related factors must be considered.
- Recent sodium measurements are reassuring. Both September and November 2026 values are within commonly used reference intervals, unlike the historical low sodium measurement in 2021.
- Potassium remained stable. This is useful information in the context of my cardiovascular history.
- Chloride showed no measurable change. The September and November results were identical.
- Calcium remained within commonly used reference intervals. The modest decline does not establish an abnormal trend.
- Missing measurements should not be interpreted as normal results. The recent matrix does not establish trends for magnesium, bicarbonate, or urine albumin.
- Laboratory methods may influence comparisons. Measurements from different laboratories should be interpreted with attention to their methods and reference intervals.
- Continued observation is more useful than premature conclusions. Repeated creatinine, eGFR, BUN, and relevant urine measurements can help distinguish temporary variation from persistent abnormalities.
Summary of Kidney Function and Electrolyte Trends
The recent laboratory record identifies a measurable change in kidney filtration estimates between September and November 2026.
Creatinine increased from 0.90 to 1.09 mg/dL, while reported eGFR decreased from 81.64 to 64 mL/min/1.73 m².
These findings deserve continued observation, particularly in the context of hypertension and advanced age.
However, the available measurements do not independently establish chronic kidney disease or progressive kidney damage.
BUN has been elevated in documented historical measurements, including 40 mg/dL in June 2024 and 32 mg/dL in September 2026. My high-animal-protein dietary pattern is relevant to interpreting these results, although it does not establish their cause.
The recent electrolyte findings are comparatively stable.
Sodium remained within commonly used reference intervals, representing an important contrast with the hyponatremia documented during my systemic inflammatory illness in 2021.
Potassium, chloride, and calcium also remained within commonly used reference intervals.
The recent matrix does not establish trends for magnesium, bicarbonate, or urine albumin.
Overall, the electrolyte results are reassuring, while the change in creatinine and eGFR represents the most important finding requiring continued longitudinal assessment.
Central Understanding: My recent kidney and electrolyte laboratory results show generally stable sodium, potassium, chloride, and calcium concentrations, but a measurable increase in creatinine and decrease in estimated kidney filtration between September and November 2026. Elevated BUN may be influenced by dietary protein and other factors. The most important next step in understanding these findings is continued comparison over time, without assuming that a short-term laboratory change necessarily represents progressive kidney disease.
7.3.3 — Thyroid Function Trends
Overview
Thyroid function is an important component of my Health Inventory because I have a history of hypothyroidism and receive levothyroxine replacement therapy.
Thyroid hormones influence metabolic activity, body temperature, cardiovascular function, energy regulation, digestion, and many other physiological processes.
The principal laboratory measurements used to evaluate thyroid function are thyroid-stimulating hormone (TSH), Free T4, and, in selected circumstances, Free T3. Thyroid antibody measurements provide additional information about possible autoimmune thyroid disease.
My recent laboratory history includes thyroid testing through Function Health in June and November 2026 and WellMed in September 2026.
These measurements provide an opportunity to examine whether thyroid hormone concentrations have remained stable and whether the results are consistent with adequate thyroid replacement.
However, the measurements were obtained through different laboratories, and the available reports do not provide a complete set of TSH, Free T4, and Free T3 results at every testing date.
The purpose of this subsection is to identify the documented thyroid trends, explain their clinical significance, and consider their relationship to my medical history.
Important Laboratory Trends and Their Significance
1. Recent Thyroid Laboratory Results
The following table summarizes the verified measurements from the available 2026 reports.
| Measurement | June 2026 Function Health | September 2026 WellMed | November 2026 Function Health |
|---|---|---|---|
| TSH | 1.87 mIU/L | 0.67 µIU/mL | Not reported |
| Free T4 | 1.20 ng/dL | 1.11 ng/dL | Not reported |
| Free T3 | Not verified for June | 2.27 pg/mL | 2.40 pg/mL |
| TPO Antibodies | Less than 1 IU/mL | Not reported | Not reported |
| Thyroglobulin Antibodies | Less than 2 IU/mL | Not reported | Not reported |
Trend interpretation:
The documented TSH and Free T4 measurements were within their respective laboratory reference intervals.
Free T3 was also within the reported reference intervals in September and November 2026.
The available results are generally consistent with satisfactory biochemical thyroid replacement during the periods measured.
However, because the November report does not establish a new TSH or Free T4 result, it cannot independently confirm that the entire thyroid hormone profile remained unchanged after September.
2. Thyroid-Stimulating Hormone (TSH) Trend
TSH is produced by the pituitary gland and helps regulate thyroid hormone production.
In most individuals receiving levothyroxine for primary hypothyroidism, TSH is the principal laboratory measurement used to guide replacement therapy.
The documented results were:
- June 2026 — 1.87 mIU/L
- September 2026 — 0.67 µIU/mL
TSH decreased by 1.20 mIU/L, approximately 64%.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The decrease indicates a change in pituitary thyroid signaling between the two measurements.
However, a lower TSH does not necessarily indicate excessive thyroid replacement.
TSH may vary because of medication absorption, timing, changes in thyroid hormone requirements, illness, and laboratory differences.
At age 90, avoiding excessive thyroid replacement is particularly important because persistently suppressed TSH may increase the risk of atrial fibrillation and bone loss.
The September TSH of 0.67 was within the laboratory reference interval and was not suppressed.
Nevertheless, the downward change is worth retaining in the longitudinal record.
3. Free T4 Trend
Free T4 measures the unbound fraction of thyroxine circulating in the bloodstream.
Levothyroxine is a synthetic form of T4, making this measurement relevant to my thyroid replacement treatment.
The documented results were:
- June 2026 — 1.20 ng/dL
- September 2026 — 1.11 ng/dL
Free T4 decreased by 0.09 ng/dL, approximately 7.5%.
Both results were within their respective laboratory reference intervals.
Clinical interpretation:
The change is modest.
It does not establish worsening hypothyroidism or excessive thyroid replacement.
Free T4 may be affected by the timing of blood collection relative to the levothyroxine dose, differences in laboratory methods, and other physiological factors.
The normal TSH measurements provide important additional context.
4. Free T3 Trend
Free T3 measures the unbound portion of triiodothyronine, the more biologically active thyroid hormone.
Much of the body’s T3 is produced through conversion of T4 in peripheral tissues.
My recent documented results were:
- September 2026 — 2.27 pg/mL
- November 2026 — 2.40 pg/mL
Free T3 increased by 0.13 pg/mL, approximately 5.7%.
Both results were within their respective laboratory reference intervals.
Historical context:
Earlier Function Health testing had identified Free T3 below that laboratory’s reference interval.
The recent results therefore provide useful information about a previously noted laboratory concern.
Clinical interpretation:
The September and November measurements are reassuring because neither was flagged as low.
However, the results do not establish that the underlying reason for the earlier low Free T3 has been identified or resolved.
Free T3 concentrations may be influenced by illness, nutritional status, medications, and laboratory methodology.
In individuals with primary hypothyroidism receiving levothyroxine, Free T3 is generally not the principal measurement used to adjust treatment.
The combination of TSH, Free T4, symptoms, and clinical history remains more informative.
5. Thyroid Peroxidase Antibodies
Thyroid peroxidase antibodies, commonly called TPO antibodies, may be elevated in autoimmune thyroid disease.
The June 2026 Function Health result was:
TPO antibodies — less than 1 IU/mL
The laboratory classified this result as within range.
Clinical interpretation:
This result does not provide evidence of elevated TPO antibodies at the time of testing.
However, a negative TPO antibody result does not exclude every possible cause of autoimmune thyroid disease.
The result should be interpreted in the context of my established hypothyroidism diagnosis and any earlier thyroid investigations.
A longitudinal antibody trend cannot be established from this single verified result.
6. Thyroglobulin Antibodies
Thyroglobulin antibodies may be present in certain autoimmune thyroid conditions.
The June 2026 Function Health result was:
Thyroglobulin antibodies — less than 2 IU/mL
The laboratory classified this result as within range.
Clinical interpretation:
The result does not indicate elevated thyroglobulin antibodies at the time of testing.
Together with the TPO antibody result, it provides useful information about the absence of detectable elevations in these two thyroid antibody measurements during June 2026.
However, these findings do not establish the original cause of my hypothyroidism.
7. Overall Thyroid Hormone Pattern
The available 2026 results show three important findings.
First, the documented TSH measurements were within their respective laboratory reference intervals.
Second, Free T4 remained within range in both June and September.
Third, Free T3 was within range in September and November, following an earlier reported low measurement.
Clinical interpretation:
The overall pattern is consistent with reasonably stable biochemical thyroid function during the periods represented.
There is no documented evidence in these measurements of markedly elevated TSH, suppressed TSH, or substantially abnormal Free T4.
However, the available record does not establish that thyroid hormone concentrations were identical throughout the year.
The most appropriate conclusion is that the verified results were generally reassuring, while continued periodic monitoring remains important.
Relevance to My Health History
Established Hypothyroidism
My medical history includes hypothyroidism treated with levothyroxine.
The purpose of replacement therapy is to provide adequate thyroid hormone while avoiding excessive treatment.
The recent TSH and Free T4 measurements provide useful evidence about treatment adequacy.
Both documented TSH results were within their laboratory reference intervals.
This supports continued clinical evaluation of the current replacement regimen rather than assuming that a medication adjustment is necessary based on the available measurements alone.
Levothyroxine Treatment
My recorded levothyroxine dose has been 75 micrograms daily.
Levothyroxine absorption may be influenced by food, supplements, medications, and the timing of administration.
Calcium and iron supplements can interfere with absorption and are generally separated from levothyroxine by at least four hours.
Consistency in administration is important when interpreting changes in TSH and Free T4.
Any medication adjustment should be directed by my treating clinician.
Atrial Fibrillation and Thyroid Hormone Balance
My cardiovascular history includes atrial fibrillation.
Excess thyroid hormone activity can increase the likelihood of cardiac rhythm disturbances.
This makes avoidance of thyroid overreplacement particularly important.
The September TSH of 0.67 was within the WellMed reference interval, although lower than the June measurement.
This finding does not establish overreplacement, but it illustrates why thyroid function should continue to be monitored in the context of my cardiovascular history.
Age and Thyroid Replacement
At age 90, thyroid hormone requirements and treatment considerations may differ from those of younger adults.
Excessive replacement may contribute to cardiac rhythm problems and bone loss.
Conversely, insufficient replacement may contribute to fatigue, cold intolerance, constipation, and other symptoms.
The goal is not to achieve the lowest possible TSH but to maintain appropriate thyroid function while considering age, symptoms, and cardiovascular health.
Carnivore Diet and Nutritional Status
Since January 1, 2024, I have followed a strict carnivore diet.
Thyroid hormone metabolism is influenced by nutritional status, energy intake, and illness.
Changes in dietary intake or body weight may affect thyroid hormone requirements in some circumstances.
However, the available laboratory results do not establish that my diet caused the earlier low Free T3 or the changes observed during 2026.
History of Systemic Inflammation
My medical history includes a severe systemic inflammatory illness in 2021.
Significant illness can affect thyroid hormone metabolism and may temporarily lower circulating T3 concentrations.
This phenomenon is sometimes described as non-thyroidal illness syndrome.
However, the available information does not establish that this mechanism explains my earlier low Free T3.
The possibility is relevant background rather than a confirmed diagnosis.
Thyroid Function and Cholesterol
Thyroid hormone influences cholesterol metabolism.
Insufficient thyroid hormone activity may contribute to elevated LDL cholesterol.
My recent cardiovascular laboratory history includes elevated LDL cholesterol and ApoB.
However, the documented 2026 TSH and Free T4 measurements do not provide clear evidence of uncontrolled hypothyroidism as the explanation for these lipid abnormalities.
The relationship between thyroid status and cholesterol should be considered, but the available results do not establish causation.
Important Considerations
- The documented TSH measurements were within range. The decrease from 1.87 to 0.67 is worth recording but does not independently establish excessive thyroid replacement.
- Free T4 remained within range. The modest decline between June and September does not establish worsening hypothyroidism.
- Free T3 was within range in September and November. This is reassuring in view of the earlier reported low result.
- Different laboratories may produce different results. Comparisons should consider laboratory methods and reference intervals.
- TSH remains the principal monitoring measurement for most patients with primary hypothyroidism. Free T3 is generally supplementary rather than the primary basis for levothyroxine adjustment.
- Avoiding excessive replacement is important at age 90. Atrial fibrillation and bone health make this consideration especially relevant.
- Thyroid antibodies were not elevated in June 2026. This finding does not establish the original cause of hypothyroidism or exclude every form of autoimmune thyroid disease.
- Medication timing and absorption can influence results. Consistent levothyroxine administration helps make longitudinal comparisons more meaningful.
- Thyroid function may influence cholesterol metabolism. However, the available thyroid measurements do not establish that hypothyroidism caused the elevated LDL cholesterol.
- Continued monitoring is more useful than interpreting isolated changes. Repeated TSH and Free T4 measurements, together with symptoms and clinical history, provide the strongest basis for ongoing assessment.
Summary of Thyroid Function Trends
The available 2026 thyroid laboratory results are generally reassuring.
TSH decreased from 1.87 in June to 0.67 in September, while remaining within the respective laboratory reference intervals.
Free T4 decreased modestly from 1.20 to 1.11 ng/dL, also remaining within range.
Free T3 increased from 2.27 pg/mL in September to 2.40 pg/mL in November, with both results within their respective reference intervals.
These recent Free T3 findings are important because an earlier Function Health measurement had been reported below range.
The June 2026 TPO and thyroglobulin antibody results were not elevated.
My history of hypothyroidism, levothyroxine treatment, atrial fibrillation, and advanced age makes continued thyroid monitoring important.
The available measurements do not establish a need for changing thyroid treatment, nor do they provide evidence of markedly uncontrolled thyroid dysfunction.
Central Understanding: My documented 2026 thyroid measurements show TSH and Free T4 within their respective reference intervals and recent Free T3 results within range following an earlier low measurement. The overall pattern is reassuring, but continued monitoring is important because appropriate thyroid replacement must balance adequate hormone levels against the risks of excessive treatment, particularly at age 90 with a history of atrial fibrillation.
7.3.4 — Inflammation and Autoimmune Trends
Overview
Inflammation and autoimmune laboratory trends are particularly important in my Health Inventory because of the severe systemic inflammatory illness I experienced in 2021 and the subsequent discovery of persistent autoimmune antibody abnormalities.
During the earlier illness, I experienced substantial joint and muscle pain accompanied by markedly elevated inflammatory markers. The illness required medical treatment and significantly affected my physical well-being.
My more recent laboratory results present a different picture. Measurements of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) have been substantially lower than the historical values associated with the 2021 illness.
At the same time, antinuclear antibodies (ANA) have remained strongly positive, including high titers with a homogeneous staining pattern.
This distinction is important because inflammatory markers and autoimmune antibodies measure different biological processes.
CRP and ESR provide information about inflammatory activity, while ANA and disease-specific antibodies provide information about immune recognition and possible autoimmune conditions.
A strongly positive ANA does not necessarily mean that severe inflammation is occurring, and normal inflammatory markers do not exclude every autoimmune disease.
The purpose of this subsection is to examine the documented changes in inflammatory and autoimmune measurements, identify the most important patterns, and consider their relationship to my medical history.
Important Laboratory Trends and Their Significance
1. Historical and Recent Inflammatory Measurements
The following table summarizes the principal documented findings.
| Measurement | 2021 Illness | June 2026 | September 2026 | November 2026 |
|---|---|---|---|---|
| CRP | 32 mg/L | Not established here | Less than 1.0 mg/L | — |
| High-Sensitivity CRP | — | — | — | 2.3 mg/L |
| ESR | 71 mm/hr | 6 mm/hr | 18 mm/hr | — |
| ANA Titer | — | 1:1280 | 1:640 | — |
| ANA Pattern | — | Homogeneous | Homogeneous | — |
| Anti-dsDNA | — | — | 2.6 EIA U/mL | — |
| Anticardiolipin IgA | — | — | Less than 9 APL U/mL | — |
A dash indicates that no verified result for that date is included in this comparison; it does not mean that the measurement was normal or that the test was never performed.
The 2021 values are historical findings from my Health Inventory. The 2026 values are drawn from the available laboratory reports.
Trend interpretation:
The most striking change is the substantial reduction in general inflammatory markers compared with 2021.
However, ANA remains strongly positive.
The recent laboratory results therefore suggest that the severe systemic inflammatory pattern documented in 2021 is not currently reflected in the same degree of CRP or ESR elevation.
They do not establish that every autoimmune process has disappeared.
2. C-Reactive Protein (CRP) Trend
CRP is produced primarily by the liver in response to inflammatory signaling.
It can rise substantially during infection, tissue injury, systemic inflammation, and other medical conditions.
My documented results include:
- 2021 — CRP 32 mg/L
- September 2026 — CRP less than 1.0 mg/L
The September measurement was more than 31 mg/L lower than the historical result.
Clinical interpretation:
This represents a substantial difference in measured inflammatory activity.
The 2021 CRP concentration was markedly elevated, consistent with the severe inflammatory illness documented at that time.
The September 2026 CRP was within the WellMed reference interval.
This is an encouraging finding because it indicates that the same degree of CRP elevation was not present during the September assessment.
However, CRP is nonspecific.
It cannot identify the cause of inflammation, and a normal result does not exclude all inflammatory or autoimmune conditions.
3. High-Sensitivity CRP — November 2026
High-sensitivity CRP measures the same protein as conventional CRP but is designed to detect lower concentrations more precisely.
The November 2026 Function Health result was:
High-sensitivity CRP — 2.3 mg/L
The laboratory flagged this measurement as above its reference range.
Clinical interpretation:
The November result indicates a measurable low-level CRP concentration.
It is substantially below the historical CRP concentration of 32 mg/L recorded during the 2021 illness.
However, conventional CRP and high-sensitivity CRP should not be treated as interchangeable trend measurements without considering assay sensitivity and laboratory methods.
The September conventional CRP result of less than 1.0 mg/L and the November hs-CRP result of 2.3 mg/L do not establish a progressive inflammatory trend.
They indicate different measurements obtained at different times.
Because hs-CRP may also be used in cardiovascular risk assessment, the November result has relevance beyond autoimmune evaluation.
4. Erythrocyte Sedimentation Rate (ESR) Trend
ESR measures how quickly red blood cells settle in a sample of blood.
It is influenced by inflammatory proteins and several other factors, including age, anemia, and red blood cell characteristics.
The documented measurements were:
- 2021 — 71 mm/hr
- June 2026 — 6 mm/hr
- September 2026 — 18 mm/hr
The June 2026 ESR was 65 mm/hr lower than the historical measurement.
The September result was 53 mm/hr lower than the 2021 value.
Clinical interpretation:
Both recent measurements were substantially below the value recorded during the severe inflammatory illness.
The increase from 6 in June to 18 in September is a measurable change.
However, the September value remained within the WellMed reference interval of 0–20 mm/hr.
ESR can vary because of age, anemia, laboratory conditions, and other factors.
The change does not independently establish renewed systemic inflammatory disease.
5. Antinuclear Antibody (ANA) Trend
ANA testing detects antibodies that react with structures within the cell nucleus.
ANA may be present in several autoimmune conditions, but positive results can also occur without a defined systemic autoimmune disease.
The documented 2026 measurements were:
- June 2026 — ANA 1:1280
- September 2026 — ANA 1:640
Both results were strongly positive.
Clinical interpretation:
The September titer was one dilution lower than the June titer.
This does not necessarily represent a clinically meaningful improvement.
ANA titers may vary because of laboratory methods and biological variation.
Most importantly, ANA titer alone is not a reliable measurement of autoimmune disease activity.
The continued positive ANA is an important feature of my medical history, but it must be interpreted alongside symptoms, physical examination, disease-specific antibodies, and other laboratory findings.
6. ANA Homogeneous Pattern
Both the June and September 2026 ANA results were reported with a homogeneous staining pattern.
The homogeneous pattern may occur with antibodies directed against nuclear components, including chromatin, histones, or DNA-associated structures.
It can be seen in certain autoimmune conditions but is not specific to a single diagnosis.
Clinical interpretation:
The persistence of the homogeneous pattern indicates that the general ANA staining characteristic remained similar across the two measurements.
However, the pattern does not independently establish systemic lupus erythematosus or another particular autoimmune disorder.
The clinical significance depends on the complete evaluation.
7. Anti-Double-Stranded DNA Antibodies
Anti-dsDNA antibodies are associated with certain autoimmune conditions, particularly systemic lupus erythematosus.
The September 2026 result was:
Anti-dsDNA — 2.6 EIA U/mL
The WellMed reference interval was 0.0–10.0 EIA U/mL.
The result was within range.
Clinical interpretation:
The September measurement did not show elevated anti-dsDNA antibodies by that assay.
This is useful information in the context of the strongly positive ANA.
However, a normal anti-dsDNA result does not exclude every autoimmune disease or independently establish the absence of lupus.
The combination of positive ANA and normal anti-dsDNA requires clinical interpretation rather than assuming either a definite diagnosis or complete exclusion of disease.
8. Anticardiolipin IgA Antibodies
Anticardiolipin antibodies are part of the broader family of antiphospholipid antibody measurements.
They may be evaluated when certain clotting or autoimmune conditions are suspected.
The September 2026 result was:
Anticardiolipin IgA — less than 9 APL U/mL
The laboratory reference interval was 0–11 APL U/mL.
The result was within range.
Clinical interpretation:
This measurement did not demonstrate elevated anticardiolipin IgA.
However, it does not represent a complete antiphospholipid antibody evaluation.
Anticardiolipin IgG and IgM, beta-2 glycoprotein I antibodies, and lupus anticoagulant testing address other aspects of antiphospholipid antibody assessment.
The clinical importance depends on the reason testing was performed and the patient’s medical history.
9. Other Autoimmune Antibodies
My laboratory library includes categories for rheumatoid factor, CCP antibodies, complement proteins, and several additional disease-specific autoimmune markers.
These measurements can help distinguish among different autoimmune conditions when interpreted in the appropriate clinical setting.
However, the recent laboratory matrix does not provide a sufficiently complete chronological series for these markers to establish reliable numerical trends.
Clinical interpretation:
No conclusion about increasing or decreasing disease-specific antibody activity should be drawn without reviewing the actual results and dates.
The absence of a trend in this subsection is a limitation of the available verified data, not evidence that the markers were always normal.
10. Relationship Between ANA and Inflammatory Markers
One of the most important findings in my laboratory history is the difference between ANA positivity and general inflammatory activity.
In June 2026, ANA was strongly positive at 1:1280 while ESR was only 6 mm/hr.
In September 2026, ANA remained strongly positive at 1:640 while CRP was less than 1.0 mg/L and ESR was 18 mm/hr.
Clinical interpretation:
These findings demonstrate that strong ANA positivity can coexist with relatively low general inflammatory marker concentrations.
ANA reflects the presence of particular antibodies.
CRP and ESR reflect different aspects of inflammation.
Neither category should be used as a substitute for the other.
This distinction is central to understanding my recent laboratory results.
Relevance to My Health History
Severe Systemic Inflammatory Illness in 2021
The severe inflammatory illness in 2021 represents an important turning point in my medical history.
At that time, CRP and ESR were markedly elevated, and I experienced substantial pain and physical impairment.
The historical measurements of CRP 32 mg/L and ESR 71 mm/hr are consistent with significant systemic inflammation.
However, these tests alone do not establish the exact cause of that illness.
The subsequent improvement in inflammatory measurements is an important longitudinal finding.
Improvement in Symptoms
My health history includes substantial improvement in joint and muscle discomfort compared with the period of severe inflammation.
This improvement has been personally significant.
The lower recent CRP and ESR measurements are consistent with a substantially different inflammatory state from that documented in 2021.
However, laboratory measurements cannot independently establish the precise reason for symptom improvement.
Carnivore Diet
Since January 1, 2024, I have followed a strict carnivore diet.
I have reported substantial improvement in inflammation-related symptoms during the broader period of dietary and health changes.
The recent inflammatory markers provide objective information about my current condition.
However, the available laboratory comparisons do not establish that the diet caused the reduction in CRP or ESR.
The effects of earlier treatment, the natural course of illness, medications, and other factors must also be considered.
Persistent Positive ANA
Despite the substantial improvement in general inflammatory markers, ANA remains strongly positive.
This finding suggests persistent detectable antinuclear antibody activity.
However, it does not establish that active tissue damage or progressive autoimmune disease is occurring.
The most meaningful interpretation requires consideration of symptoms and disease-specific findings.
Immunology Follow-Up
My medical history includes ongoing evaluation by my immunologist, Dr. Saifi.
The combination of persistent ANA positivity and relatively low recent inflammatory markers is particularly relevant to this specialist evaluation.
The laboratory record provides a useful distinction between immune antibody findings and general inflammatory activity.
Cardiovascular Health
My cardiovascular history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm.
Systemic inflammation can influence cardiovascular health, and hs-CRP may contribute supplementary information to cardiovascular risk assessment.
The November hs-CRP result of 2.3 mg/L therefore has relevance beyond autoimmune evaluation.
However, hs-CRP does not replace LDL cholesterol, ApoB, blood pressure, imaging, or other cardiovascular assessments.
Age and Laboratory Interpretation
At age 90, interpretation of inflammatory markers requires consideration of age-related physiological changes and other medical conditions.
ESR may be influenced by anemia and age.
CRP may rise with infection, injury, or other inflammatory processes unrelated to autoimmune disease.
Consequently, an isolated abnormality should not automatically be interpreted as a recurrence of the 2021 illness.
Important Considerations
- The 2021 inflammatory illness was accompanied by markedly elevated CRP and ESR. These measurements provide important historical evidence of significant systemic inflammation.
- Recent general inflammatory markers are substantially lower. The 2026 measurements do not reproduce the severe inflammatory pattern documented in 2021.
- ANA remains strongly positive. The June and September 2026 results indicate persistent antinuclear antibody positivity.
- A decrease in ANA titer does not necessarily indicate clinical improvement. ANA titers are not reliable standalone measurements of autoimmune disease activity.
- Normal CRP and ESR do not exclude autoimmune disease. Some autoimmune conditions may remain active without substantial elevation of these markers.
- Anti-dsDNA was within range in September 2026. This provides useful information but does not independently establish or exclude a specific diagnosis.
- Anticardiolipin IgA was within range. This result should not be interpreted as a complete evaluation of antiphospholipid antibodies.
- The November hs-CRP measurement requires separate interpretation. It should not be treated as directly interchangeable with the September conventional CRP result.
- Symptom history remains essential. Laboratory findings are most meaningful when considered alongside physical function, pain, swelling, fatigue, and other clinical observations.
- The available evidence does not establish the cause of improvement. The relationship among dietary changes, previous treatment, and the natural history of the illness cannot be determined from the laboratory trends alone.
Summary of Inflammation and Autoimmune Trends
My inflammatory and autoimmune laboratory history reveals two important and distinct patterns.
The first is the substantial reduction in general inflammatory markers compared with the severe illness of 2021.
During that illness, CRP was approximately 32 mg/L and ESR was 71 mm/hr.
By 2026, ESR measurements were 6 and 18 mm/hr, while September CRP was less than 1.0 mg/L.
These results demonstrate that the marked inflammatory abnormalities present in 2021 were not reproduced in the recent measurements.
The second pattern is persistent strong ANA positivity.
ANA remained positive at 1:1280 in June 2026 and 1:640 in September 2026, with a homogeneous staining pattern on both occasions.
The September anti-dsDNA and anticardiolipin IgA results were within their respective laboratory reference intervals.
The November hs-CRP result of 2.3 mg/L indicates measurable low-level inflammation but does not establish recurrence of the severe inflammatory illness.
Taken together, the findings demonstrate why general inflammatory activity and autoimmune antibody measurements must be interpreted separately.
My reported improvement in symptoms is an important part of the overall health picture, but the available evidence does not establish a single cause.
Central Understanding: My laboratory history shows a substantial reduction in general inflammatory markers since the severe illness of 2021, while ANA remains strongly positive. These findings are not contradictory. ANA measures the presence of certain antibodies, whereas CRP and ESR provide information about inflammatory activity. The most important conclusion is that my recent laboratory results reflect a substantially different inflammatory pattern from 2021, although continued clinical assessment remains necessary to understand the significance of persistent autoimmune antibody positivity.
7.3.5 — Complete Blood Count and Immune Cell Trends
Overview
The complete blood count (CBC) is one of the most useful laboratory examinations for evaluating blood health, oxygen transport, immune cell activity, and the body’s ability to produce normal blood cells.
Unlike Section 7.2, which explained the meaning of individual blood count measurements, this subsection examines changes in my actual laboratory results and considers their significance over time.
My medical history includes a severe systemic inflammatory illness in 2021, accompanied by anemia and other laboratory abnormalities. Later records also identified an elevated eosinophil percentage in June 2024.
The more recent laboratory results from June, September, and November 2026 provide an opportunity to examine changes in hemoglobin, red blood cell counts, white blood cells, platelets, and immune cell populations.
One important finding is the return of mild anemia during 2026.
Hemoglobin decreased from 13.6 g/dL in June to 12.4 g/dL in September and 12.3 g/dL in November.
At the same time, the red blood cells remained normal in average size, producing a pattern described as normocytic anemia.
The recent white blood cell and platelet results provide additional information about bone marrow activity and immune cell populations.
The purpose of this subsection is to identify the most meaningful trends, distinguish reassuring findings from abnormalities that deserve continued observation, and consider their relationship to my medical history.
Important Laboratory Trends and Their Significance
1. Recent Complete Blood Count Measurements
The following table summarizes the verified recent measurements.
| Measurement | June 2026 | September 2026 | November 2026 |
|---|---|---|---|
| White Blood Cells (K/µL) | — | 4.27 | 4.60 |
| Red Blood Cells (M/µL) | — | 4.18 | 3.97 |
| Hemoglobin (g/dL) | 13.6 | 12.4 | 12.3 |
| Hematocrit (%) | — | 38.6 | 37.2 |
| MCV (fL) | — | 92.3 | 93.7 |
| MCH (pg) | — | 29.7 | 31.0 |
| MCHC (g/dL) | — | 32.1 | 33.1 |
| RDW (%) | — | 13.0 | 13.9 |
| Platelets (K/µL) | — | 182 | 170 |
| MPV (fL) | — | 10.0 | 10.3 |
A dash indicates that a verified value is not included for that date in this comparison.
Trend interpretation:
The most important finding is the decline in hemoglobin and red blood cell measurements.
White blood cells increased slightly between September and November, while platelets decreased modestly but remained within their respective laboratory reference intervals.
The red blood cell indices remained consistent with normal-sized red blood cells.
These findings provide the foundation for evaluating the recent anemia.
2. Hemoglobin Trend
Hemoglobin is the protein in red blood cells responsible for transporting oxygen throughout the body.
My documented measurements include:
- 2021 — 11.4 g/dL
- June 2026 — 13.6 g/dL
- September 2026 — 12.4 g/dL
- November 2026 — 12.3 g/dL
The 2021 measurement occurred during my severe systemic inflammatory illness.
By June 2026, hemoglobin was substantially higher.
However, hemoglobin decreased by 1.2 g/dL between June and September 2026.
The November measurement was another 0.1 g/dL lower.
The overall decline between June and November was 1.3 g/dL, approximately 9.6%.
Clinical interpretation:
The recent results demonstrate mild anemia.
For adult men, hemoglobin below approximately 13 g/dL commonly meets the definition of anemia, although laboratory reference intervals vary.
The decline is important because it indicates a change from the higher June measurement.
The November result suggests that the anemia persisted through the latest laboratory assessment.
However, these results do not establish the cause.
Possible explanations include inflammation, kidney-related factors, nutritional deficiencies, blood loss, chronic illness, or disorders affecting blood cell production.
The appropriate interpretation requires consideration of other laboratory measurements and clinical findings.
3. Red Blood Cell Count Trend
The red blood cell count measures the number of circulating red blood cells.
The recent measurements were:
- September 2026 — 4.18 million/µL
- November 2026 — 3.97 million/µL
The count decreased by 0.21 million/µL, approximately 5%.
Both results were below the respective laboratory reference intervals.
Clinical interpretation:
The decline supports the hemoglobin findings.
A lower red blood cell count may occur when the body produces fewer cells, loses blood, or destroys red blood cells more rapidly than normal.
The count alone does not distinguish among these possibilities.
The combination of reduced hemoglobin, hematocrit, and red blood cell count is more informative than any one measurement.
4. Hematocrit Trend
Hematocrit represents the proportion of blood volume occupied by red blood cells.
The recent measurements were:
- September 2026 — 38.6%
- November 2026 — 37.2%
Hematocrit decreased by 1.4 percentage points.
Clinical interpretation:
Both measurements were below their laboratory reference intervals.
The decrease is consistent with the lower red blood cell count and hemoglobin concentration.
Because hematocrit can also be influenced by changes in plasma volume, it should be interpreted together with the other CBC measurements.
5. Mean Corpuscular Volume (MCV)
MCV measures the average size of red blood cells.
The recent measurements were:
- September 2026 — 92.3 fL
- November 2026 — 93.7 fL
Both results were within their respective reference intervals.
Clinical interpretation:
The normal MCV indicates that the circulating red blood cells were normal in average size.
This produces a normocytic anemia pattern.
Normocytic anemia may occur with chronic inflammation, kidney disease, blood loss, hemolysis, or impaired red blood cell production.
It is a description of the red blood cells rather than a diagnosis of the underlying cause.
6. Mean Corpuscular Hemoglobin (MCH)
MCH measures the average amount of hemoglobin contained within each red blood cell.
The recent measurements were:
- September 2026 — 29.7 pg
- November 2026 — 31.0 pg
Both results were within their respective laboratory reference intervals.
Clinical interpretation:
The measurements indicate that the average amount of hemoglobin per red blood cell remained within the expected range.
The modest increase does not establish a separate disorder.
7. Mean Corpuscular Hemoglobin Concentration (MCHC)
MCHC measures the concentration of hemoglobin within red blood cells.
The recent measurements were:
- September 2026 — 32.1 g/dL
- November 2026 — 33.1 g/dL
Both results were within their respective reference intervals.
Clinical interpretation:
The normal MCHC supports the description of a normochromic red blood cell pattern.
Together with the normal MCV, the recent findings are consistent with normocytic, normochromic anemia.
8. Red Cell Distribution Width (RDW)
RDW measures variation in red blood cell size.
The recent measurements were:
- September 2026 — 13.0%
- November 2026 — 13.9%
Both measurements were within their respective reference intervals.
Clinical interpretation:
The results do not demonstrate marked variation in red blood cell size.
This provides useful supplementary information when evaluating anemia.
However, a normal RDW does not exclude nutritional deficiencies, chronic disease, or other causes of anemia.
9. White Blood Cell Count Trend
White blood cells participate in the body’s response to infection, inflammation, and other immune challenges.
The recent measurements were:
- September 2026 — 4.27 K/µL
- November 2026 — 4.60 K/µL
The count increased by 0.33 K/µL, approximately 7.7%.
The September measurement was slightly below the WellMed reference interval.
The November measurement was classified as within range by Function Health.
Clinical interpretation:
The November result is reassuring compared with the mildly low September count.
However, the measurements were obtained through different laboratories.
The change does not independently establish increased or decreased immune function.
The individual white blood cell populations provide additional information.
10. Neutrophil Trend
Neutrophils are important immune cells involved particularly in responses to bacterial infections and tissue injury.
The September WellMed report recorded:
- Neutrophils — 51.8%
- Absolute neutrophils — 2.21 K/µL
The November Function Health report recorded:
- Neutrophils — 49.9%
- Absolute neutrophils — 2,295 cells/µL
The November absolute count is equivalent to 2.295 K/µL.
Clinical interpretation:
The absolute neutrophil counts were similar and within their respective laboratory reference intervals.
This is more informative than comparing the percentages alone.
The recent measurements do not indicate neutropenia.
11. Lymphocyte Trend
Lymphocytes include several immune cell populations involved in adaptive immune responses.
The recent measurements were:
| Date | Lymphocytes | Absolute Count |
|---|---|---|
| September 2026 | 32.1% | 1.37 K/µL |
| November 2026 | 35.1% | 1.615 K/µL |
Clinical interpretation:
The absolute lymphocyte count increased modestly.
Both measurements were within their respective laboratory reference intervals.
The change does not independently establish abnormal immune activation.
12. Monocyte Trend
Monocytes participate in immune surveillance, inflammation, and the removal of damaged material.
The recent measurements were:
| Date | Monocytes | Absolute Count |
|---|---|---|
| September 2026 | 11.0% | 0.47 K/µL |
| November 2026 | 9.0% | 0.414 K/µL |
Clinical interpretation:
The percentage decreased, while the absolute count remained within the laboratory reference intervals.
The difference is modest and does not establish a significant abnormality.
13. Eosinophil Trend
Eosinophils participate in certain immune responses, including allergic reactions and responses to some parasitic infections.
They may also increase with certain medications, inflammatory conditions, and other disorders.
My documented history includes:
- June 2024 — Eosinophils 19%
- September 2026 — Eosinophils 4.2%
- November 2026 — Eosinophils 5.3%
The November absolute eosinophil count was 244 cells/µL.
Clinical interpretation:
The eosinophil percentage was substantially lower in the recent measurements than in June 2024.
This is an important historical comparison.
However, eosinophil percentages depend partly on the proportions of other white blood cells.
The absolute eosinophil count is generally more useful for determining whether true eosinophilia is present.
The November absolute count of 244 cells/µL was within the Function Health reference interval.
Because the June 2024 absolute count is not established in this comparison, the historical 19% result should not be treated as proof of a particular degree of absolute eosinophilia.
14. Basophil Trend
Basophils are a relatively small population of white blood cells involved in immune and inflammatory responses.
The recent measurements were:
- September 2026 — 0.7%
- November 2026 — 0.7%
The November absolute count was 32 cells/µL.
Clinical interpretation:
The percentage was unchanged.
The November absolute count was within the laboratory reference interval.
No significant basophil abnormality is evident from these measurements.
15. Platelet Count Trend
Platelets are essential for normal blood clotting and participate in certain inflammatory processes.
The recent measurements were:
- September 2026 — 182 K/µL
- November 2026 — 170 K/µL
The platelet count decreased by 12 K/µL, approximately 6.6%.
Both results were within their respective laboratory reference intervals.
Clinical interpretation:
The modest decline does not establish thrombocytopenia.
The recent results indicate that the platelet count remained within the expected laboratory range.
However, platelet count alone does not determine overall bleeding or clotting risk.
16. Mean Platelet Volume (MPV)
MPV measures the average size of circulating platelets.
The recent measurements were:
- September 2026 — 10.0 fL
- November 2026 — 10.3 fL
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The difference is small.
MPV is influenced by laboratory methods and sample handling and should not be used alone to diagnose a platelet disorder.
17. Iron Studies and the Recent Anemia
The September 2026 WellMed report included the following measurements:
| Measurement | September 2026 |
|---|---|
| Iron | 103 µg/dL |
| Ferritin | 117.3 ng/mL |
| Total Iron Binding Capacity | 298 µg/dL |
| Unsaturated Iron Binding Capacity | 195 µg/dL |
| Iron Saturation | 35% |
These measurements were within the laboratory’s stated reference intervals.
Clinical interpretation:
The September iron studies do not demonstrate an obvious pattern of depleted iron stores.
However, normal iron measurements do not identify the cause of the anemia.
The persistence of mild anemia in November makes the longitudinal hemoglobin pattern important.
Further interpretation may require consideration of reticulocyte count, kidney function, vitamin status, inflammation, possible blood loss, and other clinical findings.
Relevance to My Health History
Anemia During the 2021 Inflammatory Illness
During my severe systemic inflammatory illness in 2021, hemoglobin was documented at approximately 11.4 g/dL.
This represented anemia occurring in the setting of significant systemic inflammation.
By June 2026, hemoglobin had increased to 13.6 g/dL.
The more recent decline to 12.3 g/dL in November represents a new change in the laboratory pattern.
However, the recent anemia should not automatically be attributed to the same cause as the 2021 anemia.
Persistent Mild Anemia in Late 2026
The September and November measurements indicate persistent mild anemia.
The normal MCV and MCHC suggest a normocytic, normochromic pattern.
This finding deserves attention because anemia in older adults may have several causes, including nutritional deficiencies, kidney-related factors, chronic inflammation, blood loss, and bone marrow disorders.
The laboratory findings do not establish which explanation applies.
Kidney Function
My recent kidney measurements showed an increase in creatinine and a decrease in reported eGFR between September and November 2026.
Kidney function can influence red blood cell production through the hormone erythropoietin.
However, the available results do not establish that kidney dysfunction caused the anemia.
The relationship is worth considering in the broader medical assessment.
History of Systemic Inflammation
Chronic inflammation can interfere with iron utilization and red blood cell production.
My history of severe inflammation makes this mechanism relevant.
However, recent CRP and ESR measurements were much lower than during the 2021 illness.
Consequently, the current laboratory record does not establish active systemic inflammation as the explanation for the recent anemia.
Carnivore Diet and Nutritional Health
Since January 1, 2024, I have followed a strict carnivore diet.
Beef and other animal foods provide iron and vitamin B12, both of which are important for red blood cell production.
The September iron studies were within their stated reference intervals.
However, dietary intake alone does not establish adequate absorption or utilization of every nutrient.
The anemia should therefore be interpreted using actual laboratory findings rather than assumptions based on diet.
History of Elevated Eosinophils
The June 2024 eosinophil percentage of 19% was an unusual historical finding.
The September and November 2026 percentages were substantially lower.
The November absolute eosinophil count was within range.
This represents an important difference from the earlier differential count, although the original cause of the elevated percentage is not established.
Medication History and Bleeding Risk
My medical history includes aspirin use, previous anticoagulant treatment, and implantation of a Watchman device.
Medication history is relevant when evaluating anemia because blood loss may contribute to declining hemoglobin.
However, the available laboratory results do not establish that bleeding has occurred.
The presence or absence of gastrointestinal symptoms, visible bleeding, or other clinical findings would be important in determining whether blood loss requires investigation.
Age and Blood Cell Production
At age 90, blood count changes deserve careful interpretation.
Aging may be accompanied by changes in bone marrow reserve and a higher prevalence of medical conditions associated with anemia.
However, anemia should not automatically be considered a normal consequence of aging.
Persistent unexplained anemia may warrant further evaluation according to its severity, progression, symptoms, and overall clinical context.
Important Considerations
- Hemoglobin declined during 2026. The decrease from 13.6 g/dL in June to 12.3 g/dL in November is the most important recent CBC trend.
- Mild anemia persisted in September and November. The latest measurement did not demonstrate a return to the June hemoglobin level.
- The anemia is normocytic. Normal MCV measurements indicate that the red blood cells remained normal in average size.
- Normal iron studies do not establish the cause of anemia. They reduce concern for an obvious iron-depletion pattern but do not exclude every form of iron deficiency or other causes.
- White blood cells increased slightly. The November WBC count was within the Function Health reference interval after the mildly low September measurement.
- Absolute immune cell counts are particularly useful. Percentages alone can be misleading when the total white blood cell count changes.
- The eosinophil percentage is substantially lower than in June 2024. The November absolute eosinophil count was also within range.
- Platelet counts remained within range. The modest decline between September and November does not establish a platelet disorder.
- Historical anemia and recent anemia may have different causes. The presence of severe inflammation in 2021 does not prove that the same mechanism explains the 2026 findings.
- Persistent anemia deserves clinical attention. The most useful assessment considers symptoms, repeat blood counts, kidney function, nutritional markers, medication history, and possible blood loss.
Summary of Complete Blood Count and Immune Cell Trends
My recent complete blood count results reveal an important change in red blood cell measurements during 2026.
Hemoglobin declined from 13.6 g/dL in June to 12.4 g/dL in September and 12.3 g/dL in November.
Red blood cell count and hematocrit were also below their respective laboratory reference intervals in September and November.
MCV and MCHC remained within range, producing a pattern of mild normocytic, normochromic anemia.
This finding is important because I previously experienced anemia during the severe inflammatory illness in 2021.
However, the available evidence does not establish that the recent anemia has the same cause.
The September iron studies were within their laboratory reference intervals.
White blood cells increased modestly between September and November, with the latest measurement classified as within range.
The recent absolute neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts were within their respective laboratory reference intervals.
The historical eosinophil percentage of 19% in June 2024 contrasts with the substantially lower percentages recorded in September and November 2026.
Platelet counts remained within range despite a modest decline.
Overall, the most important finding is the persistent mild anemia, while the recent white blood cell differential and platelet measurements are comparatively reassuring.
Central Understanding: My 2026 blood count trends show a meaningful decline in hemoglobin and red blood cell measurements, resulting in persistent mild normocytic anemia. White blood cells and platelets remained near or within their respective laboratory reference intervals, and the previously elevated eosinophil percentage was substantially lower in the recent reports. The principal concern requiring continued assessment is the cause and persistence of the anemia rather than evidence of a broad abnormality affecting every blood cell population.
7.3.6 — Metabolic Health Trends
Overview
Metabolic laboratory measurements provide important information about how my body regulates blood glucose, produces and uses insulin, processes nutrients, and responds to periods of fasting.
These measurements are particularly relevant because I began following a strict carnivore diet on January 1, 2024. My diet consists primarily of beef, eggs, butter, salt, and raw whole milk.
The recent laboratory record includes glucose, hemoglobin A1c, insulin, leptin, and uric acid measurements. I have also recorded personal fasting glucose and blood ketone measurements.
Unlike Section 7.2, which explained the significance of individual metabolic markers, this subsection examines the changes in my actual results and considers what they may mean for my health.
The recent findings show normal glucose measurements, a small reduction in hemoglobin A1c, and consistently low insulin measurements.
My personal fasting measurements also demonstrate that I can achieve substantial nutritional ketosis during an extended fast.
However, the June 2026 uric acid result was elevated.
The purpose of this subsection is to identify the meaningful metabolic patterns, distinguish favorable findings from unresolved concerns, and evaluate the results within the context of my dietary history, age, and other medical conditions.
Important Laboratory Trends and Their Significance
1. Recent Metabolic Laboratory Results
The following table summarizes the verified laboratory measurements.
| Measurement | June 2026 | September 2026 | November 2026 |
|---|---|---|---|
| Glucose | 66 mg/dL | 84 mg/dL | 84 mg/dL |
| Hemoglobin A1c | 5.5% | — | 5.4% |
| Insulin | 2.1 µIU/mL | — | 2.1 µIU/mL |
| Leptin | 0.4 ng/mL | — | — |
| Uric Acid | 8.1 mg/dL | — | — |
A dash indicates that no verified result is included for that date in this comparison.
Trend interpretation:
Glucose increased between June and September 2026 and remained unchanged in November.
Hemoglobin A1c decreased slightly from June to November.
Insulin remained at the same measured concentration.
Leptin was low in absolute concentration but classified as within range by Function Health.
Uric acid was elevated in June, but no later measurement is available in this comparison to establish whether it increased, decreased, or remained stable.
2. Blood Glucose Trend
Glucose is the principal circulating sugar used by many tissues for energy.
My recent laboratory measurements were:
- June 2026 — 66 mg/dL
- September 2026 — 84 mg/dL
- November 2026 — 84 mg/dL
The June measurement was 18 mg/dL lower than the September and November measurements.
Clinical interpretation:
The September and November results were within their respective laboratory reference intervals.
The June value of 66 mg/dL was lower and falls below the commonly used fasting glucose threshold of 70 mg/dL.
However, the clinical significance depends on fasting duration, symptoms, medications, and other circumstances.
The September report did not establish fasting status, so its glucose value should not automatically be classified as fasting glucose.
The three measurements do not demonstrate persistent hyperglycemia.
They also do not establish that glucose is always normal between laboratory examinations.
3. Hemoglobin A1c Trend
Hemoglobin A1c estimates average blood glucose exposure over approximately the preceding two to three months.
My historical laboratory record includes:
| Year | Hemoglobin A1c |
|---|---|
| 2015 | 5.7% |
| 2016 | 5.1% |
| 2019 | 5.5% |
| February 2021 | 5.6% |
| June 2026 | 5.5% |
| November 2026 | 5.4% |
The earlier values are retained from my historical Health Inventory, while the recent measurements are verified against the 2026 laboratory record.
Trend interpretation:
The historical measurements show some variation but no sustained upward progression in the selected results.
The June 2026 A1c was 5.5%.
By November, it had decreased to 5.4%.
The change was 0.1 percentage point.
Clinical interpretation:
Both recent values are below the commonly used prediabetes threshold of 5.7%.
This is a favorable finding.
However, the small change between June and November may reflect ordinary biological or laboratory variation rather than a meaningful change in glucose regulation.
A1c may also be affected by anemia, changes in red blood cell lifespan, and certain medical conditions.
Because my recent CBC results demonstrate mild anemia, this consideration is particularly relevant.
The available measurements are reassuring but should not be treated as a complete assessment of metabolic health.
4. Insulin Trend
Insulin is produced by the pancreas and helps regulate glucose movement into cells and other aspects of energy metabolism.
My recent measurements were:
- June 2026 — 2.1 µIU/mL
- November 2026 — 2.1 µIU/mL
The results were identical.
Both were classified as within range by Function Health.
Clinical interpretation:
The measurements indicate low circulating insulin concentrations at the times of testing.
Low insulin may occur during fasting or when carbohydrate intake is restricted.
My dietary pattern makes this an expected possibility.
However, insulin measurements must be interpreted in relation to glucose, fasting status, and the conditions of sample collection.
A low insulin concentration alone does not prove optimal insulin sensitivity or exclude every metabolic disorder.
5. Relationship Between Glucose and Insulin
Glucose and insulin provide complementary information.
The June 2026 laboratory record contained:
- Glucose — 66 mg/dL
- Insulin — 2.1 µIU/mL
The November record contained:
- Glucose — 84 mg/dL
- Insulin — 2.1 µIU/mL
Clinical interpretation:
These combinations are consistent with low insulin concentrations accompanying relatively low or normal glucose concentrations.
They do not suggest the pattern of elevated glucose accompanied by high circulating insulin.
However, without confirmed fasting conditions and additional clinical information, these measurements should not be used to calculate or interpret a definitive insulin resistance index.
6. Personal Fasting Glucose Measurement
On January 4, 2026, I recorded the following measurements after approximately 24 hours of fasting:
- Blood glucose — 78 mg/dL
- Blood ketones — 4.7 mmol/L
- Glucose Ketone Index — approximately 0.9
These measurements were obtained under explicitly documented fasting conditions.
Clinical interpretation:
The glucose concentration was within the usual fasting reference range.
The blood ketone concentration demonstrated substantial ketosis.
The calculated glucose ketone index was consistent with a state of marked nutritional ketosis.
However, this was a single personal measurement under a specific fasting condition.
It should not be interpreted as representative of every day or every fasting period.
7. Blood Ketones and Nutritional Ketosis
Blood beta-hydroxybutyrate is a ketone body produced primarily by the liver.
Ketone production generally increases when carbohydrate availability is low and fatty acid utilization increases.
My January 2026 blood ketone result was:
4.7 mmol/L after approximately 24 hours of fasting
Clinical interpretation:
This measurement demonstrates that I was in substantial ketosis at the time of testing.
It is consistent with the combined effects of fasting and a very-low-carbohydrate dietary pattern.
However, ketone concentration alone does not establish improved cardiovascular health, kidney function, or overall longevity.
It also does not establish that a higher ketone concentration is necessarily better.
The measurement is most useful as evidence of the metabolic state present during the recorded fast.
8. Glucose Ketone Index
The glucose ketone index compares blood glucose, expressed in mmol/L, with blood beta-hydroxybutyrate.
My recorded January 2026 values were:
- Glucose — 78 mg/dL
- Ketones — 4.7 mmol/L
Converting glucose to mmol/L gives approximately 4.33 mmol/L.
Dividing 4.33 by 4.7 produces a GKI of approximately 0.92.
This agrees with my recorded value of 0.9.
Clinical interpretation:
The low GKI reflects the combination of relatively low glucose and substantial ketone production.
However, GKI is not a standard clinical measure of cardiovascular risk, insulin sensitivity, or longevity.
Its principal value in my Health Inventory is documenting the metabolic response to fasting.
9. Leptin
Leptin is produced primarily by adipose tissue and participates in the regulation of energy balance.
The June 2026 Function Health result was:
Leptin — 0.4 ng/mL
The laboratory classified the result as within range.
Clinical interpretation:
The concentration is low in absolute terms.
Leptin levels are influenced by body fat, energy intake, fasting, and other factors.
My relatively lean body composition and dietary pattern may be relevant.
However, the measurement does not independently establish an abnormal metabolic condition.
Because only one verified leptin result is available, no longitudinal trend can be determined.
10. Uric Acid
Uric acid is produced during the breakdown of purines and is eliminated primarily through the kidneys.
The June 2026 Function Health result was:
Uric acid — 8.1 mg/dL
The laboratory classified this result as above range.
Clinical interpretation:
The elevated measurement is an important finding.
Uric acid concentrations may be influenced by kidney function, dietary purines, alcohol intake, hydration, genetics, medications, and metabolic factors.
A diet containing substantial amounts of meat may contribute to uric acid production.
Ketosis can also temporarily influence renal uric acid handling.
However, the available laboratory result does not establish the cause of the elevation.
Elevated uric acid may be associated with gout and certain kidney stone risks, although a single elevated measurement does not establish either condition.
A later measurement would be useful for determining whether the elevation persisted.
11. Relationship Between Uric Acid and Kidney Function
My recent kidney laboratory record includes elevated BUN and changes in creatinine and estimated GFR.
Because the kidneys eliminate much of the body’s uric acid, kidney function is relevant to uric acid interpretation.
However, the June 2026 uric acid measurement and later kidney measurements were obtained at different times.
The available information does not establish that impaired kidney filtration caused the elevated uric acid.
It also does not establish that elevated uric acid caused kidney damage.
The relationship should be considered as part of the broader metabolic and kidney assessment.
12. Triglycerides and Metabolic Health
Triglycerides provide supplementary information about metabolic regulation.
My recent measurements were:
- June 2026 — 85 mg/dL
- September 2026 — 54 mg/dL
- November 2026 — 45 mg/dL
All were below the commonly used threshold of 150 mg/dL.
Clinical interpretation:
The relatively low triglyceride concentrations are consistent with a favorable aspect of my metabolic profile.
Low triglycerides often accompany carbohydrate restriction and may be associated with improved insulin sensitivity in some individuals.
However, triglycerides do not provide a complete assessment of metabolic or cardiovascular health.
As discussed in Section 7.3.1, my LDL cholesterol and atherogenic particle measurements remain important independent considerations.
Relevance to My Health History
Carnivore Diet Since January 2024
My strict carnivore diet is an important part of the context for interpreting metabolic measurements.
Very-low-carbohydrate diets commonly reduce post-meal glucose and insulin responses and promote greater reliance on fatty acids and ketones.
My recent glucose, insulin, and ketone measurements are consistent with aspects of this metabolic pattern.
However, the laboratory results do not establish that the diet caused every observed change.
Previous Glucose and A1c History
My historical A1c measurements include a value of 5.7% in 2015, followed by lower measurements in subsequent years.
The recent values of 5.5% and 5.4% remain below the usual prediabetes threshold.
This is reassuring, although the selected measurements do not provide a continuous year-by-year metabolic history.
Fasting Practices
My January 2026 personal measurements demonstrate a strong ketogenic response after approximately 24 hours without food.
This information is useful for understanding how my metabolism responds to fasting.
However, prolonged fasting at advanced age requires consideration of hydration, nutritional adequacy, medications, and preservation of muscle mass.
The ability to produce high ketone concentrations does not by itself establish that extended fasting is beneficial.
Cardiovascular Health
My cardiovascular history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm.
The recent glucose and triglyceride findings are favorable in certain respects.
However, these findings do not eliminate the significance of elevated LDL cholesterol and ApoB.
Metabolic and cardiovascular risk should therefore be assessed together rather than allowing one group of favorable measurements to outweigh unrelated concerns.
Kidney Function
My kidney laboratory trends include elevated BUN and a recent change in creatinine and eGFR.
These findings are relevant to uric acid metabolism and hydration.
However, the available results do not establish progressive kidney disease or a causal relationship with my dietary practices.
Mild Anemia
My recent CBC measurements demonstrate mild anemia.
This is relevant because changes in red blood cell production or lifespan can influence A1c independently of average blood glucose.
The recent A1c values are reassuring but should be interpreted alongside actual glucose measurements.
Age and Nutritional Health
At age 90, preserving muscle mass, strength, mobility, and adequate nutrition is particularly important.
Normal glucose and low insulin are useful metabolic findings, but they are not sufficient to establish overall nutritional adequacy.
Body weight, physical function, dietary intake, and other laboratory measurements remain important components of the Health Inventory.
Important Considerations
- Recent glucose measurements were not elevated. The September and November results were both 84 mg/dL.
- The June glucose measurement was lower. The result of 66 mg/dL should be interpreted with attention to fasting conditions and symptoms.
- Hemoglobin A1c remained below the usual prediabetes threshold. The decrease from 5.5% to 5.4% is small and may reflect ordinary variation.
- Insulin remained low. Both June and November measurements were 2.1 µIU/mL.
- Low insulin alone does not establish optimal insulin sensitivity. Glucose, fasting status, and the broader clinical picture remain important.
- My January fasting measurements demonstrated substantial ketosis. The ketone concentration of 4.7 mmol/L reflects the metabolic state during that specific fast.
- The glucose ketone index is descriptive rather than diagnostic. It should not be treated as a validated measure of overall health or longevity.
- Uric acid was elevated in June 2026. The result of 8.1 mg/dL deserves continued observation, particularly in the context of diet and kidney function.
- Low triglycerides are favorable but do not eliminate cardiovascular risk. Elevated LDL cholesterol and ApoB remain separate concerns.
- Metabolic health requires a comprehensive assessment. Laboratory measurements should be considered alongside physical function, nutrition, hydration, body composition, and medical history.
Summary of Metabolic Health Trends
My recent metabolic laboratory results show generally favorable glucose regulation, low insulin concentrations, and substantial ketone production during a documented extended fast.
Glucose was 66 mg/dL in June 2026 and 84 mg/dL in both September and November.
Hemoglobin A1c decreased slightly from 5.5% in June to 5.4% in November.
Insulin remained at 2.1 µIU/mL in both June and November.
These findings do not indicate persistent hyperglycemia in the available measurements.
My January 2026 personal fasting results demonstrated glucose of 78 mg/dL, ketones of 4.7 mmol/L, and a glucose ketone index of approximately 0.9 after about 24 hours of fasting.
This confirms substantial ketosis during that particular fasting period.
The June 2026 leptin measurement was classified as within range.
However, uric acid was elevated at 8.1 mg/dL, representing an important finding that cannot yet be evaluated as a trend because no later verified result is available.
The recent triglyceride measurements were also relatively low, providing supplementary information about metabolic regulation.
Overall, the findings demonstrate several reassuring metabolic characteristics, but they do not establish that every aspect of metabolic or cardiovascular health is optimal.
Central Understanding: My recent metabolic laboratory trends show normal or relatively low glucose measurements, stable low insulin, hemoglobin A1c below the usual prediabetes threshold, and substantial ketosis during a documented extended fast. These findings are consistent with aspects of my very-low-carbohydrate dietary pattern. However, elevated uric acid and the broader cardiovascular and kidney findings remain important considerations. The most useful interpretation is a balanced assessment of both favorable measurements and unresolved concerns rather than relying on any single metabolic marker.
7.3.7 — Liver Function and Protein Chemistry Trends
Overview
The liver performs many essential functions, including processing nutrients, producing important blood proteins, regulating aspects of metabolism, and helping remove substances from the body.
Laboratory measurements associated with liver health provide useful information about liver cell injury, bile processing, and protein chemistry.
However, the commonly used term liver function tests includes several measurements that do not directly measure the liver’s overall functional capacity.
ALT and AST are primarily markers of cellular injury. Alkaline phosphatase and GGT can provide information about bile duct-related processes. Bilirubin reflects several aspects of red blood cell breakdown and liver processing.
Albumin and total protein provide additional information about circulating proteins, although their concentrations may be influenced by nutrition, inflammation, hydration, kidney losses, and other conditions.
My recent laboratory record includes measurements from September and November 2026 that permit direct comparison of several important liver-related markers.
These results are particularly relevant because I follow a strict carnivore diet, have a history of severe systemic inflammation, and am interested in preserving health and physical function as I age.
The purpose of this subsection is to identify the documented trends, explain their significance, and distinguish reassuring findings from conclusions that cannot be established from blood chemistry alone.
Important Laboratory Trends and Their Significance
1. Recent Liver and Protein Chemistry Measurements
The following table summarizes the verified results.
| Measurement | September 2026 | November 2026 |
|---|---|---|
| ALT (SGPT) | 28 U/L | 20 U/L |
| AST (SGOT) | 27 U/L | 23 U/L |
| Alkaline Phosphatase | 51 U/L | 51 U/L |
| Total Bilirubin | 0.7 mg/dL | 0.6 mg/dL |
| Albumin | 4.0 g/dL | 4.0 g/dL |
| Total Protein | 7.1 g/dL | 7.2 g/dL |
| Globulin | — | 3.2 g/dL |
| Albumin/Globulin Ratio | — | 1.3 |
A dash indicates that no verified result is included for that date in this comparison.
All measurements shown were within their respective laboratory reference intervals.
Trend interpretation:
The results demonstrate a generally stable liver-related chemistry profile.
ALT and AST decreased modestly.
Alkaline phosphatase and albumin remained unchanged.
Bilirubin decreased slightly, while total protein increased by a small amount.
These findings do not demonstrate a pattern of progressively increasing liver enzymes during the period examined.
2. Alanine Aminotransferase (ALT) Trend
ALT is an enzyme found primarily in liver cells.
When liver cells are injured, ALT may increase in the bloodstream.
My recent measurements were:
- September 2026 — 28 U/L
- November 2026 — 20 U/L
ALT decreased by 8 U/L, approximately 28.6%.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The lower November value is reassuring in the sense that it does not indicate an increase in this marker of liver cell injury.
However, the decrease should not automatically be interpreted as proof that liver health improved.
Both measurements were already within range.
ALT can vary because of biological factors, laboratory differences, medications, illness, and other circumstances.
Normal ALT also does not exclude every form of liver disease.
3. Aspartate Aminotransferase (AST) Trend
AST is found in the liver and several other tissues, including skeletal muscle.
It may increase with liver injury, muscle injury, and other conditions.
My recent measurements were:
- September 2026 — 27 U/L
- November 2026 — 23 U/L
AST decreased by 4 U/L, approximately 14.8%.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The November result does not indicate increased AST activity.
The modest decrease is consistent with the overall stable laboratory pattern.
Because AST is not specific to the liver, its interpretation should consider ALT, other laboratory measurements, and clinical circumstances.
4. Relationship Between ALT and AST
ALT and AST are frequently evaluated together.
My recent measurements were:
| Date | ALT | AST |
|---|---|---|
| September 2026 | 28 | 27 |
| November 2026 | 20 | 23 |
Both enzymes remained within range.
Clinical interpretation:
The combined findings do not demonstrate a biochemical pattern of active, substantial liver cell injury at either testing date.
However, normal liver enzymes cannot establish the absence of liver fibrosis, fatty liver disease, or other structural abnormalities.
The ALT-to-AST relationship should not be used alone to diagnose a liver condition.
5. Alkaline Phosphatase Trend
Alkaline phosphatase is an enzyme associated with several tissues, including the liver and bones.
It is often evaluated when investigating possible bile duct abnormalities.
My recent measurements were:
- September 2026 — 51 U/L
- November 2026 — 51 U/L
The results were identical.
Both were within their respective laboratory reference intervals.
Clinical interpretation:
This represents a stable recent measurement.
There is no documented rise in alkaline phosphatase during the interval.
However, alkaline phosphatase alone cannot establish that all bile duct or bone-related conditions are absent.
6. Gamma-Glutamyl Transferase (GGT)
GGT is an enzyme commonly used in evaluating liver and bile duct-related abnormalities.
The June 2026 Function Health result was:
GGT — 10 U/L
The laboratory classified this result as within range.
Clinical interpretation:
The June measurement was reassuring.
However, the available recent record does not provide a paired September or November GGT result.
Consequently, no recent numerical trend can be established.
The normal June result should not be interpreted as proof that GGT remained unchanged throughout the year.
7. Total Bilirubin Trend
Bilirubin is produced primarily during the normal breakdown of hemoglobin.
The liver processes bilirubin so that it can be eliminated from the body.
My recent measurements were:
- September 2026 — 0.7 mg/dL
- November 2026 — 0.6 mg/dL
The difference was 0.1 mg/dL.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The results indicate stable bilirubin concentrations during the interval.
The small decrease does not establish a meaningful change in liver function.
The measurements do not suggest elevated bilirubin at either testing date.
8. Albumin Trend
Albumin is the most abundant protein in blood plasma and is produced by the liver.
It helps maintain fluid balance and transports various substances through the bloodstream.
My recent measurements were:
- September 2026 — 4.0 g/dL
- November 2026 — 4.0 g/dL
The measurements were identical.
Both were within their respective laboratory reference intervals.
Clinical interpretation:
The stable albumin concentration is a reassuring finding.
It indicates that serum albumin was maintained within the expected range at both testing dates.
However, albumin is influenced by inflammation, hydration, kidney losses, and other factors.
A normal albumin concentration does not independently establish adequate nutritional intake or exclude every form of liver disease.
9. Total Protein Trend
Total protein measures the combined concentration of albumin and globulins in the blood.
My recent measurements were:
- September 2026 — 7.1 g/dL
- November 2026 — 7.2 g/dL
Total protein increased by 0.1 g/dL.
Both results were within their respective laboratory reference intervals.
Clinical interpretation:
The small difference indicates a generally stable total protein concentration.
There is no documented substantial increase or decrease during the interval.
However, total protein alone does not determine whether dietary protein intake is sufficient or excessive.
10. Globulin
Globulins are a group of proteins that include immunoglobulins and other circulating proteins.
The November 2026 Function Health result was:
Globulin — 3.2 g/dL
The laboratory classified this result as within range.
Clinical interpretation:
The measurement does not demonstrate an abnormal globulin concentration.
This is relevant to my history of positive ANA and systemic inflammation.
However, total globulin does not directly measure ANA activity or identify a specific autoimmune condition.
Because no paired September globulin measurement is verified here, a numerical trend cannot be established.
11. Albumin-to-Globulin Ratio
The albumin-to-globulin ratio compares the concentrations of these two groups of proteins.
The November 2026 Function Health result was:
Albumin/Globulin Ratio — 1.3
The laboratory classified the result as within range.
Clinical interpretation:
The measurement is consistent with the normal albumin and globulin concentrations reported in November.
However, one measurement does not establish a longitudinal trend.
The ratio should be interpreted together with the underlying protein concentrations.
12. Relationship Between Liver Enzymes and Protein Chemistry
The November 2026 results included:
- ALT — 20 U/L
- AST — 23 U/L
- Alkaline phosphatase — 51 U/L
- Total bilirubin — 0.6 mg/dL
- Albumin — 4.0 g/dL
- Total protein — 7.2 g/dL
- Globulin — 3.2 g/dL
All were classified as within range.
Clinical interpretation:
The combination provides a reassuring biochemical picture.
There is no documented elevation of the principal liver enzymes or bilirubin.
Albumin and total protein were maintained within their respective laboratory reference intervals.
However, these measurements do not directly establish normal liver structure or exclude all liver disease.
Other clinical information, imaging, and selected additional testing may be relevant when medically indicated.
Relevance to My Health History
Carnivore Diet
Since January 1, 2024, I have followed a strict carnivore diet.
The liver plays an important role in processing dietary nutrients, regulating energy metabolism, and producing ketones.
My recent liver-related laboratory results remained within their respective reference intervals.
This is reassuring.
However, the findings do not establish that my diet caused the normal results or that the diet is free of long-term risks.
History of Systemic Inflammation
My medical history includes a severe systemic inflammatory illness in 2021.
Inflammatory conditions can influence circulating proteins and certain liver-related laboratory measurements.
The recent albumin and total protein results were stable and within range.
However, these measurements alone do not determine whether an autoimmune or inflammatory condition is active.
Persistent Positive ANA
My recent laboratory history includes strongly positive ANA measurements.
Autoimmune conditions can sometimes involve the liver, but ANA positivity alone does not establish autoimmune liver disease.
The normal recent ALT, AST, alkaline phosphatase, and bilirubin measurements do not demonstrate an active biochemical pattern of substantial liver injury.
However, they do not independently exclude every autoimmune liver condition.
Medication History
My medical history includes reactions to several medications.
Some medications can affect liver enzymes or liver function.
The recent laboratory measurements do not demonstrate elevated ALT or AST.
However, normal results at these testing dates do not establish that every past medication exposure was without effect.
Nutritional Health
Albumin and total protein are sometimes discussed in nutritional assessments.
My recent values were within their respective reference intervals.
However, these measurements are not direct tests of dietary protein adequacy.
Nutritional assessment should also consider body weight, muscle mass, strength, physical function, and other relevant findings.
Kidney Function
Albumin and other proteins may be lost through the kidneys in certain conditions.
My recent serum albumin was normal.
However, a normal blood albumin concentration does not exclude abnormal urinary albumin excretion.
Kidney-related assessment therefore remains separate from the interpretation of serum protein chemistry.
Age and Liver Health
At age 90, preserving adequate nutrition, physical function, and organ health is important.
The recent liver-related measurements are reassuring.
However, normal laboratory values should be interpreted as one component of the overall assessment rather than a complete guarantee of liver health.
Important Considerations
- ALT remained within range. The decrease from 28 to 20 U/L does not demonstrate progressive liver enzyme elevation.
- AST remained within range. The decrease from 27 to 23 U/L is consistent with the stable recent biochemical pattern.
- Alkaline phosphatase was unchanged. Both September and November measurements were 51 U/L.
- Bilirubin remained normal. The small decrease from 0.7 to 0.6 mg/dL does not establish a clinically important change.
- Albumin remained stable. Both measurements were 4.0 g/dL.
- Total protein remained stable. The change from 7.1 to 7.2 g/dL was small.
- Globulin and the albumin/globulin ratio were within range in November. No paired September results are verified for these measurements.
- GGT was within range in June. A recent longitudinal trend cannot be established from the single verified measurement.
- Normal liver-related chemistry does not exclude every liver condition. Blood tests cannot independently establish normal liver structure or absence of fibrosis.
- The results should be interpreted within the broader Health Inventory. Diet, inflammation, medications, kidney function, nutritional status, and clinical history remain relevant.
Summary of Liver Function and Protein Chemistry Trends
My September and November 2026 laboratory results show a generally stable liver-related chemistry profile.
ALT decreased from 28 to 20 U/L, while AST decreased from 27 to 23 U/L.
Both enzymes remained within their respective laboratory reference intervals.
Alkaline phosphatase was unchanged at 51 U/L.
Total bilirubin decreased slightly from 0.7 to 0.6 mg/dL.
Albumin remained unchanged at 4.0 g/dL, while total protein increased slightly from 7.1 to 7.2 g/dL.
The November globulin concentration of 3.2 g/dL and albumin/globulin ratio of 1.3 were also within range.
The June GGT measurement of 10 U/L was classified as within range, although no recent paired measurement is available to establish a trend.
Taken together, the recent results do not demonstrate elevated liver enzymes, increased bilirubin, or a substantial abnormality in serum protein concentrations.
These findings are reassuring, particularly in the context of my medical history and dietary practices.
However, they do not establish that all aspects of liver health or nutritional status are normal.
Central Understanding: My recent liver and protein chemistry measurements show a stable and generally reassuring pattern. ALT, AST, alkaline phosphatase, bilirubin, albumin, and total protein remained within their respective laboratory reference intervals, with only modest changes between September and November 2026. These findings do not demonstrate active substantial liver cell injury or abnormal serum protein concentrations, but they cannot independently establish the absence of every liver disorder or confirm complete nutritional adequacy.
7.3.8 — Nutritional Health Trends
Overview
Nutritional health is an important component of my Health Inventory because adequate vitamins, minerals, proteins, and essential fatty acids are necessary for maintaining physical strength, immune function, blood cell production, and normal metabolic activity.
Since January 1, 2024, I have followed a strict carnivore diet consisting primarily of beef, eggs, butter, salt, and raw whole milk.
My experience with this dietary pattern has included substantial improvement in the joint and muscle discomfort that affected me during earlier years.
However, improvement in symptoms does not independently establish that every nutritional requirement is being met.
At age 90, nutritional adequacy is particularly important for maintaining muscle mass, bone health, mobility, and physical independence.
The recent laboratory record includes iron studies, vitamin D, methylmalonic acid, homocysteine, magnesium, zinc, and specialized fatty acid measurements.
These findings provide useful information about selected aspects of nutritional status.
The available record does not provide repeated measurements for every nutrient, so some findings can be evaluated as trends while others must be treated as individual observations.
The purpose of this subsection is to examine the verified nutritional measurements, identify meaningful changes, and consider their significance in relation to my diet, recent anemia, and long-term health goals.
Important Laboratory Trends and Their Significance
1. Recent Nutritional Laboratory Measurements
The following table summarizes the principal verified measurements.
| Measurement | June 2026 | September 2026 |
|---|---|---|
| Iron | 135 µg/dL | 103 µg/dL |
| Ferritin | 105 ng/mL | 117.3 ng/mL |
| Total Iron Binding Capacity | 327 µg/dL | 298 µg/dL |
| Iron Saturation | 41% | 35% |
| Unsaturated Iron Binding Capacity | — | 195 µg/dL |
| Vitamin D | 106 ng/mL | — |
| Methylmalonic Acid | 93 nmol/L | — |
| Homocysteine | 14.2 µmol/L | — |
| RBC Magnesium | 4.7 mg/dL | — |
| Zinc | 92 µg/dL | — |
A dash indicates that a verified result is not included for that date in this comparison.
The June Function Health report classified the listed iron, methylmalonic acid, homocysteine, magnesium, and zinc results as within range.
The September WellMed iron measurements were also within their respective reference intervals.
Vitamin D was flagged as above range.
Trend interpretation:
The iron measurements changed modestly between June and September but remained within their respective laboratory reference intervals.
Ferritin increased slightly.
The other nutrients have only one verified measurement in this comparison, so no numerical trend can be established.
2. Serum Iron Trend
Serum iron measures the amount of iron circulating in the blood, primarily bound to transferrin.
My recent measurements were:
- June 2026 — 135 µg/dL
- September 2026 — 103 µg/dL
Serum iron decreased by 32 µg/dL, approximately 23.7%.
Both results were within their respective laboratory reference intervals.
Clinical interpretation:
The decline does not independently establish iron deficiency.
Serum iron can vary with time of day, recent food intake, inflammation, and other factors.
For this reason, it should be interpreted alongside ferritin, transferrin saturation, and the complete blood count.
3. Ferritin Trend
Ferritin is a protein that stores iron.
Serum ferritin is commonly used to estimate the body’s iron stores.
My recent measurements were:
- June 2026 — 105 ng/mL
- September 2026 — 117.3 ng/mL
Ferritin increased by 12.3 ng/mL, approximately 11.7%.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The results do not demonstrate depleted ferritin concentrations.
This is relevant because my September and November blood counts identified mild anemia.
However, ferritin can increase during inflammation and may not always reflect iron stores accurately in every medical condition.
The results should therefore be interpreted with the broader iron studies and inflammatory history.
4. Total Iron Binding Capacity Trend
Total iron binding capacity, or TIBC, provides information about the blood’s capacity to bind and transport iron.
My recent measurements were:
- June 2026 — 327 µg/dL
- September 2026 — 298 µg/dL
TIBC decreased by 29 µg/dL, approximately 8.9%.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The modest decrease does not establish a specific nutritional disorder.
TIBC is affected by transferrin concentrations and may change with nutritional status, inflammation, and other conditions.
Its greatest value is in combination with serum iron, ferritin, and iron saturation.
5. Iron Saturation Trend
Iron saturation measures the proportion of available iron-binding sites occupied by iron.
My recent measurements were:
- June 2026 — 41%
- September 2026 — 35%
Iron saturation decreased by 6 percentage points.
Both measurements were within their respective laboratory reference intervals.
Clinical interpretation:
The results do not demonstrate the typical low-saturation pattern associated with iron deficiency.
However, normal iron saturation does not establish the cause of the recent anemia.
The finding is reassuring but not definitive.
6. Relationship Between Iron Status and Anemia
My recent hemoglobin measurements were:
- June 2026 — 13.6 g/dL
- September 2026 — 12.4 g/dL
- November 2026 — 12.3 g/dL
The September iron studies were within their respective laboratory reference intervals.
Clinical interpretation:
The recent anemia does not show an obvious laboratory pattern of depleted iron stores.
The normal MCV measurements also indicate that the red blood cells were normal in average size.
However, these findings do not establish the cause of the anemia.
Other possibilities include kidney-related factors, inflammation, blood loss, impaired red blood cell production, or nutritional deficiencies not identified by the available iron measurements.
The distinction is important because taking additional iron without an established need would not necessarily address the underlying problem.
7. Vitamin B12
Vitamin B12 is essential for normal red blood cell production, neurological function, and DNA synthesis.
Animal foods, including beef, eggs, and dairy products, contain vitamin B12.
My dietary pattern therefore includes recognized food sources of this vitamin.
However, the available recent laboratory matrix does not provide a verified numerical serum B12 result for this comparison.
Clinical interpretation:
Dietary intake does not guarantee adequate absorption.
Vitamin B12 absorption can be affected by age, gastrointestinal conditions, medications, and other factors.
Consequently, a conclusion about my current serum B12 concentration cannot be established from diet alone.
The June methylmalonic acid result provides additional information relevant to B12 status.
8. Methylmalonic Acid (MMA)
Methylmalonic acid is a metabolic compound that may increase when cellular vitamin B12 availability is inadequate.
The June 2026 Function Health result was:
Methylmalonic Acid — 93 nmol/L
The laboratory classified this result as within range.
Clinical interpretation:
The normal MMA measurement is reassuring and does not suggest substantial functional vitamin B12 deficiency at the time of testing.
However, MMA is not a complete substitute for clinical assessment or all other B12-related testing.
Kidney function can also influence MMA concentrations.
Because only one verified result is available, no numerical trend can be established.
9. Folate
Folate is essential for DNA synthesis and normal red blood cell production.
It is particularly important during the formation of new cells.
The recent laboratory matrix does not provide a verified folate result for this comparison.
Clinical interpretation:
My dietary pattern includes limited plant foods, which are common sources of folate.
However, animal foods also contain varying amounts of folate.
The available evidence does not establish either folate deficiency or adequate folate status.
Because of the recent anemia, folate remains a relevant nutrient to consider in the broader nutritional assessment.
10. Homocysteine
Homocysteine is an amino acid intermediate involved in several metabolic pathways.
Its concentration may be influenced by vitamin B12, folate, vitamin B6, kidney function, genetics, and other factors.
The June 2026 Function Health result was:
Homocysteine — 14.2 µmol/L
The laboratory classified this result as within range.
Clinical interpretation:
The result was within the reporting laboratory’s reference interval.
However, homocysteine is influenced by multiple factors and should not be treated as a direct measure of any single vitamin.
The result does not independently establish optimal B12, folate, or B6 status.
11. Vitamin D
Vitamin D is important for calcium regulation, bone health, and several other physiological processes.
The June 2026 Function Health result was:
Vitamin D — 106 ng/mL
The laboratory classified this measurement as above range.
Clinical interpretation:
This is one of the most important findings in the nutritional laboratory record.
A vitamin D concentration of 106 ng/mL is higher than generally recommended for routine health maintenance.
Although this measurement alone does not establish vitamin D toxicity, persistently elevated vitamin D may increase the risk of excessive calcium absorption and related complications.
The result is particularly relevant because of my age and the importance of maintaining bone and kidney health.
The available information does not establish the cause of the elevated concentration.
Potential contributors may include supplements or other sources of vitamin D.
The result deserves review in relation to vitamin D intake, calcium measurements, kidney function, and any relevant symptoms.
A later vitamin D measurement would be useful for determining whether the elevation persisted.
12. Calcium and Vitamin D Relationship
My recent serum calcium measurements were:
- September 2026 — 9.8 mg/dL
- November 2026 — 9.5 mg/dL
Both were within their respective laboratory reference intervals.
Clinical interpretation:
The normal calcium measurements are reassuring in the context of the elevated June vitamin D result.
They do not demonstrate hypercalcemia at those later testing dates.
However, normal calcium does not establish that an elevated vitamin D concentration is harmless or that vitamin D remained elevated.
The measurements were obtained at different times.
13. Magnesium
Magnesium is important for muscle function, nerve signaling, energy metabolism, and normal cardiac electrical activity.
The June 2026 Function Health result was:
RBC Magnesium — 4.7 mg/dL
The laboratory classified this result as within range.
Clinical interpretation:
The measurement provides useful information about red blood cell magnesium concentration.
However, RBC magnesium and serum magnesium are different tests.
The result should not be interpreted as a direct measurement of total body magnesium stores.
My history of atrial fibrillation makes adequate electrolyte balance particularly relevant.
Because only one verified RBC magnesium result is included, no trend can be established.
14. Zinc
Zinc participates in immune function, wound healing, protein synthesis, and numerous enzymatic processes.
The June 2026 Function Health result was:
Zinc — 92 µg/dL
The laboratory classified the result as within range.
Clinical interpretation:
The measurement does not indicate an abnormal zinc concentration at the time of testing.
Beef is a recognized dietary source of zinc.
However, the result does not establish the adequacy of every mineral or nutrient.
No numerical trend can be determined from the single verified measurement.
15. Omega-3 Fatty Acid Profile
Omega-3 fatty acids participate in cell membrane structure and several physiological processes.
The June 2026 Function Health report included:
| Measurement | June 2026 |
|---|---|
| Omega-3 Total / OmegaCheck | 7.6% by weight |
| EPA | 2.0% by weight |
| DHA | 4.2% by weight |
| DPA | 1.4% by weight |
The laboratory classified these measurements as within range.
Clinical interpretation:
These results provide information about the fatty acid composition measured by the laboratory.
They do not independently establish cardiovascular protection or complete essential fatty acid adequacy.
Because only one verified panel is included, no longitudinal trend can be determined.
16. Omega-6 Fatty Acid Profile
The June 2026 Function Health report included:
| Measurement | June 2026 |
|---|---|
| Omega-6 Total | 28.2% by weight |
| Linoleic Acid | 16.4% by weight |
| Arachidonic Acid | 9.1% by weight |
| Omega-6/Omega-3 Ratio | 3.7 |
| Arachidonic Acid/EPA Ratio | 4.7 |
Linoleic acid was flagged below the laboratory reference interval.
The laboratory classified the reported omega-6/omega-3 ratio, arachidonic acid, and arachidonic acid/EPA ratio as within range.
Clinical interpretation:
The low linoleic acid measurement is relevant because linoleic acid is an essential fatty acid that must be obtained from food.
However, a single fatty acid percentage does not establish clinical essential fatty acid deficiency.
The result should be interpreted in the context of the entire fatty acid profile, dietary intake, symptoms, and laboratory methods.
The omega-6/omega-3 ratio is descriptive and should not be treated as a complete measure of cardiovascular or inflammatory health.
17. Protein Nutrition
My dietary pattern includes substantial animal protein.
Protein is necessary for maintaining muscle, repairing tissues, and producing enzymes and other important molecules.
The recent serum protein measurements were:
- September 2026 — Albumin 4.0 g/dL; Total Protein 7.1 g/dL
- November 2026 — Albumin 4.0 g/dL; Total Protein 7.2 g/dL
All were within their respective laboratory reference intervals.
Clinical interpretation:
These measurements are reassuring but do not directly establish adequate dietary protein intake or preservation of muscle mass.
At age 90, physical function, strength, body weight, and muscle mass are particularly important considerations.
Relevance to My Health History
Carnivore Diet Since January 2024
My strict carnivore diet is central to interpreting nutritional health.
The diet provides substantial animal protein and recognized sources of iron, vitamin B12, and zinc.
However, the available measurements do not establish that every nutrient requirement is being met.
The low linoleic acid result and the absence of verified recent folate and serum B12 measurements illustrate why a broad nutritional assessment remains useful.
Improvement in Inflammatory Symptoms
I have experienced substantial improvement in joint and muscle discomfort during the broader period of dietary and health changes.
This improvement is important to my personal health history.
However, the nutritional laboratory measurements do not establish that the diet caused the improvement or that all nutritional needs are satisfied.
Recent Mild Anemia
The recent decline in hemoglobin makes iron, vitamin B12, folate, and other nutritional factors relevant.
The September iron studies were within range.
The June MMA measurement was also within range.
However, these findings do not establish the cause of the anemia or exclude every nutritional contribution.
Bone Health and Vitamin D
At age 90, bone health is especially important.
The elevated June vitamin D concentration deserves attention because excessive vitamin D exposure may increase the risk of hypercalcemia and related complications.
The later normal calcium measurements are reassuring but do not eliminate the need to interpret the vitamin D result carefully.
Kidney Function
My kidney laboratory record includes elevated BUN and changes in creatinine and eGFR.
Kidney function is relevant to mineral regulation, vitamin D metabolism, and the interpretation of certain nutritional markers.
However, the available data do not establish that the nutritional findings caused the kidney-related changes.
Cardiovascular Health
My cardiovascular history includes atrial fibrillation, hypertension, hyperlipidemia, and an ascending aortic aneurysm.
Magnesium, calcium, and other electrolytes are relevant to normal cardiac function.
The fatty acid profile also provides supplementary information.
However, these measurements do not replace the cardiovascular assessment of LDL cholesterol, ApoB, blood pressure, and other established risk factors.
Maintaining Strength and Independence
My long-term goal is to preserve health and function as I approach age 100.
Nutritional adequacy is essential to this objective.
Laboratory measurements are useful, but they should be interpreted alongside body weight, muscle strength, mobility, and overall physical performance.
Important Considerations
- Iron measurements remained within range. The June and September results do not demonstrate an obvious pattern of depleted iron stores.
- Ferritin increased modestly. Both measurements remained within their respective reference intervals.
- The recent anemia remains unexplained. Normal iron studies and MMA do not identify its cause.
- Vitamin B12 and folate require careful interpretation. The recent comparison does not contain verified numerical serum measurements for these vitamins.
- Methylmalonic acid was within range. The June result is reassuring regarding substantial functional B12 deficiency at that time.
- Vitamin D was elevated. The June concentration of 106 ng/mL is an important finding that deserves clinical review and follow-up.
- Later calcium measurements were normal. This is reassuring but does not establish that the elevated vitamin D concentration had resolved.
- Magnesium and zinc were within range. These findings provide useful information but do not establish complete mineral adequacy.
- Linoleic acid was below the laboratory reference interval. A single fatty acid measurement does not establish clinical essential fatty acid deficiency.
- Nutritional health involves more than laboratory values. Adequate dietary intake, absorption, muscle preservation, bone health, and physical function are essential considerations.
Summary of Nutritional Health Trends
My recent nutritional laboratory measurements provide several reassuring findings alongside a small number of important concerns.
Iron, ferritin, total iron binding capacity, and iron saturation remained within their respective laboratory reference intervals in June and September 2026.
The results do not demonstrate an obvious pattern of depleted iron stores despite the recent mild anemia.
The June methylmalonic acid, homocysteine, RBC magnesium, and zinc measurements were classified as within range.
The June fatty acid profile included several measurements within range, although linoleic acid was flagged below the laboratory reference interval.
The most important abnormal finding was vitamin D at 106 ng/mL in June 2026.
This result deserves attention because persistently excessive vitamin D exposure can have adverse effects, particularly involving calcium regulation and kidney health.
The later serum calcium measurements were within range, but no subsequent vitamin D concentration is verified in this comparison.
The available recent record does not establish numerical trends for serum vitamin B12 or folate.
Overall, the findings provide useful evidence about selected nutrients but do not establish complete nutritional adequacy.
Central Understanding: My nutritional laboratory results show generally normal iron measurements, reassuring selected vitamin-related and mineral markers, and a fatty acid profile with low linoleic acid. The most significant concern is the elevated June 2026 vitamin D concentration of 106 ng/mL. In the context of my strict carnivore diet, recent mild anemia, and advanced age, nutritional health should be assessed through both laboratory measurements and preservation of strength, body weight, bone health, and physical function.
7.3.9 — Hormones and Male Health Trends
Overview
Hormones are chemical messengers that regulate many essential functions, including metabolism, muscle maintenance, bone health, reproductive function, energy balance, and responses to physical and emotional stress.
Hormonal measurements are particularly relevant to my Health Inventory because of my age, interest in maintaining physical strength, and long-term goal of preserving health and independence.
At age 90, hormone concentrations must be interpreted carefully.
Normal aging is associated with changes in several hormonal systems, but the significance of an individual result depends on symptoms, medical history, medications, laboratory methods, and the circumstances under which the sample was collected.
My June 2026 Function Health laboratory assessment included a comprehensive group of male hormone and prostate-related measurements.
The principal findings were total testosterone of 539 ng/dL, free testosterone of 63.0 pg/mL, sex hormone binding globulin of 77 nmol/L, DHEA sulfate of 56 µg/dL, and total PSA of 4.0 ng/mL.
The laboratory classified several of these measurements as within range.
The report also included estradiol, follicle stimulating hormone, luteinizing hormone, prolactin, and cortisol.
The available verified data provide a useful hormonal profile for June 2026. However, they do not establish whether individual hormone concentrations have increased, decreased, or remained stable over previous years.
The purpose of this subsection is to examine the documented measurements, explain their significance, and identify the considerations most relevant to my health history.
Important Laboratory Measurements and Their Significance
1. June 2026 Hormone and Male Health Profile
| Measurement | June 2026 Result |
|---|---|
| Total Testosterone | 539 ng/dL |
| Free Testosterone | 63.0 pg/mL |
| Sex Hormone Binding Globulin | 77 nmol/L |
| DHEA Sulfate | 56 µg/dL |
| Estradiol (E2) | Less than 30 pg/mL |
| Follicle Stimulating Hormone (FSH) | 14.3 mIU/mL |
| Luteinizing Hormone (LH) | 6.5 mIU/mL |
| Prolactin | 4.4 ng/mL |
| Cortisol | 15.3 µg/dL |
| Total PSA | 4.0 ng/mL |
| Free PSA | 1.3 ng/mL |
| Free PSA Percentage | 33% |
These measurements were obtained on June 1, 2026.
Function Health classified total testosterone, free testosterone, SHBG, DHEA sulfate, total PSA, free PSA, free PSA percentage, and cortisol as within range.
Some other hormone measurements were reported numerically without an explicit range classification in the extracted report.
Trend interpretation:
This panel establishes a useful reference point for future comparisons.
However, because a second verified measurement is not available for most of these markers, no numerical longitudinal trend can be determined.
2. Total Testosterone
Testosterone is an important male hormone involved in muscle maintenance, bone health, sexual function, and several metabolic processes.
My June 2026 measurement was:
Total Testosterone — 539 ng/dL
Function Health classified this result as within range.
Clinical interpretation:
The measurement does not demonstrate a low total testosterone concentration according to the reporting laboratory.
This is relevant because testosterone levels often decline with advancing age.
However, total testosterone alone does not establish overall hormonal health.
Testosterone interpretation should also consider free testosterone, SHBG, symptoms, laboratory methods, and time of collection.
The result does not independently establish that testosterone treatment is necessary or beneficial.
3. Free Testosterone
Free testosterone represents the portion of testosterone that is not bound to circulating proteins.
My June 2026 measurement was:
Free Testosterone — 63.0 pg/mL
Function Health classified this result as within range.
Clinical interpretation:
The result provides useful supplementary information alongside total testosterone.
However, free testosterone measurements are method-dependent, and laboratory reference intervals can vary substantially.
The result should therefore be interpreted using the reporting laboratory’s method and reference interval.
The combination of total testosterone and free testosterone measurements does not demonstrate an obvious biochemical testosterone deficiency in the available report.
4. Sex Hormone Binding Globulin (SHBG)
SHBG is a protein produced primarily by the liver.
It binds testosterone and estradiol and influences the amount of hormone available in unbound form.
My June 2026 measurement was:
SHBG — 77 nmol/L
Function Health classified the result as within range.
Clinical interpretation:
SHBG is important because two individuals with similar total testosterone concentrations may have different free testosterone concentrations.
SHBG can be influenced by age, thyroid function, liver conditions, nutrition, and other factors.
The measured concentration should therefore be considered alongside both total and free testosterone.
The single result does not establish a trend.
5. DHEA Sulfate
Dehydroepiandrosterone sulfate, commonly called DHEA-S, is produced primarily by the adrenal glands.
It serves as a precursor for certain sex hormones.
My June 2026 measurement was:
DHEA Sulfate — 56 µg/dL
Function Health classified the result as within range.
Clinical interpretation:
DHEA-S commonly decreases with advancing age.
The June measurement was within the reporting laboratory’s reference interval.
However, DHEA-S concentration alone does not establish adrenal health, vitality, or longevity.
The result does not independently indicate a need for hormone supplementation.
6. Estradiol
Estradiol is often associated with female reproductive physiology, but it also has important functions in men.
It contributes to bone health and participates in several aspects of hormonal regulation.
My June 2026 result was:
Estradiol — less than 30 pg/mL
Clinical interpretation:
The result indicates that estradiol was below the laboratory’s reported threshold of 30 pg/mL.
It does not establish the exact concentration.
Therefore, the result should not be interpreted as proof of either abnormally low or optimal estradiol.
The clinical significance depends on the assay method, reference interval, and relevant symptoms.
7. Follicle Stimulating Hormone (FSH)
FSH is produced by the pituitary gland and participates in male reproductive regulation.
My June 2026 measurement was:
FSH — 14.3 mIU/mL
Clinical interpretation:
FSH concentrations may change with age and testicular function.
However, the extracted Function Health report does not provide a specific range classification for this measurement.
The numerical result should therefore be preserved without assigning an unsupported normal or abnormal designation.
FSH is best interpreted alongside LH, testosterone, symptoms, and the clinical reason for testing.
8. Luteinizing Hormone (LH)
LH is produced by the pituitary gland and stimulates testosterone production by the testes.
My June 2026 measurement was:
LH — 6.5 mIU/mL
Clinical interpretation:
The measurement provides information about hormonal signaling between the pituitary gland and testes.
However, a single LH concentration cannot establish whether this regulatory system is functioning optimally.
Interpretation requires the laboratory reference interval and consideration of testosterone measurements.
9. Prolactin
Prolactin is produced by the pituitary gland.
Although best known for its role in lactation, it also participates in hormonal regulation in men.
My June 2026 measurement was:
Prolactin — 4.4 ng/mL
Clinical interpretation:
The numerical result does not suggest a markedly elevated prolactin concentration.
However, the extracted report does not provide a specific reference-range classification for this measurement.
No conclusion about a longitudinal prolactin trend can be established.
10. Cortisol
Cortisol is produced by the adrenal glands and participates in metabolism, blood pressure regulation, immune responses, and adaptation to stress.
My June 2026 measurement was:
Cortisol — 15.3 µg/dL
Function Health classified the result as within range.
Clinical interpretation:
Cortisol concentrations vary substantially throughout the day.
A single measurement must therefore be interpreted in relation to collection time and the clinical reason for testing.
The result does not independently establish normal adrenal function or exclude every adrenal disorder.
It also does not provide a direct measure of psychological stress.
11. Total Prostate-Specific Antigen (PSA)
PSA is a protein produced by prostate tissue.
It may be measured as part of prostate health assessment.
My June 2026 measurement was:
Total PSA — 4.0 ng/mL
Function Health classified this result as within range.
Clinical interpretation:
PSA can be influenced by prostate enlargement, inflammation, infection, procedures, and prostate cancer.
A single PSA result cannot distinguish among these possibilities.
At age 90, decisions about further PSA testing or investigation depend heavily on overall health, symptoms, previous PSA history, life expectancy, and personal preferences.
The result should not be interpreted as proof that prostate cancer is present or absent.
12. Free PSA
Free PSA measures the portion of circulating PSA that is not bound to proteins.
My June 2026 measurement was:
Free PSA — 1.3 ng/mL
Function Health classified the result as within range.
Clinical interpretation:
Free PSA is generally interpreted together with total PSA rather than as an isolated measurement.
Its principal value is in selected clinical situations where additional information may help interpret an elevated or borderline total PSA.
13. Free PSA Percentage
The free PSA percentage compares free PSA with total PSA.
My June 2026 result was:
Free PSA Percentage — 33%
Function Health classified the result as within range.
Clinical interpretation:
The percentage is calculated from the relationship between free and total PSA.
A relatively higher free PSA percentage may be associated with a lower probability of prostate cancer in certain populations undergoing evaluation.
However, this relationship is not a diagnostic test and does not eliminate cancer risk.
The usefulness of the measurement at age 90 depends on the broader clinical context and whether further testing would provide meaningful benefit.
14. Relationship Between Testosterone and Prostate Health
Testosterone and prostate health are sometimes discussed together because androgen signaling influences prostate tissue.
My June 2026 measurements included:
- Total Testosterone — 539 ng/dL
- Free Testosterone — 63.0 pg/mL
- Total PSA — 4.0 ng/mL
- Free PSA Percentage — 33%
Clinical interpretation:
These results provide a useful hormonal and prostate-related reference point.
However, the measurements do not establish a direct causal relationship between testosterone concentration and PSA.
They also do not independently support testosterone treatment.
Any consideration of hormone therapy would require assessment of symptoms, cardiovascular history, prostate health, and potential treatment risks.
Relevance to My Health History
Maintaining Muscle Strength and Physical Independence
At age 90, maintaining muscle strength and mobility is a major health priority.
Testosterone participates in muscle maintenance, but physical function depends on many additional factors.
Adequate nutrition, resistance exercise when appropriate, neurological function, cardiovascular health, and other medical conditions all contribute.
The June testosterone measurements are reassuring, but they do not independently establish muscle health.
Carnivore Diet
My dietary pattern includes substantial animal protein and fat.
Dietary intake and overall energy balance can influence hormonal physiology.
However, the available June 2026 hormone panel does not establish that my carnivore diet caused the measured concentrations.
A meaningful dietary effect cannot be determined without appropriate longitudinal evidence.
Thyroid Function
I have a history of hypothyroidism and take levothyroxine.
Thyroid status can influence SHBG and other aspects of hormonal regulation.
Consequently, the SHBG measurement should be interpreted in the context of thyroid laboratory findings.
However, the available data do not establish that thyroid treatment caused the measured SHBG concentration.
Cardiovascular Health
My cardiovascular history includes hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm.
This history is important when considering the potential risks and benefits of hormonal treatments.
The laboratory results do not demonstrate a clear biochemical indication for testosterone replacement.
Hormone treatment decisions would require individualized medical evaluation rather than relying on age or a single laboratory measurement.
Prostate Health
The June 2026 PSA measurements provide a useful reference point.
However, at age 90, prostate-related decisions should emphasize symptoms, expected benefits, possible harms, and personal goals.
The value of additional screening is not determined by PSA concentration alone.
Bone Health
Testosterone and estradiol contribute to maintaining bone health in men.
The June measurements provide some information about hormonal status.
However, they do not directly measure bone density or fracture risk.
Bone health requires separate assessment when clinically appropriate.
Long-Term Health Goals
My goal of reaching age 100 while preserving health and independence requires attention to multiple aspects of physical function.
Hormonal measurements are one component of that assessment.
They should not be interpreted as direct predictors of longevity.
Important Considerations
- Total testosterone was within range. The June result of 539 ng/dL does not demonstrate low total testosterone according to Function Health.
- Free testosterone was within range. The result of 63.0 pg/mL provides supplementary information about circulating testosterone.
- SHBG was within range. Its concentration is relevant to the relationship between total and free testosterone.
- DHEA sulfate was within range. The result does not independently establish adrenal health or a need for supplementation.
- Estradiol was reported as less than 30 pg/mL. The exact concentration cannot be determined from that result.
- FSH, LH, and prolactin require contextual interpretation. Their numerical values should not be assigned unsupported range classifications.
- Cortisol was within range. The measurement must be interpreted in relation to collection time and clinical circumstances.
- Total PSA was 4.0 ng/mL. The result does not independently establish the presence or absence of prostate cancer.
- Free PSA percentage was 33%. This provides supplementary information but is not diagnostic.
- The verified panel establishes a baseline, not a trend. Earlier or later dated measurements are necessary to determine whether these hormone concentrations have changed over time.
Summary of Hormones and Male Health Trends
My June 2026 Function Health laboratory assessment provides a useful profile of male hormones and prostate-related measurements.
Total testosterone was 539 ng/dL, and free testosterone was 63.0 pg/mL.
Both were classified as within range.
SHBG was 77 nmol/L, and DHEA sulfate was 56 µg/dL, also within the reporting laboratory’s reference intervals.
Estradiol was reported as less than 30 pg/mL.
FSH was 14.3 mIU/mL, LH was 6.5 mIU/mL, and prolactin was 4.4 ng/mL.
Cortisol was 15.3 µg/dL and classified as within range.
The prostate-related measurements included total PSA of 4.0 ng/mL, free PSA of 1.3 ng/mL, and free PSA percentage of 33%.
These results provide useful information about hormonal and prostate-related status at the time of testing.
However, the available verified record does not establish longitudinal changes in these measurements.
The most important interpretation is therefore that the June 2026 panel provides a baseline for future comparison.
At age 90, hormonal and prostate-related measurements should be interpreted in relation to symptoms, physical function, medical history, and the likely benefits and risks of further evaluation or treatment.
Central Understanding: My June 2026 hormone panel provides a generally reassuring reference point, including total and free testosterone concentrations classified as within range. The PSA measurements also provide useful information but are not diagnostic of prostate disease. Because the verified record contains only one dated set of most hormone measurements, this subsection establishes a baseline rather than demonstrating hormonal trends. The principal health objective remains preservation of strength, mobility, and independence rather than attempting to achieve particular hormone concentrations without a clear clinical indication.
7.3.10 — Specialized Laboratory Markers and Additional Health Trends
Overview
The final subsection of Section 7.3 examines specialized laboratory measurements that do not fit naturally into the preceding categories of cardiovascular health, kidney function, thyroid function, inflammation, blood counts, metabolism, liver chemistry, nutrition, or hormones.
These measurements include pancreatic enzymes, environmental exposure markers, urinalysis, and selected additional laboratory findings.
Although many of these tests are not performed during every laboratory examination, they provide useful supplementary information about specific aspects of health.
My recent Function Health assessments included measurements of amylase, lipase, lead, mercury, and several urine characteristics.
The November 2026 urinalysis also provides information about urinary protein, glucose, blood, inflammatory markers, and microscopic findings.
Most of the available results were classified as within range.
One exception was the cloudy appearance of the November urine sample.
The purpose of this subsection is to explain the significance of these specialized measurements, identify findings that deserve attention, and distinguish individual observations from established longitudinal trends.
Important Laboratory Measurements and Their Significance
1. Specialized Laboratory Results
| Measurement | Date | Result |
|---|---|---|
| Amylase | June 2026 | 47 U/L |
| Lipase | June 2026 | 19 U/L |
| Lead | June 2026 | 2.4 µg/dL |
| Mercury | June 2026 | Less than 5 µg/L |
| Urine Appearance | November 2026 | Cloudy |
| Urine Color | November 2026 | Yellow |
| Urine Specific Gravity | November 2026 | 1.008 |
| Urine pH | November 2026 | 5.5 |
| Urine Protein | November 2026 | Negative |
| Urine Glucose | November 2026 | Negative |
| Urine Ketones | November 2026 | Negative |
| Urine Blood | November 2026 | Negative |
| Urine Nitrite | November 2026 | Negative |
| Urine Leukocyte Esterase | November 2026 | Negative |
The pancreatic enzymes and environmental markers were classified as within range by Function Health.
The urine appearance was flagged as outside the laboratory’s expected range.
Most other urinalysis findings were classified as within range.
Trend interpretation:
These results establish useful reference measurements.
However, the verified record does not contain enough repeated results to determine numerical trends for most of these markers.
2. Amylase
Amylase is an enzyme involved in carbohydrate digestion.
It is produced primarily by the pancreas and salivary glands.
The June 2026 Function Health result was:
Amylase — 47 U/L
The laboratory classified the result as within range.
Clinical interpretation:
The measurement does not demonstrate elevated amylase at the time of testing.
This is reassuring.
However, normal amylase does not independently exclude all pancreatic disorders.
Amylase is not a direct measure of the pancreas’s overall digestive or insulin-producing capacity.
3. Lipase
Lipase is an enzyme involved in the digestion of dietary fats.
It is produced primarily by the pancreas.
The June 2026 Function Health result was:
Lipase — 19 U/L
The laboratory classified the result as within range.
Clinical interpretation:
The measurement does not demonstrate elevated lipase at the time of testing.
This is reassuring, particularly because my diet contains substantial amounts of fat.
However, the result does not establish that every aspect of pancreatic function is normal.
Lipase is most useful when interpreted in the context of symptoms and other clinical findings.
4. Relationship Between Amylase and Lipase
My June 2026 results were:
- Amylase — 47 U/L
- Lipase — 19 U/L
Both were within their respective laboratory reference intervals.
Clinical interpretation:
The combined results do not demonstrate elevated pancreatic enzymes.
However, normal enzyme concentrations do not establish the absence of chronic pancreatic disease or impaired digestive enzyme production.
The measurements are best preserved as reassuring observations rather than interpreted as a comprehensive assessment of pancreatic health.
5. Blood Lead
Lead is a toxic metal that may affect the nervous system, kidneys, blood pressure, and other organs.
The June 2026 Function Health result was:
Lead — 2.4 µg/dL
The laboratory classified the result as within range.
Clinical interpretation:
The measurement does not indicate a markedly elevated blood lead concentration.
However, lead exposure is not considered beneficial at any concentration.
The result should be interpreted as a measurement of exposure rather than a guarantee that no exposure-related risk exists.
A single measurement does not establish whether lead exposure has increased or decreased over time.
6. Blood Mercury
Mercury exposure may occur through certain foods, environmental sources, and occupational activities.
The June 2026 Function Health result was:
Mercury — less than 5 µg/L
The laboratory classified the result as within range.
Clinical interpretation:
The result indicates that mercury was below the laboratory’s reported threshold.
The exact concentration cannot be determined from this result.
It does not demonstrate elevated mercury exposure according to the reporting laboratory.
However, one measurement does not establish a long-term exposure trend.
7. Urine Appearance
The November 2026 Function Health report described the urine appearance as:
Cloudy
The laboratory flagged this finding as outside its expected range.
Clinical interpretation:
Cloudy urine may result from several factors, including crystals, mucus, cells, bacteria, or sample handling.
Cloudiness alone does not establish a urinary tract infection or kidney disorder.
The remaining urinalysis measurements provide important context.
In this case, several findings commonly associated with urinary inflammation or infection were negative.
8. Urine Color
The November 2026 result was:
Yellow
The laboratory classified the result as within range.
Clinical interpretation:
Yellow is a common normal urine color.
However, color alone does not establish hydration status or kidney health.
9. Urine Specific Gravity
Urine specific gravity reflects the concentration of dissolved substances in urine.
The November 2026 result was:
1.008
The laboratory classified the result as within range.
Clinical interpretation:
The measurement indicates a relatively dilute urine sample.
This may reflect fluid intake or other physiological circumstances.
However, a single measurement does not establish chronic overhydration, impaired kidney concentration, or any specific disorder.
The result should be interpreted alongside fluid intake, kidney function, and clinical circumstances.
10. Urine pH
Urine pH measures acidity or alkalinity.
The November 2026 result was:
pH 5.5
The laboratory classified the result as within range.
Clinical interpretation:
The result indicates acidic urine.
Urine pH can be influenced by diet, metabolism, medications, and other factors.
A diet containing substantial animal protein may contribute to a more acidic urine environment.
However, the single measurement does not establish that my diet caused the result.
Acidic urine may be relevant when considering certain kidney stone risks, particularly in the context of elevated uric acid.
The result does not establish that kidney stones are present.
11. Urine Protein
The November 2026 result was:
Negative
Clinical interpretation:
The absence of detectable protein on this urinalysis is reassuring.
However, a routine urine dipstick is less sensitive than a urine albumin-to-creatinine ratio for detecting small amounts of albumin.
A negative result therefore does not independently exclude every form of kidney disease.
12. Urine Glucose
The November 2026 result was:
Negative
Clinical interpretation:
The result indicates that glucose was not detected in the urine by this test.
This is consistent with the normal blood glucose measurement reported in November.
However, urine glucose testing is not a substitute for blood glucose or hemoglobin A1c assessment.
13. Urine Ketones
The November 2026 result was:
Negative
Clinical interpretation:
The negative result does not contradict my earlier January 2026 blood ketone measurement of 4.7 mmol/L.
The two measurements were obtained at different times and under different conditions.
Urine ketone tests primarily detect acetoacetate, while blood ketone measurements commonly assess beta-hydroxybutyrate.
Consequently, urine ketone results do not directly measure blood beta-hydroxybutyrate concentration.
The November result should not be interpreted as proof that my body was incapable of producing ketones.
14. Urine Blood
The November 2026 result was:
Negative
The microscopic examination also reported:
Red Blood Cells — None Seen
Clinical interpretation:
These findings are reassuring because they do not demonstrate detectable blood in the urine at the time of testing.
However, they do not establish the absence of every urinary tract condition.
15. Urine Nitrite and Leukocyte Esterase
The November 2026 results were:
- Nitrite — Negative
- Leukocyte Esterase — Negative
Clinical interpretation:
These findings do not provide laboratory evidence of a typical bacterial urinary tract infection.
However, negative results do not exclude every infection, particularly if symptoms are present.
The findings should be interpreted together with the microscopic examination.
16. Microscopic Urinalysis
The November 2026 report included:
| Measurement | Result |
|---|---|
| Red Blood Cells | None Seen |
| White Blood Cells | None Seen |
| Bacteria | None Seen |
| Hyaline Casts | None Seen |
| Squamous Epithelial Cells | None Seen |
The laboratory classified these results as within range.
Clinical interpretation:
The absence of visible white blood cells and bacteria is reassuring.
The absence of red blood cells is also reassuring.
The findings do not demonstrate an obvious inflammatory or bleeding abnormality in the urine sample.
However, a single normal microscopic examination cannot exclude every urinary tract or kidney condition.
17. Relationship Between Cloudy Urine and Other Findings
The November urine sample was cloudy, but the following findings were negative or absent:
- Urine protein
- Urine glucose
- Urine blood
- Nitrite
- Leukocyte esterase
- Microscopic red blood cells
- Microscopic white blood cells
- Bacteria
Clinical interpretation:
The combined findings are more reassuring than the cloudy appearance alone might suggest.
Cloudiness may occur without infection.
The result should be preserved as an observation rather than interpreted as evidence of a specific disease.
18. Thyroid Antibody Measurements
The June 2026 Function Health report included:
- Thyroid Peroxidase Antibodies — Less than 1 IU/mL
- Thyroglobulin Antibodies — Less than 2 IU/mL
Both were classified as within range.
Clinical interpretation:
These results do not demonstrate elevated thyroid antibodies according to the reporting laboratory.
This is relevant to my history of hypothyroidism.
However, normal thyroid antibody results do not establish the original cause of hypothyroidism or exclude every thyroid condition.
These findings supplement the thyroid assessment already presented in Section 7.3.3.
19. Blood Type
The Function Health report includes a historical blood typing result from June 10, 2025:
- ABO Group — A
- Rh Factor — Positive
My blood type is therefore documented as:
A Positive (A+)
Clinical interpretation:
Blood type is a stable inherited characteristic.
It is useful medical information but not a laboratory trend.
It should be retained in the Health Inventory for identification and reference purposes.
Relevance to My Health History
Carnivore Diet and Pancreatic Function
My diet contains substantial amounts of animal fat and protein.
The June amylase and lipase results were within their respective laboratory reference intervals.
This is reassuring but does not establish that every aspect of digestion or pancreatic function is normal.
Kidney Function and Urinalysis
My recent kidney laboratory results include elevated BUN and changes in creatinine and estimated GFR.
The November urinalysis did not demonstrate detectable protein, blood, white blood cells, or bacteria.
These findings provide useful supplementary information.
However, the urinalysis does not replace kidney filtration measurements or more sensitive urine albumin testing.
Uric Acid and Urine Acidity
The June 2026 uric acid measurement was elevated at 8.1 mg/dL.
The November urine pH was 5.5.
These findings are relevant because elevated uric acid and acidic urine may be associated with certain kidney stone risks.
However, the measurements do not establish that kidney stones are present or that one finding caused the other.
Fasting and Ketone Production
My January 2026 personal fasting measurements demonstrated substantial blood ketone production.
The November urine ketone result was negative.
The difference reflects measurements obtained at different times using different methods.
The two findings should be preserved separately rather than treated as contradictory.
History of Hypothyroidism
The June thyroid antibody measurements were within range.
These findings provide supplementary information about thyroid-related autoimmunity.
However, they do not replace the assessment of TSH, free T4, and free T3.
Environmental Exposure
The June lead and mercury measurements were within the reporting laboratory’s reference intervals.
This is reassuring.
However, the measurements do not establish that exposure is absent or that future exposure cannot occur.
Maintaining Health at Age 90
My long-term goal is to preserve physical independence and reach age 100.
Specialized laboratory measurements can help identify selected concerns that may not be apparent from routine blood chemistry.
However, their greatest value comes from interpretation alongside symptoms, medical history, physical function, and the broader laboratory record.
Important Considerations
- Amylase and lipase were within range. The June results do not demonstrate elevated pancreatic enzymes.
- Lead and mercury were within the laboratory’s reporting limits. These findings do not establish a long-term exposure trend.
- The November urine sample was cloudy. This finding alone does not establish infection or kidney disease.
- Urine protein was negative. This is reassuring but does not replace sensitive urine albumin testing.
- Urine blood was negative. No red blood cells were seen on microscopic examination.
- Urinary infection markers were negative. Nitrite, leukocyte esterase, white blood cells, and bacteria did not demonstrate an obvious infection pattern.
- Urine pH was 5.5. The acidic measurement is relevant to the broader discussion of uric acid and kidney stone risk.
- Urine ketones were negative in November. This does not contradict the earlier blood ketone measurement obtained during fasting.
- Thyroid antibodies were within range. These results supplement but do not replace the thyroid function assessment.
- Most specialized measurements are baseline observations. Repeated measurements would be required to establish meaningful longitudinal trends.
Summary of Specialized Laboratory Markers and Additional Health Trends
My recent specialized laboratory results provide several reassuring observations.
The June 2026 pancreatic enzyme measurements were within range, with amylase at 47 U/L and lipase at 19 U/L.
Blood lead was 2.4 µg/dL, while mercury was reported as less than 5 µg/L.
Both were classified as within range.
The November 2026 urinalysis showed cloudy urine, but the remaining findings were generally reassuring.
Urine protein, glucose, ketones, blood, nitrite, and leukocyte esterase were negative.
Microscopic examination showed no red blood cells, white blood cells, bacteria, hyaline casts, or squamous epithelial cells.
Urine specific gravity was 1.008, and pH was 5.5.
The acidic urine measurement is relevant to my elevated uric acid history, although no kidney stone diagnosis can be established from these results.
The June thyroid antibody measurements were also within range.
My blood type is documented as A Positive.
Overall, the specialized laboratory results provide useful supplementary information but do not establish significant longitudinal trends because most measurements were obtained at only one verified testing date.
Central Understanding: My specialized laboratory results are generally reassuring, including normal pancreatic enzyme measurements, environmental exposure markers within laboratory limits, and a November urinalysis without detectable protein, blood, or typical infection markers. The cloudy urine appearance and acidic urine pH are observations that require interpretation within the broader clinical context. These measurements complete the laboratory trend assessment by documenting additional aspects of health that may become useful for future comparisons.
Section 7.3 — Master Summary
Laboratory Trends and Overall Health Assessment
Overview
Section 7.3 brings together the findings from my laboratory archive and examines their significance within the context of my medical history, dietary practices, and long-term health objectives.
My Health Inventory contains 40 laboratory reports extending from 2013 through November 2026. The most detailed recent comparisons involve Function Health testing in June and November 2026 and WellMed testing in September 2026.
The purpose of this Master Summary is not to repeat every laboratory measurement. Instead, it identifies the most important findings, distinguishes reassuring results from areas requiring continued attention, and establishes a practical framework for future monitoring.
At age 90, my primary objective is to preserve health, strength, mobility, mental clarity, and physical independence while pursuing my goal of reaching age 100.
My laboratory results should therefore be evaluated not only against reference intervals but also in relation to my cardiovascular history, previous systemic inflammation, hypothyroidism, nutritional practices, and overall physical function.
Overall Assessment: My recent laboratory results demonstrate several reassuring findings, particularly in glucose regulation, selected inflammatory markers, liver chemistry, and iron status. However, elevated atherogenic cholesterol markers, mild anemia, persistent autoimmune antibody positivity, elevated vitamin D and uric acid, and changes in kidney filtration measurements remain important considerations.
1. Cardiovascular Health
Principal Findings
| Measurement | June 2026 | September 2026 | November 2026 |
|---|---|---|---|
| Total Cholesterol | 284 | 252 | 249 |
| LDL Cholesterol | 183 | 168 | 157 |
| HDL Cholesterol | 82 | 73 | 78 |
| Triglycerides | 85 | 54 | 45 |
All cholesterol and triglyceride values are expressed in mg/dL.
Additional June 2026 findings included:
- Apolipoprotein B (ApoB) — 139 mg/dL, above range
- LDL Particle Number — 2,483 nmol/L, above range
Assessment
Total cholesterol and LDL cholesterol decreased between June and November 2026.
Triglycerides also decreased, while HDL cholesterol remained relatively high.
These changes are favorable in certain respects.
However, LDL cholesterol remained elevated in November, and the June ApoB and LDL particle number results indicate a substantial concentration of atherogenic lipoprotein particles.
Low triglycerides and high HDL cholesterol do not eliminate the cardiovascular significance of elevated LDL cholesterol and ApoB.
This finding deserves particular attention because my medical history includes hypertension, atrial fibrillation, hyperlipidemia, and an ascending aortic aneurysm.
Central Finding: Cardiovascular lipid risk remains one of the most important unresolved laboratory concerns despite improvement in several conventional lipid measurements.
2. Kidney Function and Electrolytes
Principal Findings
| Measurement | September 2026 | November 2026 |
|---|---|---|
| BUN | 32 mg/dL | 37 mg/dL |
| Creatinine | 0.90 mg/dL | 1.09 mg/dL |
| eGFR | 81.64 | 64 |
| Sodium | 140 mmol/L | 137 mmol/L |
| Potassium | 4.4 mmol/L | 4.3 mmol/L |
The eGFR values are expressed in mL/min/1.73 m².
Assessment
BUN remained elevated.
Creatinine increased between September and November, while estimated GFR decreased.
Although the November eGFR remained above 60, the change deserves continued observation.
Different laboratories and calculation methods may contribute to some variation.
High dietary protein intake, hydration, medications, and other physiological factors can influence selected kidney-related measurements.
The November urinalysis was reassuring because protein and blood were negative.
However, a negative routine urinalysis does not replace a urine albumin-to-creatinine ratio.
Sodium and potassium remained within their respective laboratory reference intervals.
Central Finding: Kidney function requires continued monitoring, particularly because of persistent BUN elevation and the recent difference in creatinine and eGFR. The available results do not independently establish progressive chronic kidney disease.
3. Thyroid Function
Principal Findings
My medical history includes hypothyroidism treated with levothyroxine.
Recent thyroid measurements included:
- June 2026 TSH — 1.87 mIU/L
- September 2026 TSH — 0.67 µIU/mL
- September 2026 Free T4 — 1.11 ng/dL
- September 2026 Free T3 — 2.27 pg/mL
- November 2026 Free T3 — 2.4 pg/mL
The June thyroid antibody measurements were also within their reporting laboratory’s reference intervals.
Assessment
The recent measurements provide a generally reassuring picture of thyroid laboratory control.
However, individual thyroid values must be interpreted using the relevant laboratory reference intervals and collection dates.
My earlier history of low free T3 remains relevant.
At age 90, excessive thyroid hormone replacement can be particularly important because of potential effects on heart rhythm and bone health.
Central Finding: Recent thyroid laboratory measurements are generally reassuring, but continued appropriate monitoring remains important because of my hypothyroidism and cardiovascular history.
4. Inflammation and Autoimmune Health
Principal Findings
My medical history includes severe systemic inflammation in 2021 and persistent positive autoimmune serology.
Recent findings included:
- June 2026 ANA — 1:1280, homogeneous
- September 2026 ANA — 1:640, homogeneous
- September 2026 CRP — less than 1.0 mg/L
- September 2026 ESR — 18
- November 2026 high-sensitivity CRP — 2.3 mg/L
Assessment
The positive ANA remains a significant feature of my medical history.
The decrease in ANA titer between June and September should not automatically be interpreted as a proportional decrease in autoimmune disease activity.
ANA titers do not directly measure inflammation or establish a specific autoimmune diagnosis.
The September CRP and ESR findings were reassuring relative to the severe inflammatory episode documented in 2021.
However, November high-sensitivity CRP was flagged above the reporting laboratory’s range.
Standard CRP and high-sensitivity CRP measurements are not directly interchangeable without considering the assay and clinical context.
Central Finding: Persistent ANA positivity remains an important immunological finding, but the recent laboratory record does not demonstrate a return to the severe systemic inflammatory state experienced in 2021.
5. Complete Blood Count and Immune Cells
Principal Findings
| Measurement | June 2026 | September 2026 | November 2026 |
|---|---|---|---|
| Hemoglobin | 13.6 | 12.4 | 12.3 |
Hemoglobin is expressed in g/dL.
Additional November findings included:
- RBC — 3.97 million/µL
- Hematocrit — 37.2%
- MCV — 93.7 fL
- WBC — 4.60 thousand/µL
- Platelets — 170 thousand/µL
Assessment
Hemoglobin decreased from June to September and remained mildly reduced in November.
The normal MCV indicates a normocytic pattern.
The September iron studies did not demonstrate an obvious iron deficiency pattern.
White blood cell and platelet measurements were generally reassuring in November.
My history includes anemia during the severe inflammatory illness of 2021.
However, the recent anemia cannot automatically be attributed to that earlier episode.
Potential causes require consideration of kidney function, inflammation, blood loss, nutritional status, and other clinical factors.
Central Finding: Mild normocytic anemia is an important recent change that deserves continued evaluation rather than being assumed to be a normal consequence of aging.
6. Metabolic Health
Principal Findings
| Measurement | June 2026 | September 2026 | November 2026 |
|---|---|---|---|
| Glucose | 66 mg/dL | 84 mg/dL | 84 mg/dL |
| Hemoglobin A1c | 5.5% | — | 5.4% |
| Insulin | 2.1 µIU/mL | — | 2.1 µIU/mL |
My January 4, 2026 personal measurements after approximately 24 hours of fasting included:
- Glucose — 78 mg/dL
- Blood ketones — 4.7 mmol/L
- Glucose Ketone Index — approximately 0.9
The June 2026 uric acid measurement was 8.1 mg/dL, above range.
Assessment
The recent glucose and A1c measurements do not indicate persistent hyperglycemia.
Insulin concentrations were low at both verified testing dates.
My January fasting measurements demonstrated substantial nutritional ketosis during that particular fast.
These findings are consistent with aspects of my very-low-carbohydrate dietary pattern.
However, they do not establish that every aspect of metabolic health is optimal.
The elevated uric acid result is an important separate consideration, particularly in relation to kidney health and potential kidney stone risk.
Central Finding: Glucose-related measurements are generally reassuring, but elevated uric acid requires continued attention.
7. Liver Function and Protein Chemistry
Principal Findings
| Measurement | September 2026 | November 2026 |
|---|---|---|
| ALT | 28 U/L | 20 U/L |
| AST | 27 U/L | 23 U/L |
| Alkaline Phosphatase | 51 U/L | 51 U/L |
| Total Bilirubin | 0.7 mg/dL | 0.6 mg/dL |
| Albumin | 4.0 g/dL | 4.0 g/dL |
| Total Protein | 7.1 g/dL | 7.2 g/dL |
Assessment
The recent liver-related laboratory measurements were within their respective reference intervals.
ALT and AST decreased modestly, while alkaline phosphatase and albumin remained unchanged.
These findings do not demonstrate a pattern of increasing liver enzyme activity.
However, normal liver enzymes do not exclude every liver disorder or establish normal liver structure.
Central Finding: Liver-related blood chemistry is one of the more reassuring areas of my recent laboratory record.
8. Nutritional Health
Principal Findings
June and September iron studies were within their respective laboratory reference intervals.
Additional June 2026 measurements included:
- Vitamin D — 106 ng/mL, above range
- Methylmalonic Acid — 93 nmol/L, within range
- Homocysteine — 14.2 µmol/L, within range
- RBC Magnesium — 4.7 mg/dL, within range
- Zinc — 92 µg/dL, within range
- Linoleic Acid — 16.4% by weight, below range
Assessment
The iron studies were generally reassuring and did not demonstrate the typical pattern of depleted iron stores.
The normal methylmalonic acid measurement was also reassuring regarding substantial functional vitamin B12 deficiency at the time of testing.
However, serum B12 and folate results were not verified in the recent comparison.
The elevated vitamin D concentration is a significant finding.
Although later calcium measurements were within range, they do not establish that the vitamin D elevation resolved.
The low linoleic acid result also deserves contextual interpretation, although it does not independently establish essential fatty acid deficiency.
Central Finding: Nutritional measurements show several reassuring findings, but elevated vitamin D and incomplete information about selected nutrients warrant attention.
9. Hormones and Male Health
Principal Findings
The June 2026 Function Health assessment included:
- Total Testosterone — 539 ng/dL
- Free Testosterone — 63.0 pg/mL
- SHBG — 77 nmol/L
- DHEA Sulfate — 56 µg/dL
- Total PSA — 4.0 ng/mL
- Free PSA Percentage — 33%
Assessment
Total and free testosterone were classified as within range.
The other hormone and prostate-related measurements provide useful reference information.
However, the verified record does not contain sufficient repeated measurements to establish meaningful longitudinal trends.
At age 90, decisions involving prostate evaluation or hormone treatment should be based on symptoms, medical history, potential benefits, and potential harms rather than laboratory values alone.
Central Finding: The June hormone panel establishes a useful baseline but does not identify a clear biochemical testosterone deficiency.
10. Specialized Laboratory Markers
Principal Findings
The June 2026 pancreatic enzyme measurements were:
- Amylase — 47 U/L
- Lipase — 19 U/L
Both were within range.
Environmental exposure markers were also within the reporting laboratory’s limits.
The November urinalysis showed cloudy urine but otherwise generally reassuring findings:
- Protein — Negative
- Blood — Negative
- Glucose — Negative
- Nitrite — Negative
- Leukocyte Esterase — Negative
- Bacteria — None Seen
- Urine pH — 5.5
- Specific Gravity — 1.008
Assessment
The pancreatic enzyme measurements did not demonstrate elevation.
The urinalysis did not demonstrate an obvious infection or bleeding pattern.
The cloudy appearance was an isolated finding without accompanying typical infection markers.
The acidic urine measurement is relevant to the elevated uric acid result but does not establish kidney stones.
Central Finding: Specialized laboratory measurements are generally reassuring and provide useful reference points for future comparisons.
11. Most Important Findings Requiring Continued Attention
The following findings deserve particular attention in future laboratory reviews.
| Priority Area | Principal Finding | Reason for Continued Attention |
|---|---|---|
| Cardiovascular | Elevated LDL cholesterol, ApoB, and LDL particle number | Atherogenic cardiovascular risk |
| Blood Health | Mild normocytic anemia | Cause remains undetermined |
| Kidney Health | Elevated BUN and recent change in eGFR | Need to establish stability |
| Autoimmune Health | Persistent strongly positive ANA | Requires interpretation with symptoms and disease-specific findings |
| Nutritional Health | Vitamin D 106 ng/mL | Potential consequences of excessive vitamin D exposure |
| Metabolic Health | Uric Acid 8.1 mg/dL | Relevance to gout and kidney stone risk |
| Inflammation | hs-CRP 2.3 mg/L in November | Requires interpretation alongside other inflammatory measurements |
These findings do not necessarily represent seven separate diseases.
They identify laboratory abnormalities or patterns that deserve appropriate clinical interpretation and monitoring.
The order shown is organizational rather than a formal medical risk ranking.
12. Most Reassuring Findings
Several recent measurements provide useful reassurance.
Glucose regulation: Recent A1c values remained below the usual prediabetes threshold, and September and November glucose measurements were within range.
Liver chemistry: ALT, AST, alkaline phosphatase, bilirubin, albumin, and total protein remained within their respective laboratory reference intervals.
Iron status: Recent iron studies did not demonstrate an obvious pattern of depleted iron stores.
Electrolytes: Recent sodium, potassium, and calcium concentrations were within their respective laboratory reference intervals.
White blood cells and platelets: November measurements were within the reporting laboratory’s reference intervals.
Urinalysis: November testing did not demonstrate detectable protein, blood, or typical urinary infection markers.
Pancreatic enzymes: June amylase and lipase were within range.
These findings are encouraging, but no individual group of normal laboratory results establishes complete health or eliminates unrelated medical risks.
13. Relationship to My Carnivore Diet
My strict carnivore diet began January 1, 2024.
I have experienced substantial improvement in the severe joint and muscle discomfort that previously affected my quality of life.
The recent laboratory results demonstrate several characteristics consistent with a very-low-carbohydrate dietary pattern, including low insulin, relatively low triglycerides, and substantial ketone production during fasting.
However, the diet must be considered in relation to the entire laboratory profile.
Elevated LDL cholesterol and ApoB, elevated uric acid, and selected nutritional findings remain important considerations.
The available evidence does not establish that the diet caused every favorable or unfavorable laboratory result.
My personal improvement in symptoms is important, but it should be considered alongside objective measurements and long-term health outcomes.
14. Relationship to My Medical History
My laboratory trends must be interpreted within the context of several established medical conditions.
Cardiovascular history: Hypertension, hyperlipidemia, atrial fibrillation, and an ascending aortic aneurysm make cardiovascular risk assessment especially important.
Hypothyroidism: Continued thyroid monitoring is relevant to energy metabolism, heart rhythm, and bone health.
Systemic inflammatory history: The severe illness experienced in 2021 provides important historical context for interpreting current inflammation and blood counts.
Autoimmune serology: Persistent ANA positivity remains relevant, but it does not independently establish active systemic autoimmune disease.
Kidney-related measurements: Elevated BUN and changes in filtration estimates require interpretation in relation to hydration, diet, age, and medical history.
Nutritional status: Maintaining muscle mass and adequate nutrition is especially important at age 90.
The most useful Health Inventory assessment therefore integrates laboratory measurements with symptoms, physical function, medical history, and the observations of my physicians.
15. Laboratory Monitoring Strategy
My laboratory monitoring plan involves approximately four assessments per year, using Function Health and WellMed.
This approach provides an opportunity to compare both standard laboratory measurements and selected advanced biomarkers.
For future comparisons, the following principles are important:
- Record the actual specimen collection date rather than assuming that testing occurred during the originally planned month.
- Preserve the reporting laboratory, units, reference intervals, and fasting status when known.
- Compare results obtained using different laboratories cautiously.
- Distinguish a single abnormal result from a persistent pattern.
- Avoid interpreting small numerical differences as definite improvement or deterioration.
- Give greater attention to measurements that are clinically relevant to my established medical conditions.
- Record medication, supplement, and dietary changes that may influence laboratory interpretation.
- Preserve abnormal findings even when later measurements return to range.
- Avoid assuming that a missing measurement represents a normal result.
- Evaluate laboratory trends alongside physical health, symptoms, and functional ability.
The November 2026 Function Health assessment was collected earlier than originally intended.
It should remain identified by its actual November collection date rather than being assigned to December.
No additional December 2026 laboratory report should be assumed without an actual specimen and verified results.
16. Overall Health Assessment
The laboratory evidence presents a mixed but understandable picture.
Several measurements are reassuring.
Glucose regulation appears generally favorable in the recent record.
Liver chemistry is stable.
Electrolytes remain within their respective reference intervals.
Iron studies do not demonstrate an obvious deficiency pattern.
The November urinalysis does not show an obvious infection or bleeding pattern.
However, the laboratory record also identifies important concerns.
Elevated LDL cholesterol and ApoB remain relevant to cardiovascular risk.
Mild anemia has reappeared and requires continued interpretation.
Kidney filtration measurements changed between September and November.
ANA remains strongly positive.
Vitamin D and uric acid were elevated in June.
These findings should not be dismissed simply because other measurements are favorable.
At the same time, isolated abnormalities should not automatically be interpreted as evidence of serious disease.
The purpose of continued monitoring is to distinguish temporary variation from persistent or clinically meaningful change.
17. Final Summary
Section 7.3 provides an organized assessment of my laboratory results across ten major health categories.
The findings demonstrate that many important laboratory measurements are stable or within their respective reference intervals.
They also identify several areas requiring continued attention, especially cardiovascular lipoproteins, blood counts, kidney measurements, autoimmune markers, vitamin D, and uric acid.
My Health Inventory is most useful when these findings are considered together rather than in isolation.
The objective is not to obtain perfect laboratory numbers.
The objective is to identify meaningful changes, recognize potential health risks, and preserve the physical and mental capabilities necessary for continued independence.
At age 90, the most important measures of success include strength, mobility, stability, nutritional adequacy, cardiovascular health, and the ability to continue meaningful daily activities.
The laboratory record supports this objective by providing measurable evidence that can be compared over time.
Central Understanding: My laboratory trends show a number of reassuring findings alongside several important unresolved concerns. The greatest value of Section 7.3 is its ability to distinguish stable health measurements from changes that deserve continued attention. By combining laboratory trends with my medical history, dietary practices, and physical function, the Health Inventory provides a practical foundation for informed health decisions as I pursue my goal of reaching age 100 while maintaining strength, independence, and quality of life.